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ABSTRACT 
Skeletal muscle regenerates in response to disease or injury through the activation of 
quiescent muscle stem cells and their subsequent differentiation into multi-nucleated 
myotubes. Understanding the molecular mechanisms of regeneration is critical to exploit 
this pathway for use in tissue repair. Data shown here demonstrate that MEF2A plays an 
essential role in skeletal muscle regeneration in adult mice. Regenerating muscle from 
MEF2A knockout mice displays widespread necrosis, reduced myofiber cross-sectional 
area, and a significant reduction in Pax7-positive progenitors. The existence of activated 
progenitor cells that co-express MEF2A and Pax7 is also documented in adult 
regenerative myogenesis. MEF2A controls this process through its direct regulation of 
the largest known mammalian rnicroRNA (rniRNA) cluster, the Gtl2-Dio3 locus. All 
miRNAs (>40) within this cluster are coordinately downregulated in MEF2A-deficient 
regenerating muscle, and a subset of the Gtl2-Dio3 rniRNAs represses secreted Frizzled-
related proteins (sFRPs), inhibitors of Wnt signaling. Consistent with downregulation of 
this rniRNA cluster, expression of sFRPs is upregulated and Wnt signaling is inhibited in 
MEF2A-deficient regenerating muscle. Furthermore, overexpression of Gtl2-Dio3 
VI 
miRNAs, miR-433 and miR-410, restores myotube formation in MEF2A-deficient 
myoblasts. Thus, miRNA-mediated modulation of Wnt signaling by MEF2A is a 
requisite step for proper muscle regeneration, and represents an attractive pathway for 
enhancing regeneration of diseased muscle. 
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1.1 Introduction 
1 
CHAPTER! 
Introduction 
This dissertation focuses on the role of the transcription factor MEF2A in the 
process of mammalian skeletal muscle regeneration. Muscle regeneration is the adult 
process of skeletal myogenesis, in which a resident population of muscle-specific stem 
cells, known as satellite cells, is activated to repair injured tissue. During regeneration 
activated satellite cells transition through a series of progenitor cell stages toward 
myogenic commitment and differentiation to repair damaged muscle. However, many of 
these intermediate stages are as yet undefined. The studies described herein highlight six 
novel findings which characterize MEF2A as a marker of myogenic progenitors in 
regeneration and a critical regulator of the regenerative myogenic process. First, I 
demonstrate that MEF2A is required for proper skeletal muscle function postnatally, in 
contrast to previous research indicating that MEF2A was dispensible in this tissue 
(Potthoff et al. 2007a, Potthoff et al. 2007b). I show for the first time that MEF2 is 
critically important for muscle regeneration, and that MEF2A is co-expressed with Pax7 
in activated muscle progenitors after injury. As it is widely assumed that MEF2A is 
expressed in late differentiation after the downregulation of Pax7, the data shown here 
demonstrate that the onset of MEF2A expression is much earlier in regeneration than 
previously appreciated. In this process, I have found that MEF2A transcriptionally 
regulates the expression of the largest known mammalian microRNA cluster, Gtl2-Dio3, 
2 
and that miRNAs from this cluster regulate the expression of sFRP2 to control Wnt 
signaling. Finally, this study demonstrates a new connection between MEF2 and Wnt 
signaling in a mammalian biological process. The scientific findings from this work will 
contribute to a greater understanding of mammalian muscle regeneration, the specific 
function of MEF2A in this process, and how the mechanics of regeneration may be 
harnessed for the enhancement of muscle repair in disease. 
1.2 Striated Muscle Differentiation 
1.2.1 Mammalian Myogenesis 
In mammals, muscle forms through a process known as myogenesis. Myogenesis 
involves the differentiation of muscle precursor cells into mature myocytes during both 
embryonic development and adult muscle regeneration. During embryogenesis, 
gastrulation takes place at embryonic day 7 (E7.0) in mice and Carnegie Stage 7 (15-17 
days) in humans to form the ectoderm, endoderm, and mesoderm germ layers (Mok and 
Sweetman 2011). From the nascent mesoderm, populations of cells are segregated for the 
formation of heart as well as skeletal muscles of the body. At this time, pre-cardiac 
progenitor cells arising from the mesoderm migrate under the head folds to form the 
cardiac crescent and initiate heart formation (van Weerd et al. 2011, Buckingham et al. 
2005). A short time later, mesodermal cells (somites) positioned next to the notochord 
and neural tube give rise to the dorsal dermomyotome, and subsequent myotome, from 
which skeletal muscle forms (Yokoyama and Asahara 2011). 
Cardiac and skeletal muscle are both forms of striated muscle, named for the 
striated pattern of their contractile subunits visible by electron microscopy. Each 
3 
contractile subunit, called a sarcomere, consists of myosin and actin filaments which 
move against one another to lengthen or shorten the muscle during contraction (Figure 
1.1). Sarcomeres are linked end to end at the Z-disc, which produces the striated pattern, 
and are bundled together into larger contractile units called myofibrils. Many myofibrils 
are further bundled together within each myofiber, a single multi-nucleated muscle cell 
(Figure 1.2) (Widmaier et al. 2011, Braun and Gautel2011, Scime et al. 2009). 
In addition to their similar structure, both cardiac and skeletal myogenic pathways 
converge on the same small group of transcription factors and signaling molecules to 
carry out myogenesis. During development, Wnt (wingless), BMP (bone morphogenic 
protein), and FGF (fibroblast growth factor) signaling cascades provide positional cues 
and proliferation versus differentiation signals to myogenic precursors (Yokoyama and 
Asahara 2011 , van Weerd et al. 2011). Furthermore, cardiac and skeletal muscle each use 
MEF2 (myocyte enhancer factor 2) transcription factors to orchestrate the formation of 
mature myocytes (Potthoff and Olson 2007). The high degree of similarity between 
cardiac and skeletal myogenesis makes each system a valuable tool for discerning 
information about the other. 
1.2.2 Skeletal Muscle 
Skeletal muscle in mammals has a mutli-layered contractile structure designed for 
voluntary and controlled motility. Each skeletal muscle is composed of many myofibers 
bundled together to form a larger muscle group. Each myofiber possesses multiple nuclei 
positioned just beneath the sarcolemma, the cell ' s plasma membrane. Just outside the 
sarcolemma, but beneath the basal lamina, resides a population of adult muscle-specific 
4 
stem cells called satellite cells which contribute to muscle homeostasis and repair (Figure 
1.2, Scime et al. 2009). Together, these cell types comprise a primarily post-mitotic tissue 
which retains the capacity to conduct whole muscle regeneration in response to injury. 
During development, skeletal muscle is formed from the myotome, which is 
derived from the dorsal dermomyotome shortly after gastrulation. Specification of 
myogenic progenitors within the dermomyotome begins with the expression of Pax3 and 
Pax7 (paired homeobox transcription factors) triggered by Wnt, BMP, and SHH signals 
from surrounding tissues (Figure 1.3A) (Mok and Sweetman 2011). Pax3-positive cells 
of each somite (Figure 1.3B) then migrate from the dermomyotome to form the myotome 
(Figure 1.3C) (Mok and Sweetman 2011, Yokoyama and Asahara 2011). Within the 
myotome, differentiation begins with the downregulation of Pax3, exit from the cell 
cycle, and onset of basic helix-loop-helix (bHLH) myogenic regulatory factor (MRF) 
expression. Myf5 is the first MRF expressed in determined muscle cells at E8.0 in the 
mouse, and Myf5 expression is then followed by MyoD and myogenin (Mok and 
Sweetman 2011, Molkentin et al. 1996b, Edmondson et al. 1994). Another important 
family of myogenic regulators, the MEF2 factors, is expressed around this time with the 
onset of MEF2C/MEF2B expression at E8.5 and MEF2A/MEF2D approximately 24 
hours later at E9.5 (Figure 1.4; Molkentin et al. 1996b, Edmondson et al. 1994). Loss-of-
function studies have shown that several of these transcription factors, Pax317, Myf5, 
MyoD, myogenin and MEF2C, are each critically important for proper skeletal muscle 
development (Potthoff et al. 2007a, Relaix et al. 2006, Rudnicki et al. 1993, Hasty et al. 
1993). Following cell cycle exit, myogenin initiates terminal differentiation of myoblasts 
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to form mature muscle. This process is accompanied by the expression of myosin heavy 
chain (MHC) and other markers of differentiated muscle cells (Figure 1.3C). 
Pax3/Pax7 expressing cells from the dermomyotome at this stage are also 
critically important for the specification of myogenic progenitors, which will form the 
adult satellite cell population beneath the basal lamina of postnatal muscle (Mok and 
Sweetman 2011, Kanisicak et al. 2009, Buckingham 2007). In adult muscle, this satellite 
cell population can be called upon to recapitulate many of the core transcriptional 
processes of embryonic myogenesis to regenerate and repair muscle in response to injury 
or disease (Zammit et al. 2006). A comprehensive and detailed review of how quiescent 
satellite cells are activated to differentiate and form myofibers (Figure 1.5) during 
regeneration is presented in section 1.4. 
1.2.3 C2C12 Cells: An In Vitro Differentiation Model 
C2C12 cells represent one of the most widely used in vitro models of mammalian 
striated muscle differentiation. C2C12 cells are a subcloned myoblast cell line originally 
isolated from crush-injured mouse thigh muscle (Yaffe and Saxel1977, Blau et al. 1983). 
In growth medium (Dulbecco's Modified Eagle Medium supplemented with 10% fetal 
bovine serum), C2C12 myoblasts proliferate continuously. However, under low-serum 
conditions or upon cell-cell contact, C2C12 myoblasts are capable of differentiating in 
culture. During this process, proliferating myoblasts exit the cell cycle and begin to fuse 
by differentiation day two. By the third day of differentiation in culture elongated, multi-
nucleated myotubes are visible, and can be seen actively contracting in culture by day 
five. The ability to generate contractile myotubes in culture makes C2C12 cells an ideal 
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in vitro model for recapitulating the events of striated muscle differentiation (Yaffe and 
Saxel 1977, Blau et al. 1983). Furthermore, it has been firmly established that this cell 
line expresses Pax7 and MRFs in a similar pattern to that which occurs during skeletal 
muscle development and regeneration. Pax7 is expressed in subconfluent myoblasts with 
low levels of MyoD. After 24 hours incubation in differentiation medium MyoD 
expression is upregulated, myogenin follows by 48 hours, and terminal differentiation is 
evident by differentiation day three with robust muscle creatine kinase (MCK) expression 
(Diel et al. 2008, Blais et al. 2005, Tomczak et al. 2004, Delgado et al. 2003). 
1.3 Myocyte Enhancer Factor-2 Transcription Factors 
1.3.1 Identification and Structure of MEF2 
Myocyte enhancer factor-2 (MEF2) proteins belong to the MADS-box 
superfamily of transcription factors , named for the first four family members to be 
identified: MCM1, a factor involved in mating-type selection in yeast; Agamous and 
Deficiens, homeotic factors responsible for Arabidopsis leaf identity; and .§.erum-response 
factor (SRF), a regulator of growth factor-responsive muscle genes (Black and Olson 
1998). MEF2 was originally identified in skeletal myocytes as a nuclear factor capable of 
binding a conserved AfT -rich consensus site upstream of the muscle creatine kinase 
(mck) gene (Gossett et al. 1989). Subsequently, the MEF2-binding site was identified in 
the control regions of many muscle-specific genes, which implicates MEF2 as a major 
regulator of muscle development in the three muscle lineages: skeletal, cardiac, and 
smooth. 
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Among invertebrates, Drosophila and Caenorhabditis elegans each possess one 
mej2 gene encoding a single protein product (Lilly et al. 1994, Nguyen et al. 1994, 
Dichoso et al. 2000). Vertebrates possess four mej2 genes which are located on separate 
chromosomes (Mej2a, -b, -c and -d) (Olson 2006). Each MEF2 protein contains an N-
terminal MADS-box domain as well as an adjacent MEF2 domain. Together these 
domains mediate DNA binding, dimerization and some co-factor interactions of MEF2 
proteins (Molkentin et al. 1996a, McKinsey 2002, Black and Olson 1998). Specifically, 
MEF2 factors can form homo- or heterodimers through this domain, as well as bind the 
DNA consensus sequence YTA(A/T)4TAR (Pollock and Treisman 1991, Yu et al. 1992, 
Molkentin and Olson 1996). Among vertebrate MEF2 factors the MADS/MEF2 domain 
is approximately 95% conserved, and shares significant sequence similarity with the N-
terminal region of Drosophila MEF2. Both are known to bind the MEF2 consensus site 
for activation of transcription (Potthoff and Olson 2007). 
The C-terminal domain of MEF2 factors comprises the transactivation domain. 
The carboxy termini are significantly more divergent among MEF2 factors and exhibit 
complex patterns of alternative splicing. Certain exons are expressed ubiquitously while 
others are tissue-specific, adding an additional level of complexity to MEF2 function 
(Potthoff and Olson 2007) (Figure 1.6). 
1.3.2 MEF2 Gene Expression and Developmental Timing 
MEF2A, -B, -C, and -D exhibit distinct but overlapping patterns of expression 
during embryonic development and in adult tissues. Expression of MEF2 proteins in 
neurons, chondrocytes, and muscle occurs concomitantly with the onset of their 
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differentiation programs during vertebrate embryogenesis, and are later expressed in the 
brain and lymphocytes as well. Throughout embryonic development and adulthood, 
MEF2 expression is highest in cardiac and skeletal muscle (Potthoff and Olson 2007). 
During mouse development, MEF2B and MEF2C rnRNAs are first detectable by 
in situ hybridization in the pre-cardiac mesoderm of the mouse E7 .5 stage embryo, and at 
E8.5 in the skeletal dermomyotome. Less than 24 hours later, expression of MEF2A and 
MEF2D rnRNA follows at E8.5 and E9.5 in pre-cardial and pre-skeletal muscle 
progenitors respectively (Edmondson et al. 1994, Molkentin et al. 1996b). At the protein 
level, MEF2A, MEF2C, and MEF2D are detectable in the somites and pre-cardiac 
mesoderm between E8.5-9 (Subramanian and Nadal-Ginard 1996), though MEF2 
transcriptional activity has been reported as early as E7.5 and E9.0 in cardiac and somatic 
cells, respectively (Naya et al. 1999). These results indicate that MEF2 protein is likely 
present and active shortly after it is transcribed. After E11.5, expression of MEF2B and 
MEF2C is downregulated in the myocardium, making MEF2A and MEF2D the 
predominant isoforms expressed in the adult heart. However, all four MEF2 isoforms 
continue to be expressed in skeletal muscle throughout adulthood (Edmondson et al. 
1994, Molkentin et al. 1996b ). The spatial and temporal patterns of MEF2 expression 
point to a role for this transcription factor family in the differentiation of striated muscle 
(Figure 1.4 ). 
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1.3.3 Known Roles for MEF2 in Striated Muscle 
1.3.3.1 D-MEF2 
Drosophila express a single MEF2 protein (D-MEF2) which shares significant 
homology with vertebrate MEF2 factors, pointing to the evolutionary conservation of this 
transcription factor family. Overall, D-MEF2 exhibits nearly 90% amino acid identity in 
its MADS-box domain, 68% identity in the MEF2 domain, and is also known to bind the 
same DNA consensus sequence as vertebrate MEF2 factors. The D-MEF2 C-terminal 
transactivation domain, while considerably more divergent, shares 14% amino acid 
indentity with vertebrate Mef2s (Potthoff and Olson 2007, Lilly et al. 1994). 
Expression patterns for D-MEF2 in somatic, visceral, and cardiac cell lineages 
suggest this factor to be a regulator of differentiation and organization of the Drosophila 
musculature. Indeed, D-MEF2 loss-of-function by P element insertion or EMS-
mutagenesis results in a failure of all three muscle lineages to differentiate despite proper 
specification and positioning in the developing embryo (Lilly et al. 1995, Bour et al. 
1995, Ranganayakulu et al. 1995). These studies show that D-MEF2 is required for 
myoblast differentiation, a role recapitulated through analysis of D-MEF2 ectopic 
expression in the Drosophila epidermis. In this context, D-MEF2 was shown to be 
sufficient for activation of the skeletal muscle genes tropomyosin l(Tml), f33-tubulin and 
nautilis (Lin MH et al. 1997). Together, these studies demonstrate a specific and critical 
requirement for D-MEF2 in the differentiation and assembly of myocytes in the three 
muscle lineages. 
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1.3.3.2 MEF2A 
In the developing mouse embryo, onset of Mej2a expression coincides with the 
formation of the linear heart tube at E8.5 in cardiac cells, and at E9 .5 in so mites that 
contribute to skeletal and smooth muscle formation (Black and Olson 1998). Nearly 80% 
of Mej2a-/- mice die between postnatal days 5 (P5) and P10 due to right ventricular 
dilation and myofibrillar fragmentation of the heart (Figure 1.7; Naya et al. 2002). Three 
classes of genes dysregulated in P5 Mej2a-/- hearts encode muscle structural proteins (a-
skeletal actin, CRP-1, calponin and SM22), stress-response proteins (Nur77, MKK6, 
MAP kinase kinase 1 and metallothionein), and several mitochondrial proteins (Naya et 
al. 2002). This phenotype suggests that MEF2A plays a role in the proper differentiation 
of cardiac muscle. Furthermore, a recent study by Ewen et al. (2011) demonstrated that 
MEF2A regulates costamere gene expression and cell survival in cardiomyocytes. 
Additional overexpression studies of Mej2a in the heart have further demonstrated 
that careful modulation of Mej2a expression levels is critical to proper striated muscle 
function. Transgenic mice overexpressing Mej2a under the control of the a-myosin heavy 
chain (aMHC) promoter displayed ventricular chamber dilation, thinning of ventricular 
walls and MEF2A dose-dependent activation of the fetal gene program (van Oort et al. 
2006, Durham et al. 2006, Xu et al. 2006). Additionally, work by Xu et al. (2006) 
demonstrated that MEF2A overexpression in cultured neonatal rat cardiomyocytes 
(NRCs) is sufficient to dysregulate expression of the sarcomere structural proteins aMHC 
and a-actinin, as well as several ion channel, adhesion, and extracellular matrix proteins. 
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In striking contrast to cardiac development, skeletal muscle develops normally in 
MEF2A knockout mice, with no obvious histological defects and normal fast- to slow-
fiber type transformation in response to sustained muscle activity. These data indicate 
that MEF2A may be dispensible for skeletal muscle differentiation (Potthoff et al. 2007b, 
F. Naya and C. Snyder unpublished data). However, ChiP-chip analyses by Paris et al. 
(2004) and Blais et al. (2005) on C2C12 myotubes using an anti-MEF2 antibody specific 
for MEF2A (Figure 4.8) demonstrated that MEF2A associated with a variety of 
promoters whose genes are involved in proper muscle differentiation and function. 
Furthermore, recent work by Seok et al. (2011) independently corroborated evidence I 
describe in chapter three (Figure 3.4) that C2C12 differentiation is impaired by the loss of 
MEF2A in culture. Despite the current lack of in vivo evidence that MEF2A plays a role 
in skeletal muscle, there is substantial in vitro data that suggest a function for MEF2A in 
skeletal muscle. 
1.3.3.3 MEF2B 
The expression pattern of Mef2b is concurrent with Mef2c in cardiac muscle cells, 
and lags slightly behind Mef2c in skeletal muscle lineages of the developing embryo 
(Molkentin et al. 1998). MEF2B has been characterized as a potent transcriptional 
activator, capable of binding the MEF2 consensus sequence as well as forming a hetero-
dimeric complex with myogenin and E12 to bind and activate regulatory regions of target 
genes (Molkentin et al. 1996b). A conventional Mef2b null mouse is viable with no 
apparent phenotype (Black and Olson 1998). The early expression of Mef2b in cardiac 
and skeletal muscle lineages implicates this factor in early striated muscle differentiation 
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and development. However, the absence of a muscle defect in Mef2b-/- mice suggests 
that it is dispensible during this process. It is interesting to note that Mef2d transcript 
levels were shown to be more than sevenfold upregulated in Mef2c-/- hearts (Lin Q et al. 
1997), indicating that MEF2B may share functional redundancy with MEF2C and is 
therefore upregulated in a compensatory manner. Potential functional redundancy 
between MEF2B and MEF2C could explain the viability of Mef2b-/- animals. However, 
this hypothesis remains to be explored. Regardless, as MEF2B is not expressed in the 
vasculature or smooth muscle, its function may be specific to striated muscle (Molkentin 
et al. 1996b). As myogenesis proceeds beyond early differentiation stages, MEF2B is 
expressed at highest levels in the ends of myotubes and myofibers, indicating a possible 
role for this MEF2 family member in the fusion of myotubes with the ends of myofibers 
(Molkentin et al. 1996b ). 
1.3.3.4 MEF2C 
The earliest MEF2 factor expressed during mouse embryonic development is 
Mef2c (Molkentin et al. 1996b). Mef2d knockout mice exhibit embryonic lethality by 
E9 .5 from combined cardiomuscular and cardiovascular defects (Lin Q et al. 1997, Lin et 
al. 1998). In Mef2c-/- embryos, cardiac cells organize to form the linear heart tube (E8.0) 
but display slow, irregular contractions and fail to specify the future right ventricle or 
undergo rightward looping morphogenesis (Lin Q et al. 1997). Additionally, Mef2c-/-
hearts exhibit aberrant expression of several cardiac-specific genes, including atrial 
natriuretic factor (AN F), a.-cardiac actin, a.MHC, and myosin light chain 1 a (MLCJA). 
The misexpression of eHand and dHand (Hand 1 and 2, respectively) is also observed in 
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Mef2c-/- hearts, contributing to the failed specification of the future left and right 
ventricles (Lin Q et al. 1997). Analysis of the vasculature and smooth muscle in Mef2c-/-
mutant mice has also revealed a requirement for MEF2C in proper construction of the 
vascular network and differentiation of smooth muscle cells (Lin et al. 1998). Together, 
these and other studies indicate a critical role for MEF2C in the development of the 
cardiac musculature. 
A role for MEF2C in activating expression of muscle structural genes is known to 
be conserved between cardiac and skeletal muscle. Skeletal muscle conditional deletion 
of Mef2c in mice (Mef2ccko) results in myofiber disorganization and perinatal lethality 
(Potthoff et al. 2007a). Embryonic analysis of skeletal muscle (skm) has revealed that 
Mef2ccko mutants display normal differentiation and formation of muscle fibers which 
deteriorate rapidly upon birth and exhibit downregulation of several muscle structural 
proteins, including: myomesin, M protein, myozenin 1 and 2 ( calsarcan 2 and 1, 
respectively), actin, myosin, myotilin, MCK, Bop, Srpk3, and desmin (Potthoff et al. 
2007a). Similar results were obtained in zebrafish upon morpholino-mediated knockdown 
of MEF2C and MEF2D, which resulted in downregulation of thick filament proteins in 
skeletal muscle (Hinits and Hughes 2007). Moreover, skm Mef2ccko mutants are unable to 
activate oxidative, slow fiber-type genes required for activity-dependent fast- to slow-
fiber type transformation (Potthoff et al. 2007b ). 
Overall, the above described studies implicate a conserved role for MEF2C in the 
assembly and maintenance of cytoarchitectural structures in both cardiac and skeletal 
forms of striated muscle during embryonic and perinatal development. Additionally, 
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these studies have indicated that MEF2C (and possibly other MEF2 factors) may be 
active in the precardiac mesoderm, prior to transcript detection by conventional 
molecular techniques, and potentially act redundantly to ensure proper differentiation of 
striated muscle. 
1.3.3.5 Mef2D 
The onset of M ef2d expression in the developing mouse is concomitant with 
Mef2a , appearing by E8.5 in cardiac myocytes and E9.0 in the developing somite 
myotome (Edmondson et al. 1994, Molkentin et al. 1996b). MEF2D, along with MEF2A, 
are the predominant MEF2 isoforms expressed in adult cardiomyocytes, indicating a dual 
role for MEF2D in both development and maintenance of mature muscle (Edmondson et 
al. 1994, Naya et al. 2002). Loss- and gain-of-function studies have been performed for 
MEF2D in both cardiac and skeletal muscle to ascertain its function more precisely. 
Mef2d-/- knockout mice, generated by Kim et al. (2008), are viable but display a 
blunted cardiac stress response. Cardiac stress induction by pressure overload or chronic 
~-adrenergic stimulation fails to produce classic cardiac hypertrophy, activation of the 
fetal gene program, or fibrosis in Mef2d-l- animals as compared to wild type (Kim et al. 
2008). In agreement with these results, overexpression of MEF2D in transgenic mouse 
hearts is sufficient to activate the fetal gene program and cardiac remodeling (Kim et al. 
2008). Together these results imply that MEF2D plays a role in pathological remodeling 
in response to cardiac stress in the adult heart. However, early roles for MEF2D in 
cardiac muscle development have yet to be investigated. 
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Analysis of skeletal muscle in Mef2d-/- null mice revealed no obvious histological 
abnormalities (Kim et al. 2008). However, conditional deletion of Mef2d in skeletal 
muscle suggests a role for MEF2D in the activation of slow, oxidative-fiber type muscle 
genes, as the activity-dependent ability of muscle cells to make a fast- to slow-fiber type 
transformation is lost upon deletion of Mef2c or Mef2d in skeletal muscle (Potthoff et al. 
2007b ). Additionally, morpholino knockdown of MEF2C and MEF2D in zebrafish 
skeletal muscle demonstrated a requirement for these factors in the expression of thick 
filament contractile proteins essential for proper sarcomere construction (Hinits and 
Hughes 2007). Together, these studies point to a role for MEF2D in the activation of 
specific muscle contractile proteins in adult striated muscle in response to either 
pathological or physiological cell stress. However, the precise role of MEF2D in striated 
muscle development remains to be investigated. 
1.4 Muscle Regeneration 
1.4.1 Regenerative Differentiation 
Muscle regeneration is the adult process of myogenesis which can be triggered in 
response to disease-, exercise-, or insult-induced muscle injury. Under normal conditions 
postnatal skeletal muscle is a relatively stable tissue with low myonuclei turnover, 
approximately 1-2% per week in rodents (Charge and Rudnicki 2004). However upon 
injury, skeletal myocytes have the ability to rapidly and extensively repair the damaged 
tissue. Generally, the first phase of muscle regeneration is characterized by necrosis and 
degeneration of the muscle after injury. During this time, molecular signals from the 
damaged tissue activate an inflammatory response with the widespread infiltration of 
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neutrophils into the muscle. Approximately 48 hours post-injury in mice, macrophages 
infiltrate the damaged area to clear away cell debris, and by the third day post-injury 
degeneration is largely complete. Concurrent with the onset of degeneration, progenitor 
cells resident within the muscle are activated to proliferate and repopulate the damaged 
area with myoblasts. By day three post-injury, degeneration completes., proliferating 
myoblasts exit the cell cycle, and the regeneration phase of injury response begins. 
Myoblast differentiation to reform and repair damaged muscle in mice occurs primarily 
between day three and fourteen after injury, at which time nascent myofibers with 
centrally located nuclei, a hallmark of regeneration, are clearly visible (Figure 1.8). By 
three to four weeks after injury, muscle regeneration is largely complete with near 100% 
recovery of the original myofiber area and migration of myonuclei to the periphery of the 
cells (Wallace and McNally 2009, Charge and Rudnicki 2004, Yan et al. 2003). 
A widely used method for studying skeletal muscle regeneration in mice is by 
cardiotoxin (ctox) injury to the rodent hindlimb tibialis anterior muscle. Cardiotoxin is a 
protein kinase C-specific inhibitor peptide isolated from snake venom, popularly the 
cobra species Naja nigricollis. This toxin induces depolarization and contraction of the 
muscle cells, disruption of sarcolemmal organization, and widespread cell lysis (Charge 
and Rudnicki 2004). Studies described by Wallace and McNally (2009), Charge and 
Rudnicki (2004) and Yan et al. (2003) indicate that injection of 101J.M cardiotoxin is a 
highly reproducible method for inducing widespread muscle degeneration and 
regeneration in a time frame consistent with the events described in mice above (Figure 
1.8). 
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On a molecular level, regeneration is initiated when signals from surrounding 
tissues trigger the activation of a resident population of quiescent satellite cells beneath 
the basal lamina of postnatal skeletal myofibers (Figure 1.5). Quiescent satellite cells in 
vivo are classically marked by the expression of Pax7, c-ruet, and Syndecan-3 and -4. 
Subpopulations among satellite cells have also been shown to express CD34 and Myf5, 
among other proteins (Figure 1.9). Upon activation, satellite cells rapidly upregulate 
MyoD and enter a myoblast proliferative state classically characterized by co-expression 
of Pax7 and MyoD. Myoblasts proliferate extensively to expand the progenitor 
population for muscle repair and maintenance of the satellite cell pool. Following the 
proliferative period, myoblasts may then downregulate MyoD and return to Pax7-
characterized quiescence to maintain satellite cell number, or downregulate Pax7 and 
further commit to MRF-characterized myogenic differentiation. Commitment to 
differentiation in myoblasts is signaled by exit from the cell cycle, onset of a-actinin and 
myogenin expression, and the fusion of myoblasts to form myotubes. Maturation and 
growth of myotubes generate myofibers over time to fully regenerate and repair damaged 
muscle (Figure 1.5) (Charge and Rudnicki 2004 ). While poorly characterized, MEF2 
factors also play a role in the regenerative process and are generally thought to be 
expressed after MyoD around the time of cell cycle exit and commitment to 
differentiation (Figure 1.5). 
Other signaling pathways also play critical roles in regulating the activation of 
satellite cell proliferation and commitment to myogenesis. Recently, it was established 
that a temporal switch from Notch to Wnt signaling in satellite cells is required for proper 
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myogenic regeneration (Brack et al. 2008). High Notch signaling is required during early 
stages of activation and proliferation of satellite cells, but is then downregulated when 
Wnt signaling becomes active in late progenitor stages to generate fusion-competent 
myoblasts and promote differentiation (Brack et al. 2008, Conboy et al. 2003). Tight 
temporal regulation of both Notch and Wnt signaling is necessary for proper regenerative 
progression. Ectopic expression of secreted wnts and their inhibitors, secreted frizzled-
related proteins (sFRPs), can promote premature myogenic differentiation as well as 
inhibit myogenesis, respectively (Brack et al. 2008, Descamps et al. 2008). Careful 
control and expression of molecular markers and signaling pathways involved in muscle 
regeneration are critical to proper progression of this process, which can be disrupted and 
impaired by misregulation of any component. Furthermore, recent gene profiling studies 
during the course of regeneration have indicated that several transcriptional programs 
thought to recapitulate developmental myogenesis are actually reprogrammed in adult 
muscle to orchestrate a unique differentiation program distinct from embryogenesis 
(Zhao and Hoffman 2004). 
1.4.2 Satellite Cells and Progenitors 
Skeletal muscle stem cells were first identified by Katz (1961) and Mauro (1961), 
who described electron microscopy observation of quiescent cells positioned peripherally 
to the myofiber but underneath the basement membrane, earning the name 'satellite' 
cells. Since their discovery, satellite cells have been characterized as conventional stem 
cells which are able to give rise to a differentiated cell type and maintain itself by self-
renewal (Zammit et al. 2006). While all postnatal satellite cells express Pax7 and 
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contribute to muscle maintenance and repair, satellite cells of different muscle groups 
have distinct origins. For example, satellite cells of the trunk and limbs arise from 
Pax3+/Pax7+ progenitors of the dermomyotome during embryonic development, while 
satellite cells of the extraocular and branchial arch muscles arise from the head mesoderm 
(Kang and Krauss 2010). Though the developmental origin of satellite cells may be 
important for their function, it has also been shown that their transcriptional signatures 
are reprogrammable depending on niche context, as has been demonstrated through 
transplant experiments. Together, these data indicate that origin and niche are each 
important to satellite cell function (Kang and Krauss 2010). 
Satellite cell populations within a single muscle group have also been shown to be 
heterogeneous. For example, all satellite cells are known to express Pax7, Syndecan-3 
and -4, and c-met in vivo and in vitro. However, various subpopulations are also known 
to express Myf5, CD34, and M-cadherin during quiescence in vivo (Figure 1.9) (Kang 
and Krauss 2010, Zammit et al. 2008, Charge and Rudnicki 2004). Once satellite cells are 
activated by extracellular signals to proliferate, Notch signaling becomes important for 
both expansion of the myoblast progenitor population and renewal of the stem cell pool. 
During asymmetric division of satellite cells, the Notch inhibitor Numb segregates with 
Pax7 while Notch signaling is maintained in myoblast daughter cells, indicating that 
Notch may function in satellite cell fate decisions (Punch et al. 2009, Zammit et al. 
2006). Finally, when myoblasts exit the cell cycle and commit to differentiation a 
molecular switch from Notch to Wnt signaling is made to solidify commitment to 
myogenesis (Bracket al. 2008, Otto et al. 2008). 
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While satellite cells represent the primary progenitor population responsible for 
postnatal skeletal muscle regeneration, at least two additional types of myogenic 
progenitors have been identified in adult muscle. PW1 + !PaxT interstitial cells (PICs) 
were recently identified by Mitchell et al. (2010) as myogenic progenitors able to 
contribute to muscle regeneration after turning on Pax? and MyoD expression, and are 
capable of self-renewal to maintain their progenitor population. Additionally, it was 
previously known that adult skeletal muscle harbors resident Abcg2+ progenitors called 
' side population' (SP) cells. SP cells are also found in the interstitium, typically near the 
vasculature, and have been shown to contribute to myogenesis during regeneration 
(Doyle et al. 2011, Meeson et al. 2004). While both SPs and PICs contribute to 
regenerative myogenesis, it is still unclear whether these progenitors may also function as 
satellite cell precursors. 
1.4.3 Molecular Markers of Regeneration 
As described in sections 1.4.1 and 1.4.2, there are several key transcriptional and 
cytoarchitectural markers of myogenic stages during muscle regeneration .. A variety of 
loss- and gain-of-function studies have established specialized functions for several of 
these factors in regeneration for the careful modulation of myogenic progression. 
1.4.3.1 Pax7 
Pax? is a member of the paired-box homeodomain transcription factor family 
known to be expressed in myogenic progenitors of both embryonic and adult muscles. In 
skeletal muscle, Pax? is expressed exclusively in satellite cells and activated myoblast 
progenitors making it a reliable marker of myogenic precursor cells. Additionally, the 
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availability of a good antibody through the Developmental Studies Hybridoma Bank at 
the University of Iowa, has enabled the accurate identification of satellite cells in vivo 
and in vitro (Buckingham 2007, Zammit et al. 2006). Several studies have shown that 
Pax7 expression is requisite during embryogenesis for the establishment of a postnatal 
satellite cell population, as satellite cells are rapidly lost during the postnatal period in 
Pax7-l- mice (Kuang et al. 2006, Relaix et al. 2006, Oustanina et al. 2004, Seale et al. 
2000). However, Lepper et al. (2009) more recently showed that conditional loss of Pax7 
expression postnatally does not affect the size of the satellite cell population, but rather 
delays the process of regeneration. These studies together demonstrate that Pax7 is 
required for the specification of postnatal satellite cells during embryogenesis but is 
dispensible for satellite cell survival after their entry into quiescence. Additionally, 
research performed by Collins et al. (2009) showed that Pax7 or Pax3 expression is 
necessary for Myf5, MyoD, and myogenin expression to initiate differentiation and that 
loss of either factor can impair this process. 
1.4.3.2 MyoD 
As a member of the myogenic regulatory factor (MRF) family of myogenic bHLH 
transcriptional regulators, MyoD is able to regulate transcriptional programs in skeletal 
muscle through cooperation with DNA-binding E-box proteins and MEF2 factors (Black 
et al. 1998). MyoD is a key component of myogenic differentiation, and its expression is 
turned on in activated satellite cells during regeneration where it is co-expressed with 
Pax7 (Charge and Rudnicki 2004). MyoD continues to be expressed throughout the 
differentiation of myoblasts into mature myofibers, and is critical for proper myocyte 
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differentiation. As shown by Megeney et al. (1996), MyoD-1- mice exhibit an impaired 
regeneration phenotype characterized by an increased population of myoblast progenitors 
and an abnormally low number of regenerated myofibers. Without the ability to turn on 
MyoD satellite cells enter a proliferative state they cannot exit and accumulate in the 
regenerating muscle (Zammit et al. 2004, Sabourin et al. 1999, Yablonka-Reuveni et al. 
1999). Furthermore, MyoD knockout satellite cells are differentiation defective, fail to 
appropriately express myogenin and MRF4, and exhibit severely delayed regenerative 
capacity (Cornelison et al. 2000). 
1.4.3.3 Myogenin 
Myogenin is another member of the MRF bHLH transcription factor family that 
plays an important role in the commitment of myoblasts to terminal differentiation in 
skeletal muscle. Myogenin is upregulated in proliferating myoblasts just before the cell 
cycle arrest protein p21 is activated for permanent exit from mitosis. Beyond this point, 
terminal differentiation and fusion is then completed as characterized by the expression 
of muscle-specific proteins such as myosin heavy chain (MHC) and others (Charge and 
Rudnicki 2004). Myogenin knockout mice survive embryogenesis, but die shortly after 
birth displaying a widespread lack of skeletal muscle pointing to a critical role for 
myogenin in proper muscle differentiation (Hasty et al. 1993). However, inducible 
deletion of myogenin after embryogenesis does not limit viability or muscle formation. 
Instead, myog-1- mice display 30% overall reduction in body size and modest alterations 
in Mrf4 and MyoD transcript levels (Knapp et al. 2005). Together these studies indicate 
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that myogenin is critical for embryonic muscle differentiation, but that requirements for 
this MRF in postnatal muscle growth are distinctly different. 
1.4.4 Wnt Signaling in Skeletal Muscle Differentiation 
1.4.4.1 Canonical Wnt Signaling 
Canonical Wnt signaling activates key transcriptional programs requisite for 
proper muscle differentiation during development and regeneration. This is accomplished 
through the stabilization of ~-catenin and activation of target genes through ~-catenin' s 
cooperation with T-cell factor/lymphocyte enhancer factor (TCF!Le:f) transcription 
factors. The Wnts are a secreted family of glycoproteins characterized by several 
conserved cysteine residues. While members of this family can participate in both 
canonical and non-canonical (~-catenin independent) Wnt signaling, proteins such as 
Wntl, Wnt3A, and Wnt5a typically participate in canonical signaling. In the absence of 
Wnt signaling, the multifunctional protein ~-catenin is targeted to a destruction complex 
where it undergoes phosphorylation by glycogen synthase kinse (GSK)3~ at residues 
Ser33, 37, and Thr41. Phosphorylation at these sites marks ~-catenin for proteasomal 
degradation, preventing any ~-catenin-dependent transcriptional activity. In the presence 
of Wnts, canonical signaling is activated in cells at the plasma membrane by the binding 
of Wnts with their cell-surface seven-transmembrane receptors, frizzled (Fz) proteins, 
and their lipoprotein co-receptors (LRPs). Positive signals transduced by Fz results in the 
disassembly of the cytoplasmic destruction complex composed of Axin2, adenomatous 
polposis coli (APC), and GSK3~. Inihibition of this complex stabilizes ~-catenin and 
allows for Ser9 phosphorylation on GSK3~ to promote its degradation by the 
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proteasome. Once the destruction complex is dissolved, stabilized ~-catenin then enters 
the nucleus where it acts as a co-factor for TCF/Lef transcription factors to activate Wnt 
signaling target genes (Figure 1.10) (Rao and Kiihl 2010, Kawano and Kypta 2003). 
Regulation of Wnt signaling occurs at an extracellular level as well by a family of Wnt 
inhibitors known as secreted frizzled-related proteins (sFRPs). sFRPs are able to inhibit 
Wnt signaling directly by either binding Wnt proteins extracellularly to prevent their 
association with cell-surface receptors or binding the Fz receptors themselves to prevent 
Wnt association and signal transduction (Figure 1.10) (Kawano and Kypta 2003). Wnt 
signaling is known to participate in many biological processes during embryonic 
development and adult maintenance of tissues. However, despite the expanse of 
knowledge currently available regarding Wnt function, there is still much to be learned 
about how control of this pathway contributes to muscle biology. 
1.4.4.2 Wnt Signaling During Development and Regeneration 
During muscle development and regeneration, Wnt signaling is requisite for the 
proper progression of myogenesis and differentiaton. In early embryogenesis when 
muscle precursors are specified from the mesoderm-derived dermomyotome, sonic 
headge-hog (SHH) and Wnts are considered the primary instructive signals. During this 
specification process, Wnts and SHH are responsible for activating myogenesis in the 
future dermomyotome through a Myf5 and MyoD-dependent cascades (Cossu and 
Borello 1999). Later, during postnatal muscle regeneration, Wnts are again requisite for 
the progression of myoblast proliferation into differentiation for the repair of damaged 
muscle (Tanaka et al. 2011). 
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In adult myogenesis a transition from Notch to Wnt signaling as myoblasts exit 
from the cell cycle is necessary for differentiation. In satellite cells and proliferating 
myoblasts, Wnt signals are typically low while Notch signals are high. However, as these 
cells exit mitosis and begin to differentiate, these molecular signals switch, with 
downregulation of Notch and upregulation of Wnt signaling (Bracket al. 2008). In a 27-
point regeneration time course study by Zhao and Hoffman (2004 ), it was observed that 
inhibitors of Wnt signaling, sFRPs, are highly expressed during the earliest phase of 
regeneration after muscle injury when myofibers are degenerating and satellite cells are 
proliferating to increase the myoblast population. However, as degeneration completes 
around day three post-injury and regenerative differentiation begins, several Wnts 
increase in expression while sFRPs are downregulated (Zhao and Hoffman 2004). A 
similar pattern has also been observed during C2C12 differentiation in culture, where 
Wnts are upregulated upon exit from the cell cycle (Tanaka et al. 2011). Not only is Wnt 
signaling important for proper myogenesis, but the process of differentiation is also 
sensitive to levels of Wnt signaling and can be disrupted by the inhibition or 
overexpression of Wnt components. For example, Wnt4 overexpression in chick embryos 
increases skeletal muscle mass, while sFRPl and sFRP2 overexpression in C2C12 
myoblasts or primary satellite cells prevents differentiation (Tanaka et al. 2011, 
Descamps et al. 2008). While substantial data exists detailing the impacts of Wnt 
singaling on muscle differentiation and regeneration, little is known about the 
transcriptional profile controlled by Wnt in muscle differentiation or how Wnt signaling 
itself is modulated and induced in this biological process. 
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1.4.4.2.1 sFRP 
Secreted frizzled-related proteins (sFRPs) are antagonists of the Wnt signaling 
pathway through inhibitory binding of either Wnts or their receptors. However, it remains 
unclear by what mechanism sFRPs bind either component of the signaling pathway. In 
vertebrates, there are five members of the sFRP family: sFRPl, 2, and 5 which comprise 
one related subgroup, and sFRP3 and 4 which comprise another (Kawano and Kypta 
2003). Among these proteins, distinct roles in myogenesis have been demonstrated for 
sFRPl and sFRP2, in particular. A study by Descamps et al. (2008) demonstrated that the 
addition of recombinant sFRPl or sFRP2 to C2C 12 myoblast or primary satellite cell 
cultures prevented the formation of myotubes without altering the cell cycle or inducing 
apoptosis. Additionally, these myoblasts were able to differentiate properly once sFRPs 
were removed from the media, indicating that sFRP levels carefully modulate Wnt 
signaling and the progression of differentiation in skeletal muscle cells. It has also been 
demonstrated in the heart that sFRP2 sensitively regulates cardiomyocyte differentiation 
through inhibition of Wnt3a and prevention of myogenesis (Debet al. 2008). 
1.4.4.2.2 Axin2 
Axin2 is an important protein component of the 'destruction' complex in the Wnt 
signal transduction cascade which inhibits ~-catenin activity. Axin2, together with 
GSK3~ and APC, forms a complex which sequesters ~-catenin in the cytoplasm and 
promotes its phosphorylation and subsequent targeting for proteasomal degradation via 
GSK3~ kinase activity. Additionally, Axin2 is also a target gene of TCF/Lef 
transcriptional activity, making Axin2 expression Wnt dependent. As such, Axin2 
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expression can be used as a molecular indicator of the state of Wnt signaling in muscle 
(Rao and Kuhl2011). 
1.4.4.2.3 P-catenin 
~-catenin is a multi-functional protein that functions as a cofactor for TCF/Lef 
factors in the nucleus to activate Wnt-sensitive transcriptional programs, as well as a key 
component of adherens junctions to regulate cell adhesion and cell-cell contacts (Rao and 
Kuhl 2011). It is often used as a sensitive indicator of active Wnt signaling in muscle 
cells through assessment of its accumulation in myonuclei or activation of TOP-driven 
Wnt reporter constructs which harbor 8 concatamerized TCF/Lef binding sites (Veeman 
et al. 2003). However, analysis of ~-catenin as a readout of Wnt signaling can be 
complicated in vivo by its role in interactions with cadherins at adherens junctions (Rao 
and Kuhl 2011). Therefore, analysis of active Wnt signaling in vivo must assess multiple 
components of the Wnt signaling cascade to measure the activity status of the pathway. 
Additionally, the phosphorylation status of ~-catenin can provide insight into the 
behavior of this molecule in relation to Wnt signaling measurement. For example, 
phosphorylation of ~-catenin at residues Ser33, 37, and Thr41 marks ~-catenin for 
proteasomal degradation (Rao and Kuhl 2011). However, the use of antibodies able to 
detect dephosphorylation at these residues indicates that ~-catenin is activated and able to 
translocate to the nucleus (Van Noort et al. 2002). 
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1.5 MicroRNAs: Modulators of Myogenesis 
1.5.1 MicroRNAs and Gene Regulation 
MiRNAs are small, non-coding RNAs that function post-transcriptionally by 
interacting directly with messenger RNAs to repress their expression (Bartel 2004). First 
discovered in C. elegans by Victor Ambros and colleagues (Lee et al. 1993), miRNAs are 
small (-22nt), non-coding RNAs typically found in introns and intergenic regions of the 
genome which function to translationally silence or promote degradation of targeted 
messenger RNAs. MiRs are transcribed as long primary miRNAs (pri-miRs), which can 
be up to several kilobases in length and can contain multiple miRs clustered together. Pri-
miRs are then processed by the RNase III endonuclease Drosha associated with Pasha by 
cleavage into -70-80nt precursor miRNAs (pre-miRs). Hairpin-structured pre-miRs are 
then exported from the nucleus to the cytoplasm where they are further processed by the 
enzyme Dicer into -22nt mature miRs. One strand of the cleaved, double-stranded miR is 
preferentially incorporated into the ribonucleoprotein RNA-induced silencing complex 
RISC for mRNA targeting, while the other strand is degraded (Figure 1.11). Endogenous 
miRs often exhibit imperfect complementarity to sequences within the targeted mRNAs, 
allowing for miRs to bind to hundreds or even thousands of mRNAs which it regulates. 
MicroRNAs generally target sequences within the 3' untranslated region (UTR) of 
mRNAs, but are not restricted to this area. When predicting targets for miRNAs, it has 
been demonstrated that complementarity of nucleotides in positions 2-8 at the 5' end of 
the mature miRNA, called the 'seed sequence', with the target mRNA 3'UTR is a reliable 
indication of a regulatory relationship between the two RNAs (Bartel 2004). However, 
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more recently it has been demonstrated that sequences flanking the seed sequence, 
nucleotides away from the seed site, and even guidance from miR-associated protein co-
factors can help to dictate miRNA targets (Braun et al. 2011, Licatalosi and Darnell 
2010). Together, this information makes clear the complexity of miRNA function and 
regulation, and that our knowledge of how microRNAs control biological processes is 
limited. 
1.5.2 Myogenic MicroRNAs 
To date there are several miRNAs which have been shown to play important roles 
in the regulation of myogenesis both developmentally and in a regenerative context. 
Some of these miRNAs which are highly enriched in muscle, referred to as 'myomiRs', 
include miR-1, miR-133a, miR-133b, miR-206, miR-208, miR-208b, miR-486, and miR-
499 (Giiller and Russell 2010). MiRs 1, 133, and 206 are the originally identified 
myomiRs, which are encoded in bicistronic transcripts on three separate chromosomes 
(miR-1-1/133a-2, miR-1-2/133a-1 , miR206/133b) (Chen et al. 2009, Liu and Olson 
2010). The expression of these muscle-specific miRNAs are controlled by MyoD, 
Myogenin, and MEF2 factors, and are have been shown to play roles in myoblast 
proliferation and differentiation (Giiller and Russell 2010, Crist and Buckingham 2009, 
Lagos-Quintana et al. 2002; Liu et al. 2007). For example, miR-1 and miR-206 have been 
shown to control Pax7, HDAC4, and other mRNAs in satellite cells to promote 
differentiation (Chen et al. 2010, Crist and Buckingham 2009), while miR-1 and miR-
133a were demonstrated to target MEF2 and serum response factor (SRF) mRNAs to 
promote myoblast proliferation (Chen et al. 2006). 
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Additionally, miRNAs not restricted to muscle-specific expression also play roles 
in myogenesis. For example, miR-27 regulates Pax3 expression during satellite cell 
proliferation (Crist et al. 2009), and miR-29 and miR-181 are upregulated in C2C12 
myoblasts to promote differentiation by targeting YY1 and HoxA11 transcription factors 
respectively (Wang et al. 2008, Naguibneva et al. 2006). Most recently, miR-155 was 
shown to target the 3'UTR of MEF2A to repress skeletal muscle differentiation in C2C12 
myoblasts (Seok et al. 2011), a result which independently corroborates data presented in 
chapters three and four demonstrating loss of differentiation and regenerative capacity of 
skeletal muscle in the absence of MEF2A. 
These and other more broadly expressed miRNAs have been shown to play 
important modulatory roles in a variety of skeletal muscle processes (van Rooij et al. 
2008, Chen et al. 2009). However, only a limited number of miRNAs have been linked to 
the regulation of muscle progenitors in regeneration. As the balance between proliferation 
and differentiation of progenitor cells is known to be carefully orchestrated in muscle 
regeneration (Yan et al. 2003), there likely exists additional miRNAs that modulate this 
process. 
1.5.3 Gtl2-Dio3 MicroRNA Mega-Cluster 
1.5.3.1 Gtl2-Dio3 Cluster Identification and Structure 
The Gtl2-Dio3 microRNA cluster, positioned on mouse chromosome 12 and 
human chromosome 14, represents the largest known mammalian miRNA cluster. This 
region was initially characterized in 2001 by performing human-ovine comparative 
analysis of the 250kb genomic locus to which the muscular hypertrophy callipyge (clpg) 
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mutation mapped in the sheep genome (Charlier et al. 2001). Through this and 
subsequent analyses, it has been shown that this locus encodes a variety of non-coding 
RNAs including miRNAs and small nucleolar RNAs (snoRNAs), most of which are 
exclusively expressed in this imprinted locus from the maternally inherited allele (Hagan 
et al. 2009, Tierling et al. 2006, Seitz et al. 2004, Seitz et al. 2003). In mice, 45 miRNAs 
have been identified within the Gtl2-Dio3 locus, with as many as 110 miRs predicted in 
sheep (Caiment et al. 2010). Within this chromosome 12 locus in mice, miRNAs are 
distributed throughout the 1mb region as several sub-clusters positioned within and 
between other coding and non-coding transcripts (Figure 1.12). These sub-clusters 
include the Anti-Rtll miR127/433 sub-cluster encoded within Anti-Rtll and downstream 
of the non-coding RNA transcript Gtl2, a un-named cluster of miRNAs intergenic to the 
Rian/C/DsnoRNA region and Mirg , and lastly the Mirg miRNA cluster which overlaps 
the Mirg transcript region preceding the protein-coding Dio3 gene at the most 3' end of 
the locus (Kircher et al. 2008). 
1.5.3.2 Gtl2-Dio3 Cluster Regulation and Function 
While transcripts from the Gtl2-Dio3 locus have been primarily characterized to 
have neurogenesis-related functions (Fiore et al. 2009), it has been shown that the non-
coding RNA Gt12 and other transcripts from this locus are highly enriched in both 
skeletal muscle and brain (Han et al. 2011 , Cavaille et al. 2002, Charlier et al. 2001 , C. 
Snyder and F. Naya unpublished data). Furthermore, analysis of the Gtl2 knockout mouse 
by Zhou et al. (2010) as well as deletion of the intergenic differentially methylated region 
(IG-DMR) upstream of the Gtl2 gene (Lin et al. 2007) each revealed defects in skeletal 
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muscle development and differentiation. MicroRNAs encoded downstream the Gtl2 
transcription start site were absent in muscle from these mice as well, implicating a role 
for Gtl2 and the miRNAs of the Gtl2-Dio3locus in myogenesis (Zhou et al. 2010). Mirg 
sub-cluster microRNAs have previously been shown to be important for the 
differentiation of dendrites in the brain (Fiore et al. 2009). Interestingly, studies by Fiore 
et al. (2009) and Song and Wang (2008) suggest that the Mirg miRNAs and miRs of the 
Anti-Rtll cluster are each transcriptionally regulated through separate upstream MEF2 
binding sites. However, evidence provided by Zhou et al. (2010) and others suggest that 
the entire Gtl2-Dio3 locus is coordinately transcribed, arguing for universal regulation 
through cis elements likely upstream of the cluster. However, it remains to be determined 
if the Gtl2-Dio3 microRNAs are transcribed together as a single, large primary transcript. 
1.6 Thesis Rationale 
The goal of this study is to characterize a role for the transcription factor MEF2A 
in skeletal muscle differentiation and regeneration. MEF2 is an evolutionarily conserved 
transcription factor which is required for the differentiation of all three muscle lineages in 
flies (Bouret al. 1995; Lilly et al. 1995). Furthermore, MEF2A loss-of-function analysis 
in mice reveals a role for MEF2A in striated muscle differentiation as these mice die 
suddenly after birth due to right ventricular dilation and myofibrillar fragmentation in the 
heart (Naya et al. 2002). However, analysis of skeletal muscle from these mice indicated 
that MEF2A is not requisite for proper skeletal muscle development (Potthoff et al. 
2007b ). Despite the finding that inactivating mutations in some MEF2 family members 
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result in specific perturbations in skeletal muscle development, a detailed understanding 
of MEF2 function, and in particular MEF2A, in this tissue is far from complete. 
In the present study I explored the function of MEF2A in skeletal muscle. Here I 
report that, unlike embryonic skeletal muscle development, MEF2A is required for 
regeneration in adult mice in response to muscle injury. Muscle injury in MEF2A 
knockout mice resulted in widespread necrosis, attenuated myofiber regeneration, and a 
significant reduction in Pax7-positive muscle progenitors. This impaired injury response 
was associated with a coordinate downregulation of the largest known mammalian 
miRNA cluster, the Gtl2-Dio3 locus, harboring more than 40 miRNAs. A cohort of these 
miRNAs directly targets secreted Frizzled-related protein 2 (sFRP2), an inhibitor of the 
Wnt signaling pathway. Accordingly, I detected an upregulation of sFRP2, as well as 
other sFRPs, in MEF2A-deficient regenerating skeletal muscle along with reduced Wnt 
activity. Finally, overexpression of miRNAs that directly target sFRP2 were able to 
rescue myogenic differentiation in MEF2A-deficient myoblasts. 
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Figure 1.1 The sarcomere: the contractile subunit of striated muscle. Schematic 
showing the cross-striations of a multinucleated skeletal myocyte (top left) and binuclear 
cardiomyocyte (top right), which represents a pattern created by the Z-disc regions from 
sarcomeres arranged end to end in myofibrils (Adapted from Braun and Gautel2011 ). 
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Myonucleus 
Figure 1.2 Skeletal muscle anatomy Representation of the multi-layered anatomy of a 
skeletal muscle. A single muscle cell, called a rnyofiber, is composed of many rnyofibrils 
and is multi-nucleated. The satellite cell, or muscle stern cell, is positioned outside the 
sarcolemma but beneath the basal lamina of each rnyofiber. Many rnyofibers and their 
resident population of satellite cells are bundled together with the vasculature and motor 
neurons to compose an entire muscle (Adapted from Scirne et al. 2009). 
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A. 
Figure 1.3 Skeletal muscle formation Representation of skeletal muscle formation 
during embryogenesis. (A) In mammals and amniotes, segments of the mesoderm called 
sornites (S) are positioned on either side of the neural tube (NT) during neurulation. The 
sornites then differentiate into the sclerotome (SC) and the overlying dermomyotome 
(DM). At this stage, SHH, Wnt, and BMP signals from the surrounding tissues initiate 
expression of Pax3 and Pax7 in myogenic progenitors within the DM. (B) By E10.5 in 
the mouse Pax3 expression is evident in the somite-derived DM segments along the NT 
by in situ hybridization. (C) Next, Pax3+ cells migrate from the dermomyotome to form 
the myotome (My) where progenitors will downregulate Pax3 and initiate differentiation 
as characterized by myosin heavy chain expression (MF20) (Adapted from Yokoyama 
and Asahara 2011 , Mok and Sweetman 2011). 
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Mouse Striated Muscle Development 
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Figure 1.4 MEF2 temporal expression during striated muscle differentiation The 
expression onset of MEF2 factors during mouse embryonic development is shown. The 
pattern of expression in cardiac muscle is shown in black, while a similar expression 
pattern is shown for skeletal muscle approximately one day later in red (Adapted from 
Edmonson et al. 1994, Molkentin et al. 1996b, Gary and Olson 2006). 
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Figure 1.5 Skeletal muscle differentiation Skeletal muscle differentiation is 
characterized by the activation of satellite stem cells from quiescence, which then divide 
and proliferate as myoblasts. Myoblasts can later downregulate the expression of certain 
genes to return to quiescence, or they can further commit to myogenic differentiation by 
exiting the cell cycle. Committed myoblasts are able to fuse with one another to form 
multinucleated myotubes which will mature to generate skeletal myofibers. This process 
is characterized by the sequential expression of a variety of transcription factors which 
carefully orchestrate the progression of differentiation (Adapted from Zammit et al. 
2006). 
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Figure 1.6 MEF2 transcription factor family Vertebrates express four MEF2 proteins, 
MEF2A, B, C, and D. Shown are the human MEF2 family members with the percentage 
of amino acid identity between the MADS, MEF2, and transactivation domains. All 
percentages of amino acid identity are shown relative to human MEF2A (Adapted from 
Potthoff and Olson 2007). 
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Figure 1.7 MEF2A knockout mice exhibit cardiomyocyte dysfunction Evidence of 
cardiac dysfunction in MEF2A knockout mice. Approximately 80% of MEF2A 
knockouts die perinatally due to right ventricular dilation (upper panels) and myofibrillar 
fragmentation (lower panels), whereas the remaining 20% of mice survive to adulthood. 
Photographs (upper panels) and electron micrographs (lower panels) display phenotypic 
differences between wildtype (WT) and Mej2a -1- mice at postnatal day 5. Right atria 
(ra), left atria (la), right ventricle (rv), left ventricle (lv), and mitochondria (m) are 
indicated (Adapted from Naya et al. 2002). 
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Figure 1.8 Muscle regneration timecourse Schematic depiction of skeletal muscle 
regeneration events (upper panel) and Hematoxylin & Eosin staining of tibialis anterior 
(TA) muscle sections over a time course of regeneration (lower panels). Injury-activated 
satellite cells divide to generate daughter satellite cells to maintain the stem cell pool or 
myoblasts which will proliferate and differentiate to regenerate the muscle (upper panel). 
Images of transverse TA muscle sections from control, uninjured muscle (a) as well as 
days 1 (b), 2 (c), 3 (d), 5 (e), 10 (f), and 14 (g) post-injury with cardiotoxin are shown. 
Centrally located nuclei visible in images e-g are a hallmark of regenerating myofibers 
(Adapted from Wallace and McNally 2009, Yan et al. 2003). 
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Figure 1.9 Satellite cell molecular markers Expression of the proteins which 
characterize quiescent and/or activated/proliferating satellite stem cells. M-cadherin 
through CD34 represent cell-surface satellite cell markers, while Pax7, Myf5, and MyoD 
are nuclear expressed transcription factors (Adapted from Charge and Rudnicki 2004). 
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Figure 1.10 Canonical Wnt signaling Overview of canonical Wnt signaling as 
described in the text. When Wnt signaling is active, the Axin2/APC/GSK3~ 'destruction 
complex' is inactivated and ~-catenin translocates to the nucleus to initiate TCF/Lef-
assisted transcription. Inhibitors of Wnt signaling, such as sFRPs, can block transduction 
of Wnt signals through frizzled (Fz) receptors. When Wnt signling is turned off, ~­
catenin is phosphorylated at specific residues by the 'destruction complex' and targeted 
for proteasomal degradation (Adapted from Rao and Kiihl2010). 
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Figure 1.11 miRNA pathway Flow chart of miRNA processing in metazoans post-
transcription. Steps 1-6 occur as described in the text (Adapted from Bartel2004). 
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Figure 1.12 Gtl2-Dio3 miRNA cluster Schematic of the mouse chromosome 12 Gt/2-
Dio3 locus. Relative positions of individual rniRNAs within the cluster are indicated. 
rniRNA families are also shown (Adapted from Kircher et al. 2008). 
2.1 Cell Culture 
2.1.1 Cell Lines 
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CHAPTER2 
Materials and Methods 
C2C12 myoblast, COS1, and 293A cell lines were maintained in Dulbecco's 
Modified Eagle Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine 
serum (FBS, Atlanta Biologicals), and 1% Penicillin/Streptomycin/L-glutamine 
(Invitrogen), referred to as growth media. Cells were maintained in growth media in a 
37°C humidified incubator with 5% C02. At subconfluency, adherent cells were 
passaged by washing once with 1x phosphate-buffered saline (PBS), application of 2ml 
Trypsin-EDTA (Invitrogen) for 2 minutes, and resuspending cells in 8rnl growth media. 
Cells were passaged at a 1:10 or 1:20 dilution for maintenance of cell lines. For 
differentiation assays, C2C12 cells were transduced or transfected at subconfluency, 
switched to differentiation media (DMEM with 2% horse serum and 1% 
Penicillin/Streptomycin/L-glutamine) 24 hours later, and allowed to differentiate in 
culture for one to five days, unless otherwise specified. 
2.1.2 Isolation of Primary Myoblasts 
Primary skeletal myoblasts and single myofibers were isolated from uninjured or 
cardiotoxin-injured adult mouse hindlimb muscle three or seven days post-injury. 
Isolated muscle tissue (extensor digitorum longus, EDL; or gastrocnemius) was 
immediately digested in Hanks Balanced Salt Solution (HBSS, Invitrogen) supplemented 
with lOmg/rnl collagenase type 2 (Worthington) and 5mM CaClz for two hours at 37°C 
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with rotation. Single-cell suspensions were obtained by gravity filtration through sterile 
100~-Lm cell strainer filters (BD Falcon). Isolated myofibers or single-cell suspensions 
were centrifuged for 4 minutes at 1000 rpm, and the collagenase-containing supemantant 
was removed by gentle aspiration. Cells were then resuspended in DMEM supplemented 
with 20% PBS, 1% Penicillin/Streptomycin!L-glutamine, and 2.5ng/ml basic fibroblast 
growth factor (bFGF, Atlanta Biologicals), referred to as 2X media. Primary cells were 
pre-plated on non-coated cell culture dishes and then transferred to plates coated with 
0.05mg/ml type I rat-tail collagen (BD Biosciences). Cells were cultured in DMEM 
supplemented with 20% PBS, 1% Penicillin/Streptomycin/L-glutamine, and 2.5ng/ml 
basic fibroblast growth factor (bFGF, BD Biosciences) to enrich for myoblasts. Media 
was not changed for the first 48 hours post-isolation, at which time primary myofibers or 
primary myoblasts were transferred to collagen-coated coverslips for immunostaining 
(see section 2.10.1.1). For other experiments, cultures were first enriched for primary 
myoblasts. To enrich for myoblasts, primary cell cultures were trypsinized for 30 
seconds, resuspended gently in 2X media, and passaged at a 1:2 dilution onto fresh 
collagen-coated plates. Five to six myoblast-enriching passages were performed before 
using primary myoblasts in differentiation experiments. Primary myoblasts were induced 
to differentiate in the same manner as C2C12 cells (described in section 2.1.1). 
2.2 Recombinant DNA Techniques 
2.2.1 Preparation of DHSa Competent Cells 
DH5a strain Escherichia coli (E. coli) cells were made chemically competent for 
transformation with recombinant DNA using the following protocol. DH5a E. coli cells 
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were streaked onto a Luria Broth (LB) agar plate (lOg/L casein peptone, 5g/L yeast 
extract, 5g/L NaCl, 15g/L agar) and grown overnight at 37°C. A single colony was 
picked from this plate and used to innoculate a 3rnl LB liquid culture (1 Og!L casein 
peptone, 5g/L yeast extract, 5g/L NaCl). Small E. coli cultures were grown 18-24 hours 
in a shaking incubator at 37°C, and then used to innoculate a 200rnl LB culture. E. coli 
cells were further grown to early log phase, shaking at 37°C for an additional 3 hours. 
Cells were pelleted by centrifugation at 4000rpm for 5 minutes at 4°C. Pelleted cells were 
resuspended in 20rnl of pre-chilled 10nM NaCl, and an additional 80rnl of chilled 
1 OOmM CaCh was added for a final volume of 1 OOrnl. Cells were incubated on ice for 
30-60 minutes, pelleted by centrifugation at 4000rpm for 4 minutes at 4°C, and 
resuspended in filter-sterilized, pre-chilled 17rnl 100mM CaCh with 3rnl 100% glycerol. 
Resuspended DH5a E. coli were aliquoted in 100~1 volumes to 1.5rnl microcentrifuge 
tubes, snap frozen in liquid nitrogen, and stored at -80°C. 
2.2.2 Transformation of DHSa Cells 
Frozen aliquots of chemically competent DH5a E.coli cells were thawed on ice. 
In a separate microcentrifuge tube, 10~1 of cells were pre-incubated with ::::J~g plasmid 
DNA (1-2~1) for ten minutes on ice. Competent cells were then "heat-shocked" in a 42°C 
water bath for 30 seconds to permeabilize the bacterial cell membranes and facilitate 
introduction of plasmid DNA into the cells. Fresh LB (lrnl; 250~1 for cloning ligations) 
was immediately added to transformed bacteria, cells were incubated on ice for 10 
minutes, and allowed to recover for one hour at 37°C with shaking. Approximately 250~1 
of transformed bacteria were plated on LB agar plates containing the appropriate 
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antibiotic (Amp 100 !J,g/ml, Kan 50 j..Lg/ml) to select for clones harboring the transformed 
plasmid. Plates were incubated overnight at 37°C, and single colonies were picked the 
following day to inoculate 3ml LB liquid cultures (with antibiotic). Liquid cultures were 
then used for DNA isolation and preparation (see section 2.2.3). 
2.2.3 DNA Preparation 
DNA isolation and preparation was performed by alkaline lysis of transformed 
DH5a E. coli cells. For small-scale DNA preparation (minipreps), 1.5ml of 3ml 
overnight cultures was centrifuged at 13000 rpm for 1 minute at room temperature (RT). 
The pellet was resuspended in 100!J,l of Solution #1 (50 mM glucose, 10 mM EDTA pH 
8.0, 25 mM Tris), and then lysed in 200!J.l of Solution #2 (0.2 M NaOH, 1% SDS) for 
precisely 4 minutes. Cell lysis was stopped by addition of 150!J,l Solution #3 (3M 
potassium acetate, 11.5% glacial acetic acid). Cell lysates were then separated into 
organic and aqueous phases by addition of 400!J,l 1:1 phenol: chloroform, and mixed 
thoroughly. The upper aqueous layer containing nucleic acids was removed and 
transferred to a new tube, while the lower organic phase was discarded. DNA was 
precipitated by adding 2X volumes of cold 100% ethanol and centrifuged at 13000rpm 
for 10 minutes at 4°C. DNA pellets were washed with 70% ethanol, centrifuged as 
before, and inverted to allow the DNA to dry. Dried pellets were resuspended in 20!ll 
Baxter water (sterile water for irrigation, Pharmaceutics) with 0.1mg/ml RNase and 
incubated at 37°C for 15 minutes. For large scale DNA preparation (midipreps) 
Nucleobond midiprep columns were used and DNA was isolated according to the 
manufacturer's instructions. DNA preparations were stored at -20°C. 
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2.2.4 Cloning 
For routine cloning, DNA insert fragments and vector backbone DNA were 
prepared for subcloning by digestion with restriction endonucleases (New England 
Biolabs). Generally, lJ..Lg of DNA was digested for 1 hour at 37°C with restriction 
endonucleases and the appropriate buffer, according to the manufacturer's instructions. 
Following digestion, 6X loading dye (0.7% xylene cyanol, 0.5% bromophenol blue, and 
60% glycerol in deionized water [dH20]) was added to an approximate final 
concentration of lX and samples were electrophoresed on 0.8% agarose gels (Amersham) 
containing ethidium bromide in lX TAE buffer (40mM Tris, 50mM sodium acetate, 
lmM EDTA, pH 8.0) at 120V for approximately 20 minutes. DNA gels were visualized 
and photographed under ultraviolet (UV) light. Desired DNA bands were excised from 
the gel and purified on QIAquick columns using the QIAquick Gel Extraction kit 
(Qiagen) according to the manufacturer's instructions. Purified DNA fragments were 
eluted in 30J..Ll of elution buffer (QIAquick Gel Extraction kit) for use in ligation 
reactions. Generally, ligations were performed using a 5:1 ratio of restriction enzyme-
digested insert DNA to vector DNA: l6Jll (-250ng) insert DNA, lJll (-50ng) vector 
DNA, 2.5J..Ll lOX T4 DNA ligase buffer, and lJ..Ll T4 DNA ligase (New England Biolabs) 
in a 25!11 total volume with dH20. Ligations were incubated at 16°C in a thermocycler 
for 18-24 hours, prior to use in DH5a E. coli transformation reactions. 
2.2.5 Polymerase Chain Reaction (PCR) 
2.2.5.1 PCR for Cloning 
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For amplification of DNA fragments from genomic or copy DNA (eDNA), the 
Expand Long Template PCR system with high fidelity Taq polymerase (Roche) was 
used. In general, lJ..Lg of template DNA was used in a 25J..Ll PCR containing 2.5J..Ll lOX 
polymerase buffer #2, 2J..Ll of 2.5mM dNTP mixture (New England Biolabs), lJ..Ll of 25J..LM 
primer mix (1:2:1 ratio of lOOJ..LM forward primer: Baxter water: lOOJ..LM reverse primer), 
0.5-l.OJ..Ll of Taq polymerase, and Baxter water. Samples were placed in a thermocycler 
(MJ Research) and subjected to a PCR program customized to the size of the DNA 
fragment being amplified and the melting temperature (T m) of the primers used in the 
reaction. A typical PCR program is as follows: 94°C for 4 minutes, 94°C for 30 seconds, 
57°C for 30 seconds (temperature varies with primer Tm), and 68°C for 30 seconds (time 
varies with size of the amplified fragment -1 minute per kB ). Steps 2-4 were repeated 29 
times for a total of 30 cycles, and a final extension was performed for 10 minutes at 
68°C. Samples were held at 4°C until removed from the thermocycler. 
2.2.5.2 Site-Directed Mutagenesis 
Site-directed mutagenesis was performed using overlap extension PCR for the 
generation of expression plasmids possessing mutated eDNA sequences. Initially, two 
PCR products were generated from the unmutated eDNA template in separate PCR 
reactions. One reaction used a primer mix of a forward universal primer and a reverse 
mutagenic primer, while the other reaction used a reverse universal primer and a forward 
mutagenic primer. Both mutagenic primers hybridized to the same sequence and induced 
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the same mutation(s), but were oppositely oriented to amplify different halves of the 
desired eDNA fragment. Each PCR reaction was carried out in a 25!!1 reaction volume 
containing 1!lg of template DNA, 2.5!ll lOX Thermo buffer (New England Biolabs), 2!ll 
of 2.5mM dNTP mixture (New England Biolabs), 1!ll of 25!lM primer mix (1:2:1 ratio of 
100~-LM forward primer: Baxter dH20: 100~-LM reverse primer), 0.5-l.O!ll of Taq 
polymerase (New England Biolabs), and Baxter water. The PCR reactions were run on 
thermocycler programs as described in section 2.2.5.1. PCR products from these 
reactions (reactions #1 and #2) were electrophoresed on a 0.8% agarose gel containing 
ethidium bromide in 1X TAE buffer at 120V for approximately 20 minutes. Gels were 
imaged under UV light, and the appropriate size bands corresponding to the halves of the 
eDNA fragment amplified were excised and gel extracted using the QIAquick gel 
extraction kit as described previously (section 2.2.4). These purified PCR products were 
then used as template DNA sequences for subsequent overlap extension PCR. Equal 
amounts of DNA fragments #1 and #2 0!!1 each) were combined to form a duplex DNA 
template, and then mixed with 2.5!ll lOX Thermo buffer (New England Biolabs), 2!ll of 
2.5mM dNTP mixture (New England Biolabs), 1!ll of 25!lM universal primer mix (1:2:1 
ratio of 100~-LM forward universal primer: Baxter water: 100~-LM reverse universal 
primer), 0.5-l.O!ll ofTaq polymerase (New England Biolabs), and Baxter water to a final 
volume of 25!!1. The thermocycler PCR program was run as before. The full-length 
mutated PCR product was electrophoresed on a 0.8% agarose gel as described above. The 
appropriate size band was extracted using the QIAquick gel extraction kit, and then 
subjected to digestion with restriction endonucleases (New England Biolabs) prior to 
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ligation into a destination vector as described in section 2.2.4. Mutations in eDNA 
sequences were confirmed after midiprep column purification through DNA sequencing 
(MWG Operon). 
2.2.6 Plasmids and miRNA Mimics 
MEF2A-FLAG and MEF2C-FLAG expression plasmids were generated by 
subcloning full-length mouse cDNAs into pCMV-tag4 (C-terminal FLAG epitope, 
Invitrogen), using Hindiii/Xhoi and BamHI/Xhoi restriction enzyme sites, respectively. 
MEF2B-FLAG and MEF2D-FLAG (human) were kind gifts of T. Gulick (Sanford 
Burnham Medical Research Institute). The mouse Gtl2 proximal promoter (516 bp) 
containing the MEF2 consensus binding site was cloned into the pGL3-Basic (pGL3b, 
Promega) promoter-less luciferase reporter plasmid using the Mlui/Nhei restriction 
enzyme sites. The mutant Gtl2 reporter was generated by mutating the CTT sequence of 
the -39 MEF2 site to GGG by overlap extension PCR without altering the overlapping 
TATA box (pGL3b-39MUT). For miRNA mimic assays, the 3'UTR (892 bp) of mouse 
sFRP2 (NM_009144.2; nts 1109-2000) was cloned into pMIR-REPORT (Ambion) using 
the Mlui/Spei restriction enzyme sites. The mutant pMIR-REPORT-3'UTR-sFRP2 
construct was generated by mutating the miR-410 seed sequence binding site TIATAT 
(nts 1961-1966) to GGGGGG. pMIR-REPORT-~-galactosidase (Ambion), pCMV-
Renilla-luciferase, and pTOPFLASH (Addgene) were also used for luciferase assays. 
MiRNA mimics (Negative control #1, mmu-miR-540-5p, mmu-miR-433, mmu-miR-410) 
were purchased from Ambion. MiRNA mimic 540-5p was used as the non-specific 
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control miRNA molecule in sFRP2-3'UTR reporter assays, as miR-540-Sp does not 
target sFRP2. 
2.3 shRNA Design and Expression 
The BLOCK-iT™ U6 RNAi Entry Vector Kit and Adenoviral RNAi Expression 
System (Invitrogen) were used to generate adenoviruses harboring short-hairpin RNAs 
(shRNAs) for use in RNA interference (RNAi) assays. 
2.3.1 shRNA Design 
Short-hairpin RNA oligonucleotides specific for MEF2A or LacZ were designed 
using the BLOCK-iT™ RNAi designer system (Invitrogen). MEF2A shRNAs (shMef2A) 
were designed against mouse MEF2A mRNA sequence (NM_001033713.1) using the 
BLOCK-iT™ RNAi designer algorithm 
(http://maidesigner.beta.invitrogen.com/maiexpress/). Based on the input mRNA 
sequence, 10 MEF2A shRNAs were suggested by Invitrogen. Single stranded DNA 
oligonucleotides were ordered for four MEF2A shRNAs based on the position of their 
target sequences within the 3' coding region of MEF2A, inclusion of the target sequences 
in all splice variants, and evolutionary conservation of these sequences between mouse, 
rat, and human MEF2A mRNAs. These four shRNAs were initially named for the 
position of the first nucleotide they targeted in the MEF2A mRNA sequence; their target 
sequences follow (5'73'): GTGACTTCCATTCTCCAATT (#1481), 
CAAAGTCATGCCTACAAAGT (#822), CAAAGTCATGCCTACAAAGT (#1073), 
GACTAGTGTACTCAGCAATG (#1306). Pre-validated, single-stranded DNA 
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oligonucleotides for the LacZ shRNA were included with the BLOCK-iT1M U6 RNAi 
Entry Vector Kit (Invitrogen). 
2.3.2 shRNA Cloning and Selection 
Single-stranded DNA oligonucleotides containing shRNA stem-loop sequences 
were annealed and ligated into the pENTR ™/U6 RNAi entry vector according to the 
manufacturer's instructions (Invitrogen). Ligated pENTR1M/U6-shRNA plasmids were 
then transformed into DH5a E. coli as described in section 2.2. Kanamycin-resistant 
colonies were picked, miniprepped, serially digested with Xbal and Kpnl restriction 
enzymes, and electrophoresed on a 2.5% agarose gel for 1.5 hours. Inserts were 
detectable and were - 325 bp in size. Several correct clones were purified and sent for 
sequencing (MWG Operon) using the U6 forward and M13 reverse primers, with 
optimization for sequencing hairpin DNA structures. MEF2A shRNAs and the LacZ 
shRNA (negative control) clones with correct shRNA sequences were then used in 
transient transfection assays in COS 1 cells to determine MEF2A knockdown efficacy. 
Briefly, COS 1 cells were co-transfected with pENTR 1M/U6-shRNA and a mouse MEF2A 
expression plasmid (pcDNA3-MEF2A), 48 hours post-transfection COS 1 cells were 
harvested, and protein extracts were subjected to western blotting. Immunoblot analysis 
with the MEF2 antibody (C-21, Santa Cruz Biotechnology) indicated that MEF2A 
shRNA #1306 caused the greatest level of MEF2A expression knockdown (Figure 2.1). 
As a result, MEF2A shRNA #1306 was selected for use in all subsequent MEF2A 
knockdown experiments, and hereafter will be referred to as shMef2A. 
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For the generation of adenovirus, shMef2A and shLacZ inserts from pENTR-U6-
shRNA plasmids were used in LR recombination reactions with the pAd/BLOCK-iT-
DEST vector to recombine the shRNAs from the pENTR plasmids into pAd vetors. LR 
recombination reactions were performed using the reagents and instructions provided 
with the Adenoviral RNAi Expression System kit (Invitrogen). The recombination 
reactions were transformed, plated, and picked colonies were tested on antibiotic-
selection plates to determine the success of plasmid recombination. Clones able to grow 
on Ampicillin, but not Chloramphenicol, indicated successful recombination due to 
replacement of the adenoviral Chloramphenicol-resistance cassette with the shRNA 
oligonucleotide sequence. Positive expression clones were midiprepped and used for the 
generation of adenovirus. 
2.3.3 Generation of Crude Adenovirus 
To generate crude adenovirus, the adenoviral shRNA-expression clones 
(pAd/BLOCK-iT-DEST-shRNA) were digested with Pacl in a 30 fll reaction for 5 hours 
at 37°C (10 flg of DNA and 3 f.!l of enzyme were used). The reaction was then 
phenol/chloroform extracted, EtOH precipitated and resuspended gently in 30fll of dH20 
so as not to compromise the DNA integrity. Pacl-digested DNA (ljlg) was transfected 
into 293A cells (-300,000 cells per 35mm dish) using Fugene transfection reagent 
(Promega) at a 3:1 ratio of Jll FuGENE to jlg DNA. Growth media was changed 24 
hours post-transfection, and 48 hours post-transfection the cells were trypsinized and 
transferred to a 1 OOmm plate. These cells were maintained in growth media (changed 
every 2-3 days) at 37°C with 5% C02 for approximately three weeks until -80% of cells 
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exhibited cytopathic effect (CPE- cell death characterized by loss of surface adhesion). 
Cells containing crude adenovirus were removed from the plate, with their media, by 
gently pipetting up and down. The cells and media were then transferred to 15rnl conical 
tubes, and intact cells were lysed to yield adenovirions through three freeze-thaw cycles 
(-80°C 30 minutes, 37°C 15 minutes). Cell debris was pelleted at 3000 rpm for 15 
minutes at RT and the supernatant containing crude adenovirus was aliquoted into 
cryovials and stored at -80°C. Original crude adenoviral stocks were used for all 
subsequent adenoviral amplification for purification. 
2.3.4 Adenovirus Purification 
To prepare adenovirus for purification, crude adenovirus was first amplified by 
transducing fifty 293A cell plates ( -300,000 cells per 1000mm plate) with 100j..tl of crude 
viral stock. All transduced plates typically showed 80-100% CPE within 48 hours , and 
the cells with their media was then pooled into 250rnl Nalgene bottles. The detergent 
NP40 was added to the bottles at a final concentration of 0.5%, and the bottles were 
shaken gently at RT for 10 minutes to lyse the cells. Cell debris was pelleted by 
centrifugation at 20,000 x g for 15 minutes, and the supernatant containing adenovirus 
was transferred to new sterile Nalgene bottles. To the supernatant, 0.5 volume of 20% 
PEG 8000/2.5M NaCl (for 100 rnl, add 50 rnl PEG/NaCl) was added and the mixture was 
shaken on ice for one hour. Virus was precipitated by centrifugation at 20,000 x g for 15 
minutes and the supernatant was discarded into bleach solution. The viral precipitate 
visible on the wall of the bottle (two white stripes) was resuspended in a small amount (-
4rnl) of 1X PBS. Anhydrous CsCl was added to the viral suspension at a final density of 
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1.34g/ml. The -5 ml volume was loaded into an ultracentrifuge tube (Perkin Elmer) and 
spun in a Vti90 rotor at 70,000 rpm, 18°C, for 18-24 hours. The viral band was extracted 
from the ultracentrifuge tube by piercing the side of the uncapped tube with a 1ml syringe 
and 22 gauge needle, slowly removing the largest white band containing intact virus, and 
transferring the pulled band (:S2ml) to a sterile falcon tube on ice. Viruses were then 
desalted by dialysis. An 8-inch length of dialysis tubing (2 Spectra/Par Dialysis 
Membrane, MWCO: 12-14,000, Spectrum Labs) was tied off at one end, and the viral 
solution pipette into the opposite end. The virus inside the dialysis tubing was incubated 
in dialysis solution (lOmM Tris-HCl pH 8.0 autoclaved, 1mM MgCh, 10% glycerol) at 
4°C for 2-3 hours. Three rounds of dialysis were completed. The solution containing the 
virus was then aliquoted and frozen at -80°C. 
2.3.5 Adenovirus Titering 
Adenoviral titer (plaque forming units per milliliter; pfulml) was determined 
using the End Point Dilution Assay as described in the AdenoX™ Tet Expression 
Manual (Clontech). This assay was performed in duplicate on 96-well plates. Twenty 
thousand 293A cells were seeded per well in 100J..ll media onto two 96-well plates. 
Twenty four hours post-plating, the purified adenoviral stock was serially diluted in 
100J..ll volumes and added to the wells containing cells. Specifically, eight 1:10 serial 
dilutions of virus were made ranging from 10·3 to 10·10. One hundred J..ll of each viral 
dilution was then added to 10 wells in one row (A-H), each row possessing a different 
viral dilution. The last two wells in each row received 100J..ll virus-free media to serve as 
negative controls. The plates were then incubated at 37°C for 10 days, and each well was 
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scored for the presence of CPE. The fraction of CPE-positive wells for each dilution ( 10-1 
to 10-10) was added to determine value "X". So long as fraction of CPE-positive wells for 
row H containing the highest concentration of virus (10-3) was 1, all lesser dilutions (10-\ 
10-2) were also considered to have a CPE-positive fraction of 1. Value "X" was then used 
to calculate the titer according to the Spearman-Karber method, where the formula used 
was 1 o X+O.s to provide the number of pfu/rnl for the purified viral stock. 
2.3.6 Adenovirus Transduction 
For RNAi knockdown experiments, adenoviruses harboring shRNAs were used to 
transduce, or infect, mammalian cells in culture. In all transduction experiments, 
mammalian cells (COS1, C2C12, or primary myocytes) were plated 24 hours in advance. 
Cells were transduced at sub-confluency at a multiplicity of infection (MOl) of 25 for all 
experiments, such that 25 viral particles were delivered per cell. To determine the volume 
of purified viral stock to add to the culture medium to achieve an MOl of 25, cells from 
an extra counter plate were trypsinized and counted to determine the approximate cell 
count in each experimental plate. The counter plate for each experiment was seeded at the 
same time as the experimental plates, with the same number of cells, but was not used in 
the experiment after trypsinization due to poor cell survival. The total cell count for each 
plate was then used to determine the volume of virus to use in the experiment: 
(MOI)(cell #)/(pfu/rnl). The viral titers for purified viruses were as follows: shLacZ 
1 x 1011 pfu/rnl, shMef2A 1.4x 1010 pfu/rnl. Purified viral stocks were diluted in pre-
warmed growth media or serum-free media and added directly to medium on the cell 
60 
plates. Transduced cells were incubated 18-24 hours at 37°C with the virus before the 
media was changed and the virus removed. 
2.4 Transfection Techniques 
2.4.1 General Plasmid Transfection 
General transfection of expression vectors for expression in mammalian cell lines 
was performed for all experiments through lipid-mediated plasmid delivery. For plasmid 
transfections, three different types of lipid-mediated transfection reagents were used: 
FuGENE (Roche), Trans-iT (Mirrus), and Polyethylenimine (PEl; Polysciences, Inc). In 
general, cells were seeded on cell culture dishes 24 hours prior to transfection such that 
they would be 40-70% confluent at the time of transfection, and the level of serum 
present in the media would be reduced. FuGENE was used at a 3:1 ratio (j..tl FuGENE to 
j..tg plasmid DNA) in both COS1 and C2C12 cells, while Trans-iT was used at a 3:1 ratio 
in C2C12 cells but a 1.5:1 ratio in COS1 cells. PEl was used at a ratio of 6:1 for all cell 
lines. For all transfections, the transfection reagent (pre-warmed to RT) was added 
directly to pre-warmed serum-free DMEM (100j..tl sfDMEM per 1j..tg DNA being 
transfected) in a sterile eppendorf tube, and incubated at RT for 5 minutes. DNA to be 
transfected was then added to the transfection reagent/sfDMEM mixture and incubated at 
RT for 15 minutes. Complexed DNA and transfection reagent in sfDMEM was then 
added dropwise to cell culture plates seeded 24 hours prior. Transfected cells were 
incubated 36-48 hours at 37°C before harvesting. 
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2.4.2 MicroRNA Mimic Transfection 
For the transfection of miRNA mimics (Ambion), lipid-mediated transfections 
were preformed using RNAiMAX Lipofectamine transfection reagent (Invitrogen). For 
luciferase assays in COS 1 cells analyzing the effects of miR mimics 3 'UTR of sFRP2, 
COS1 cells were reverse transfected at the time of plating. The transfection reagent/DNA 
mixture was prepared directly in each well of a 24-well cell culture plate to be transfected 
by adding 100111 OptiMEMI (commercial serum-free media, Invitrogen), 20ng of pMIR-
REPORT-3'UTR-sFRP2, 200ng of pMIR-REPORT-~gal (transfection control), and 
7.5!11 of 10!lM miR mimics (for a final concentration of 150nM), and 1111 RNAiMAX 
transfection reagent. For miR-410/miR-433 combined transfections, 3.25!11 of each 101-LM 
miR mimic stock were combined for a final concentration of 150nM. The transfection 
mixture was incubated at RT for 10-20 minutes. COS 1 cells resuspended in antibiotic-
free media (DMEM with 10%FBS only), and 40,000 cells in 400!11 volumes were plated 
per well on top of the transfection mixture (500!11 total final volume). Wells were mixed 
by swirling, and incubated 24-36 hours at 37°C prior to harvesting the cells for luciferase 
assays. MiRNA mimics used for these experiments included miR-540-5p (non-specific 
control miR not predicted to target sFRP2, product ID: PM12562), miR-410 (product ID: 
P11119), miR-433 (product ID: PM10774). All miR mimics were obtained from Ambion. 
For MEF2A knockdown rescue experiments in C2C12 cells, RNAiMAX was 
used to perform forward transfections using miR mimics from Ambion. C2Cl2 cells 
were plated in antibiotic-free DMEM at a density of 100,000 cells per well on 6-well 
plates and immediately transduced with shLacZ or shMef2A adenovirus at MOl 25. 
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Cells were then incubated at 37°C for 24 hours, after which the media was changed to 
antibiotic-free differentiation media (see section 2.1.1). C2C12 cells were then 
transfected with miR mimics as follows: In a sterile eppendorf tube 500J..ll OptiMEMI, 
4.4!!1 10!!M miR mimic (20nM final concentration), and 4.4!!1 RNAiMAX were 
combined and incubated at RT for 30 minutes. For miR-410/miR-433 combined 
transfections, 2.2111 of each 1 O!!M miR mimic stock were combined for a final 
concentration of 20nM. The transfection mixture was then added dropwise to each well 
of cells. MiRNA mimics used for these experiments included miR-negative control #1 
(non-specific control miR, cat#: AM17110), miR-410 (product ID: P11119), rniR-433 
(product ID: PM10774). All miR mimics were obtained from Ambion. 
2.5 Cell-Based Assays 
2.5.1 Luciferase Assays 
For COS1 experiments, luciferase assays were performed 24-36 hours post-
transfection using Luciferase Assay Reagent (LAR, Promega), and results were 
normalized by ~-galactosidase assay (section 2.5.2). For TOPFLASH luciferase assays, 
C2C12 cells were differentiated for three days post-transfection and subjected to 
luciferase assay using LARII (Promega) and normalized by Renilla luciferase assay 
(Promega). Allluciferase assays were performed in triplicate (N>3). 
Cells were harvested for luciferase assays at the times specified above following 
transfection. Cells were washed with 1X PBS and lysed in 1X passive lysis buffer 
(Promega) by shaking for 15 minutes at RT. To measure luciferase activity in COS 1 
cells, 5J.!l of each cell lysate was removed and placed into a well of an opaque-sided 96-
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well plate. Firefly luciferase activity was then measured by adding 30j..t.l of LAR to each 
well containing cell lysate, and performing 10 second measurements of the light 
absorbance in each well on a Perkin Elmer Victor III fluorescent/luminescent plate 
reader. To measure luciferase acitivity of the TOPFLASH plasmid in C2C12 cells at 
differentiation day three, celllysates were prepared in a 96-well plate described above. 
Firefly luciferase activity was then measured by adding 30j..t.l of LARII to each well 
containing cell lysate, and performing 10 second measurements of the light absorbance in 
each well on a Perkin Elmer Victor III fluorescent/luminescent plate reader. Following 
the first reading, 30 j..t.l of lX Stop and Glo reagent (Promega) was added and Renilla 
luciferase measurements were taken. Firefly luciferase relative light unit (RLU) values 
were then normalized to Renilla RLU values, and fold change in activity over reporter 
alone was calculated for each sample. 
2.5.2 Beta-galactosidase Assays 
To determine the transfection efficiency of each cell lysate sample used for 
luciferase assay, ~-galactosidase (~gal) assays were performed in 96-well plates. To 
measure ~gal activity, 15!-11 of cell lysates prepared for luciferase assay (see section 
2.5.1), were added to 1.5ml microcentrifuge tubes. A reaction master mix was then 
prepared from 15!-11 lOX Z-buffer (lOOmM NaH2P04, lOmM KCl, lmM MgS04), 16.5!-11 
8mg/ml ONPG, 103.5!-11 dH20, and 0.27!-11 1M ~-mercaptoethanol per sample and 135!-11 
of the master mix was added to each tube containing cell lysate. The ~gal enzymatic 
reaction was allowed to proceed 37°C in a water bath until a slight yellow color appeared 
(evidence of ONPG cleavage). To stop the reaction, 250!-11 of 1M Na2C03 was added to 
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each tube, and 200Jll of each reaction was transferred to a 96-well plate. The light 
absorbance of each well at a 415nm light wavelength was then measured on a microplate 
reader (Model 550, Bio-Rad) using Microplate Manager ill software. ~gal absorbance 
readings were then used to normalize firefly luciferase readings using LAR (see section 
2.5.1). 
2.5.3 Bradford Assays 
To determine protein concentrations of cell extracts, Bradford assays were 
performed in 96-well plates. A BSA (bovine serum albumin) standard curve was 
established by preparing six samples containing total BSA protein equal to 0.2f.lg, 0.5f.lg, 
l.Of.lg, 2.5f.lg, 5.0f.lg, and lO.Of.!g. BSA standards and protein samples were aliquoted to 
individual wells of a 96-well plate in lOf.!l volumes. 200Jll of IX Bio-Rad Protein Assay 
Buffer (dye reagent which turns blue in the presence of protein) was added to each well 
containing standards and protein extracts and an additional to a blank well (no protein 
extract). Plates were read at 595nm light wavelength on a microplate reader (Model 550, 
Bio-Rad) using Microplate Manager III software. Values were recorded for blank, 
standard curve, and sample wells. The standard curve plot was generated in Excel, with 
known BSA protein concentrations on the X axis and corresponding absorbances on the 
Y axis. A best-fit linear trend line was assigned to the plot, and the equation for the slope 
of the line (y=rnx+b) was used to solve for the unknown concentrations of the samples 
("x"), where "y" represents the absorbance value, "m" represents the slope of the line, 
and "b" represents the y-intercept value. 
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2.5.4 Chromatin Immunoprecipitation (ChiP) 
For immunoprecipitation of mouse MEF2A protein associated with chromatin 
containing the -39 bp MEF2 site within the Gtl2 promoter region, ChiP assays were 
performed on C2C12 myotubes. C2C12 myoblasts were plated on 1000mm cell culture 
dishes and transfected with 3j..lg of a FLAG epitope tagged mouse MEF2A expression 
plasmid (pcDNA3-MEF2A-FLAG). Twenty four hours post-transfection, C2C12 cells 
were switched to differentiation media (see section 2.1.1) and allowed to differentiate in 
culture for three days. On differentiation day three, myotubes were fixed with 1% 
paraformaldehyde (270j..ll of 37% PFA to lOml media) to cross-link proteins bound to 
DNA for 10 minutes at RT. This reaction was stopped by adding 385j..ll of 2.5M glycine 
(Sigma) and incubating the cultures at -20°C for 10 minutes. Cells were then washed 
twice with chilled 1X PBS and scraped from the plate in lml cold lX PBS plus protease 
inhibitors (lmM DTT, lmM PMSF, and 1X Roche inhibitor cocktail). Cells were 
pelleted by centrifugation at 2000rpm for 4 minutes at 4 oc. The supernatant was 
discarded and the cell pellet was resuspended in 800J..Ll SDS lysis buffer (1 % SDS, 10 
mM EDTA, 50 mM Tris-HCl pH 8.1) plus protease inhibitors and incubated on ice fo r 10 
minutes. The samples were then sonicated using a sonifier for 10 seconds at 25% 
amplitude and 4°C, with all samples kept on ice for at least 2 minutes between each of 
four rounds of sonication. Sonication was used to shear the chromatin into 250bp- 1kb 
fragments, as confirmed by electrophoresis on a 1.5% agarose gel. Sheared chromatin 
samples were then centrifuged at 13000rpm for 10 minutes at 4°C and diluted 10 fold in 
ChiP dilution buffer plus protease inhibitors (0.01% SDS, 1.1 % Triton X-100, 1.2mM 
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EDTA, 16.7mM Tris-HCl pH 8.1, 167mM NaCl, 1mM DTT, 1mM PMSF, 1X Roche 
inhibitor cocktail). One percent of the total volume was removed to serve as the input 
DNA sample. Then 80)ll of Protein A Agarose/Salmon Sperm DNA/BSA 50% Slurry 
was added to samples and incubated for 30 minutes to 1 hr at 4 °C with rotation. Samples 
were centrifuged at 13000 rpm for 30 seconds to 1 minute at 4 °C. The supernatant was 
put in new tube and the immunoprecipitating antibody was added (2)lg for anti-HA 
[negative control, Sigma], 2)lg or 4)lg for anti-MEF2 [Santa Cruz Biotechnology] , 4)lg 
for FLAG [Sigma]) and incubated overnight at 4°C with rotation. The following day, 
60)ll of 50% slurry was added and incubated at 4°C for 1 hour with rotation. Samples 
were centrifuged at lOOOrpm for 1 minute at 4°C and the supernatant was discarded. 
Successive washes were performed at 4°C for 3 to 5 minutes with rotation using ChiP 
Wash Buffer #1 (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 8.1, 
150mM NaCl), ChiP Wash Buffer #2 (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM 
Tris-HCl pH 8.1, 500mM NaCl), ChiP Wash Buffer #3 (0.25M LiCl, 1% NP40, 1% 
Deoxycholic Acid [w/v], 1mM EDTA, 10mM Tris-HCl pH 8.1) and two washes with TE 
buffer at room temperature. Between each wash step, samples were centrifuged for 1 
minute at 1 OOOrpm and the supernatant was removed. Following the last wash, 250).!1 of 
freshly prepared elution buffer (1 % SDS, 0.1M NaHC03) was added and the sample was 
vortexed and incubated at RT for 15 minutes with rotation. Samples were centrifuged at 
1000 rpm for 1 minute at RT. The supernatant was transferred to a fresh tube. Elution 
was repeated and 20)ll 5M NaCl was added to the combined eluates, the input samples, 
and the sonicated DNA samples and incubated at 65°C for 4 hours minimum to reverse 
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the crosslinks. Afterwards, 10fll of 0.5M EDTA, 20fll Tris-HCl pH 6.5, and 1fll20mg/ml 
Proteinase K was added and samples were incubated at 55°C for 1 hour. DNA was 
phenol/chloroform extracted and EtOH precipitated from the ChiP samples and allowed 
to dry before resuspension in 20fll Baxter water. Immunoprecipitated chromatin was 
subjected to qRT-PCR for the detection of the Gtl2 promoter sequence containing the -39 
MEF2 site. Primer sequences are listed in Table 2.1. 
2.6 Electrophoretic Mobility Shift Assays (EMSA) 
Electromobility shift assays were performed to determine the ability of MEF2A to 
bind the -39 MEF2 site found within the Gtl2 promoter region. Sense and antisense 
oligonucleotides were designed to encompass the -39Mef2 binding site, plus seven 
additional flanking nucleotides on either side of the consensus binding site and a four 
nucleotide leader sequence for radiolabeling purposes (5 ' -CCGG-1234567 -bindingsite-
1234567-3') (Figure 5.9 and section 2.12). Lypholized oligonucleotides were ordered 
from Invitrogen and resuspended in Baxter water to a 1 OOf..LM concentration. Sense and 
antisense oligonucleotides were annealed to generate a double stranded DNA probe by 
combining 2.5flg sense oligonucleotide (100!-LM stock), 2.5!-lg antisense oligonucleotide 
(100!-LM stock), 5!11 lOX buffer #2 (NEB), and Baxter water to a 50!11 final volume. The 
oligonucleotide reaction mixture was incubated at 65°C in a heat block for 20 minutes. 
The heat block was then turned off and the oligonucleotides were allowed to cool toRT 
slowly ( -1.5-2 hours). Double-stranded DNA oligonucleotides were then radioactively 
end-labeled with 32P-dCTP using the Rad-Prime Kits (Invitrogen). The labeling reaction 
was performed by combining 14.5!11 dHzO, 2fll of diluted annealed oligonucleotides 
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(lOOng/~-tl), 2.5~-tllOX buffer #2 (NEB), 2.5~-tl ATG mix (Rad-Prime Kit), 2.5~-tl 32P-dCTP 
(Perkin Elmer), and 1~-tl Klenow DNA polymerase (Rad-Prime Kit). This reaction was 
incubated at RT for 2 hours to allow radiolabeling of the double stranded 
oligonucleotides, and then diluted with 25~-tl TE buffer. Radiolabeled oligo probes were 
purified over a Sephadex G-25 (Fine) Quick Spin column (Roche), and 1~-tl was measured 
by liquid scintillation to determine the 32P count per million (cpm) and the relative 
success of the radiolabeling reaction. Approximately 50,000cpm of 32P-dCTP labeled -39 
MEF2 DNA probe (-1~-tl) was used in each gel shift reaction. The mutant MEF2 site was 
generated in the same manner as the mutant Gtl2 reporter (section 2.2.6 and 2.12), and 
labeled as described for the -39 MEF2 wildtype site. 
In gel shift reactions where in vitro translated protein was used, mouse MEF2A 
protein was translated in vitro using the TNT Coupled Rabbit Reticulocyte Lysate System 
(Promega). For this reaction, 12.5~-tl rabbit reticulocyte lysate, 1~-tl reaction buffer, 0.5~-tl 
T7 RNA polymerase, 0.5~-tl amino acid mix (-met), 0.5~-tl amino acid mix (-leu), 0.5~-tl 
RNasin (RNase inhibitor), 1~-tg pcDNA3-MEF2A (plasmid mouse MEF2A eDNA), and 
dH20 to a 25~-tl final volume. This reaction was incubated in a thermocycler at 30°C for 
2 hours, and kept on ice (or stored at -80°C) prior to use in gel shift reactions. 
EMSA, or gel shift, reactions were carried out in 10~-tl volumes containing 
50,000cpm 32P-dCTP labeled -39 MEF2 DNA probe ( -1~-tl), 2~-tl in vitro translated (IVT) 
mouse MEF2A or 25~-tg nuclear extracts from C2C12 myotubes at differentiation day 3 
(endogenous MEF2A), 1~-tl lOX gel shift buffer (125mM HEPES, pH7.6; 500mM NaCl; 
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75% Glycerol; 0.5% NP40; 1X protease inhibitors [Roche]), and dH20 to a lOj..ll final 
volume. Alternative gel shift reactions also included pre-incubation of protein extracts 
with anti-MEF2 antibodies (C-21, Santa Cruz) to supershift DNA-protein complexes on 
EMSA gels to demonstrate specificity of MEF2A binding to the -39 MEF2 site. Gel shift 
reactions were incubated at RT for 15 minutes while a 5% acrylarnide gel (6.25ml 40% 
acrylamide, 0.5X TBE, 0.05% APS, 0.05% TEMED) was pre-electrophoresed. Gel shift 
reactions were then fractionated on the 5% non-denaturing polyacrylamide gel for 1.5 
hours at 160V. Gels were then dried in a gel dryer for 1 hour at 80°C and exposed 
overnight to a phosphor-imaging screen (Amersham Biosciences). Phosphor-imaging 
screens were then imaged using a Typhoon Trio flatbed scanner (GE Healthcare). 
2. 7 Mouse Husbandry 
2.7.1 Mouse Strains 
All mouse strains used in this study were derived from a mixed background of 
129Sv and C57B6 (Jackson Laboratories). Mouse lines with this background included 
wild type (WT) and MEF2A knockout (KO) mice (Naya et al. 2002). 
2. 7.2 Genotyping 
Genomic DNA was isolated from mouse tail tip samples at weaning age (post-
natal day 20). Tail samples were digested in 200j..ll tail lysis buffer (lOmM Tris-HCl pH 
8.5, 25mM EDTA pH 8.0, 1% SDS, 100mM NaCl, 0.2mg/ml Proteinase K (NEB) at 
55°C overnight. Genomic DNA was then isolated from taillysates by phenol:chloroform 
extraction and EtOH precipitation. DNA was allowed to dry at RT for several minutes 
and 200j..ll of Baxter water was then added to resuspend the DNA. Genomic DNA was 
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then used in genotyping PCRs set up in 25j.!l final volume: lj.!l genomic DNA, 2.5f.ll lOX 
Thermo buffer (New England Biolabs), 2f.ll of 2.5mM dNTP mixture (New England 
Biolabs), lf.ll of 25f.lM primer mix (1:2:1 ratio of lOOj.!M forward primer: Baxter dH20: 
1 00j.!M reverse primer), 0.5-l.O!ll of Tag polymerase (New England Biolabs ), and Baxter 
water. The PCR reactions were run on a thermocycler program as follows: 94°C for 4 
minutes, 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds. Steps 2-4 
were repeated 29 times for a total of 30 cycles, and a final extension was performed for 
10 minutes at 72°C. Samples were held at 4°C until removed from the thermocycler. 
PCR products from these reactions were electrophoresed on a 0.8% agarose gel 
containing ethidium bromide in lX TAB buffer at 120V for approximately 20 minutes. 
Gels were imaged under UV light. Two primer sets were used for these reactions (M2A 
and Neo) and are listed in section 2.12. Mice with only a M2A band were considered 
wild type, mice with only a Neo band were considered MEF2A knockouts, and mice with 
both a M2A and Neo band were considered heterozygous for the MEF2A knockout 
allele. 
2.7.3 In Vivo Regeneration Studies 
2.7.3.1 Cardiotoxin Injection 
Mice used in all experiments were age (2-4 months) and sex-matched. Prior to 
cardiotoxin injection, mice were anesthetized with a ketamine/xylazine cocktail (50mg/kg 
ketamine, 5mglkg xylazine) via intraperitoneal injection using a lml/26G3/s" syringe (BD 
Biosciences). Fur from the right hindlimb of each mouse was then shaved and the tibialis 
anterior (TA) muscle of wild type and MEF2A knockout mice (Naya et al. 2002) were 
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injected with lO!!M cardiotoxin (Naja nigricollis, EMD chemicals) using a 0.3rnl/28G 
insulin syringe (BD Biosciences). Anesthetized mice were closely monitored until the 
anesthetic effects subsided and mice regained muscle control. Mice were then returned to 
the mouse housing facility until harvesting. 
2.7.3.2 Tissue Dissection 
Mice were anesthetized with ketamine/xylazine as before (section 2.7.3.1 ) and 
sacrificed by cervical dislocation. TA muscles were harvested at three (N=7), seven 
(N=16), and fourteen (N=7) days post-injury. Uninjured TA muscle from the 
contralateral limb of each mouse was used as a control. Whole muscle images were taken 
prior to harvesting muscle for total protein, RNA isolation, or histology. For histology, 
TA muscle was fixed in 4% paraformaldehyde for 2 hours at 4°C or left unfixed, placed 
in embedding compound (OCT), snap-frozen in dry-ice-cooled isopentane and stored at -
80°C. Transverse muscle sections (1 O!!m) created with a Leica CM 1850 cryostat 
microtome at -80°C were then immunostained with protein-specific antibodies or stained 
with hematoxylin & eosin (H&E) for visualization of basic muscle morphology. 
2.8 RNA Techniques 
2.8.1 RNA Isolation 
RNA was isolated from cells and tissue using TRIZOL reagent (Invitrogen) 
according to the manufacturer' s instructions. For tissue, skeletal muscle hindlimb was 
typically homogenized in 1-2ml of Trizol using the Polytron PT 10-35 homogenizer 
(Kinematica) for 20-30 seconds. For adherent cells grown in culture, cells were scraped 
into 350J.ll TRIZOL (for a 35mm plate) using a Cell Lifter (Corning). Harvested cell 
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samples were incubated at RT in TRIZOL for 5 minutes and were then processed for 
phase separation and RNA precipitation according to the manufacturer's instructions 
(Invitrogen). RNA pellets were washed with 75% ethanol. Excess ethanol was carefully 
removed from the pellet using a pipet tip and pellets were allowed to dry very briefly 
(usually 2-3 minutes maximum) on the benchtop. Pellets were resuspended in 30!11 of 
Baxter water and resuspended by pipetting up and down. Resuspended RNA was kept on 
ice at all times and was stored at -80°C. 
2.8.2 Microarray 
Total RNA from C2C12 cells or wild type and MEF2A knockout TA muscle 
seven days post-injury was prepared by TRIZOL isolation (Invitrogen) as described 
above (section 2.8.1). RNA quantity was determined for individual samples by 
electrophoresis on a 0.8% agarose gel. The presence of two strong bands, representing 
intact 28S and 18S rRNA, and little smearing of RNA between these bands indicated 
good RNA integrity. RNA from each sample was pooled in equimolar concentrations (In 
vitro array: N=6 UT, N=6 shMef2A, N=6 shLacZ; In vivo array: N=5 WT, N=5 KO), and 
submitted to the Boston University Microarray Facility. RNA was subjected to Agilent 
Bioanalyzer analysis as an additional measure of RNA integrity, reverse transcribed, and 
cDNAs synthesized from submitted samples were prepared and hybridized to the Mouse 
Gene 1.0 ST Array (Affymetrix). 
2.8.3 Reverse Transcription 
In general, eDNA was generated from 2.0!lg of RNA, which was reverse 
transcribed using M-MLV Reverse Transcription reagents (Promega). Reverse 
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transcription reactions were set up containing 6111 2.5mM dNTP mix (NEB), 6.7Jll 
15.4JlM random hexamers (Promega), 1111 RNasin (Promega), lJll M-MLV Reverse 
Transcriptase (Promega), 6111 5X RT buffer (Promega), and Baxter water to a final 
volume of 30!11. First RNA, dNTPs, random hexamers, and water were combined, 
incubated at 65 °C for 5 minutes, and then incubated on ice for 5 minutes. RNasin, M-
MLV RT, and RT buffer were then added and the reaction was incubated at 37°C for 1 
hour. Synthesized eDNA was stored at -20°C, and used in semi-quantitative or 
quantitative RT-PCR analyses. 
2.8.4 Semi-quantitative RT -PCR 
Semi-quantitative RT-PCR was performed in 25Jll reaction volumes. Briefly, 1111 
eDNA, 2.5Jll lOX Thermo buffer (NEB), 2111 2.5mM dNTPs (NEB), 1111 of primer mix 
(1:2:1 ratio of 100!lM forward primer: Baxter dH20: lOO!!M reverse primer), 0.25!11 of 
Taq polymerase (NEB), and Baxter water. Thermocycler programs were used with the 
following general format: 94°C for 4 minutes, 94°C for 30 seconds, 55°C for 30 seconds 
(temperature varies with melting temperature of primers), and 72°C for 30 seconds. 
Steps 2-4 were repeated 18-28 times (staying within the linear range) and a final 
extension was performed for 10 minutes at 72°C. Samples were held at 4°C until 
removed from the thermocycler, and run on 0.8% agarose gels with EtBr to visualize the 
intensity of PCR product bands. GAPDH or 18S rRNA PCR products were used as 
loading controls. All primer sequences are listed in Table 2.1. 
2.8.5 Quantitative RT-PCR 
2.8.5.1 mRNA Expression Analysis 
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Pooled total RNA isolated from TA muscle of WT and MEF2A KO mice 
(described above) or C2C12 MEF2A knockdown experiments (N=6 shLacZ, N=6 
shMef2A), was used to synthesize eDNA for qRT-PCR analysis. eDNA was synthesized 
from 2~-tg total RNA using reverse transcriptase (M-ML V) with random hexamers 
according to the manufacturer's instructions (Promega), as described in section 2.8.3. 
Quantitative RT-PCR analysis was performed in triplicate wells for each sample reaction. 
Reactions were established by combining 1!-ll eDNA (diluted 1:3 in Baxter water for TA 
muscle cDNAs), 15!-ll Power SYBR® Green Master Mix (Applied Biosystems), 6!-ll 
primer mix (5!-ll 100!-LM forward primer+ 5!-ll 100!-LM reverse primer + 190!-LM Baxter 
water), and 8!-ll Baxter water. Reaction mixtures were loaded into triplicate wells of a 384 
Well plate (8.5!11 of 30J..Ll sample reaction per well; 3 wells loaded per sample). Plates 
were briefly centrifuged and then subjected to thermocycling using the ABI Prism 
7900HT Sequence Detection System (Applied Biosystems) with the following 
amplification program: 50°C 2 minutes, 95°C 10 minutes, 95°C 15 seconds, 60°C 1 
minute; steps 3-4 were repeated 39 times for a total of 40 cycles. Detected PCR 
amplification results were then analyzed using SDS 2.2.2 software (Ambion) to 
determine CT values for each sample reaction. CT values for each gene were averaged and 
subtracted from the averaged GAPDH (internal control) CT value to determine the gene 
~CT value. The change in ~CT values for each gene between biological samples (ex: 
differentiation day 3 vs. myoblast stage C2C12 cells) was then determined by subtracting 
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the gene 11CT value in condition #2 from condition #1 to obtain the 1111CT value. Finally, 
the relative expression (fold change in expression) between samples was determined by 
calculating 2-Mct. Differences in relative expression were analyzed for significance using 
a Students T-test. A P-value of :SO.OS was considered statistically significant. 
Primers for quantitative PCR were designed or obtained from the Primer Bank 
Website (http://pga.mgh.harvard.edu/primerbank/). Sequences can be found in Table 2.1. 
2.8.5.2 Stem-loop RT-PCR for MicroRNA Expression Analysis 
Stem-loop qRT-PCR was performed for detection of mature miRNAs in vivo as 
described by Chen et al. (200S). Stem-loop specific primers for SS ribosomal RNAs and 
mature miRNAs (miR-S40-3p, miR-433, miR-49S, miR-381, miR-410) were used to 
reverse transcribe pooled TA muscle RNA samples from WT and MEF2A KO mice or 
C2C12 cells using the TaqMan miRNA Reverse Transcriptase kit (Applied Biosystems) 
according to the manufacturer's instructions. Stem-loop RT forward primers were 
designed using a 44 nt universal oligonucleotide sequence (Thompson et al. 2011) with 
six nucleotides at the 3' end of the primer corresponding to the reverse compliment of the 
3' end of the mature miRNA sequence (mirBase). These primers were used in reverse 
transcription reactions to generate cDNAs containing only the 6 amplified miRNAs: 
O.lSj.!l lOOmM dNTPs (Taqman kit), l.Sj.!l lOX reverse transcription buffer (Taqman 
kit), O.l9j.!l RNAsin (Taqman kit), 0.7Sj.!l lj.!M stem-loop specific primer, SOOng RNA, 
lj.!l (SOU) MultiScribe reverse transcriptase (Taqman kit), and nuclease-free dH20 to a 
lSj.!l final volume. All reagents, with the exception of the stem-loop primers, belonged to 
the Taqman miRNA Reverse Transcription kit (Applied Biosystems). Reverse 
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transcription reactions were carried out in a thermocycler using the following program: 
16°C 30 minutes, 42°C 30 minutes, 85°C 5 minutes, cooled to 4°C, immediately removed 
from the thermocycler and stored at -20°C. miRNA and 5S sequences were then 
amplified by qPCR using a forward-specific primer (section 2.12) and a universal reverse 
primer (Thompson et al. 2011) with the following sample reaction setup: 2J.1l miRNA-
specific eDNA, 15J.1l Power SYBR® Green Master Mix (Applied Biosystems), 0.5J.1l 
20J.1M miRNA-specific forward primer, 0.5Jll 20J.1M universal reverse primer, and 12J.1l 
dH20. Quantitative RT-PCR was performed in triplicate wells using Power SYBR® 
Green Master Mix (Applied Biosystems) with the 7900HT Sequence Detection System 
(Applied Biosystems) as described above, using a modified thermocycling program: 50°C 
2 minutes, 95°C 2 minutes, 95°C 15 seconds, 60°C 1 minute; steps 3-4 were repeated 39 
times for a total of 40 cycles. Primers used for all stem-loop qRT-PCR analyses are listed 
in section 2.12. CT values and changes in relative miRNA expression were determined as 
described in section 2.8.5.1. 
2.9 Protein Techniques 
2.9.1 Protein Isolation 
For cultured cells, protein was isolated by washing cells with 1X PBS two times 
and then scraped into 500J.1l 1X PBS using a Cell Lifter (Coming). Cells were pelleted by 
centrifugation for 1 minute at 13000 rpm at 4°C. The PBS supernatant was aspirated and 
the cell pellet was resuspended and dounce homogenized with a pestle in 200J.1l cold ELB 
buffer (50mM HEPES, 250mM NaCl, 5mM EDTA, 0.1% NP40, 1mM DIT, 1mM 
PMSF, 1X protease inhibitors (Roche) , dH20) containing protease inhibitors. 
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Homogenized cells were incubated on ice for 10 minutes and then centrifuged at 13000 
rpm for 10 minutes at 4°C. The supernatant containing the protein extract was transferred 
to a new eppendorf tubes and stored at -80°C until use. 
For mouse tissue samples isolated directly from the animals, protein was 
harvested by homogenizing tissue samples in 1-2ml ELB buffer (without 0.1% NP40) 
using the Polytron PT 10-35 homogenizer (Kinematica) for 20-30 seconds. Homogenized 
cells were then centrifuged at 13000 rpm for 10 minutes at 4°C, and the supernatant 
containing protein extract was isolated and saved as before. 
2.9.2 Western Blotting 
Whole cell protein extracts (COS1, C2C12, or TA muscle) were subjected to 
SDS-PAGE according to the following protocol: 10-2011g of protein extract (:::.20111) was 
combined with SDS-loading buffer (1.52% Tris base [w/v], 20% glycerol, 2% SDS [w/v], 
0.1% bromophenol blue [ w/v ], 2% ~-mercaptoethanol) to a 40111 final volume per protein 
sample. Protein samples with dye were denatured at 95°C for 5 minutes and the 
immediately loaded onto a 10% polyacrylamide gel (Lower separating gel: 1.9ml dH20, 
1.7ml 30% acrylamide/0.8% bis-acrylamide, 1.3ml separation buffer [375mM Tris-HCl 
pH 8.8, 0.1% SDS (w/v)], 5011110% APS, 2111 TEMED; Upper stacking gel: 2.lml dHzO, 
0.5ml 30% acrylamide/0.8% bis-acrylamide, 0.75ml stacking buffer [125 mM Tris-HCl 
pH 6.8, 0.1% SDS (w/v)], 30111 10% APS, 3111 TEMED) and electroporesed in IX SDS 
Running buffer (25mM Tris-HCl, 192mM glycine, 0.1% SDS [w/v]) at 190V for the 
desired running time (usually 1 hour). Proteins separated by molecular weight on the 
SDS-PAGE gel were then transferred to Immun-Blot PVDF membrane (Bio-Rad) at 
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200rnAmps for 1 hour at 4°C in transfer buffer (20% methanol, 20mM Tris, 150mM 
glycine) or at 50mAmps overnight at 4°C. Following transfer, the PVDF membrane was 
blocked in blotto solution (5% non-fat dry milk [w/v], 30m11X TBS) for 1 hour at RT or 
overnight at 4°C with 3D rotation. Blocked membranes were then immunoblotted using 
the following primary antibodies: rabbit anti-GAPDH (1 :5000; Santa Cruz), rabbit anti-
MEF2A (1:1000; Santa Cruz), rabbit anti-cleaved-caspase-3 (1:1000; Cell Signaling), 
mouse anti-FLAG (1:10,000; Sigma), mouse anti-~-catenin (1:1000; BD Transduction 
Laboratories), and rabbit anti-sFRP2 (1:500; Millipore). Immunoblots were washed 3 
times with 1X TBS/0.1% Tween and then incubated with the following HRP-conjugated 
secondary antibodies: Goat anti-rabbit-HRP or goat anti-mouse-HRP (both 1: 10,000; 
Sigma). Excess secondary antibody was washed from the membranes as before (3x 
washes with 1X TBS/0.1% Tween), and was then reacted with 4001!1 Western Lightning 
chemiluminescent reagent (Perkin Elmer) according to the manufacturer's instructions. 
Target protein-antibody complexes were visualized by exposing the reactive membranes 
to Blue Basic Autorad X-ray film (ISC Biosciences). 
2.10 Histology and Immunofluorescence 
2.10.1 Cell Culture 
2.10.1.1 Immunostaining 
For C2C12 experiments, C2C12 myoblasts were seeded on 0.1% gelatin-coated 
coverslips in 35mm culture dishes at a density of 100,000 cells per coverslip/dish. The 
following day, C2C12 cells were transduced with adenoviruses (shLacZ or shMef2A at 
MOl 25), switched to differentiation media 24 hours post-transduction, and allowed to 
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differentiate for three days, unless otherwise specified. For pnmary myoblast 
experiments, myoblasts were seeded onto collagen-coated coverslips in 35mm dishes at a 
density of 100,000 cells per coverslip/dish unless otherwise specified. Isolated myofibers 
were also plated on collagen-coated coverslips in 35mm dishes for culturing prior to 
immunofluoresence. 
For immunofluoresence analyses, cells were fixed on coverslips with 4% 
paraformaldehyde at 4°C for 15 minutes , permeabilized with 1xPBS/3% BSA/0.1 % 
IGEPAL for 10 minutes at RT, and blocked in Mouse On Mouse (M.O.M., Vector Labs) 
blocking solution for one hour at RT according to the manufacturer's instructions. Cells 
were then incubated with primary antibody diluted in M.O.M. blocking solution in a 
humidified chamber for 1 hour at RT or overnight at 4°C. Primary antibodies included: 
anti-a-actinin (1 :200; Sigma), anti-Pax7 (1 :2; supernatant, Developmental Studies 
Hybridoma Bank), anti-MEF2 (1:200; Santa Cruz Biotechnology), and anti-MyoD (1:200 
S-17, 1:100 M-318; Santa Cruz Biotechnology). Primary antibody was removed and cells 
were washed 3x for 20 minutes in 1X PBS/0.01 % Triton X-100. Secondary antibody was 
then applied for 1 hour at RT. Secondary antibodies included: anti-mouse Alexa Fluor 
488, 568 lgG1, and 568 lgG (H+L) (1:300); anti-rabbit Alexa Fluor 488 and 568 (1:300); 
and anti-goat Alexa Fluor 647 (1:100) (Invitrogen). Excess secondary antibody was 
washed from cells as before (3x washes in 1X PBS/0.01 % Triton X-100, 20 minutes per 
wash) and mounted in Vectashield mounting medium with DAPI (Vector Labs) on clean 
slides. Fluorescent images were taken using an Olympus DSU Spinning Disk Confocal 
microscope or FVlOi confocal imaging system. 
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2.10.1.2 TUNELAssay 
Apoptotic index was assessed by terminal dUTP nick-end labeling (TUNEL) 
assay using the Promega DeadEnd™ Fluorometric TUNEL System kit according to the 
manufacturer's instrcutions. Briefly, cells were fixed to coverslips as described in section 
2.10.1.1, washed 2x in 1X PBS, and permeabilized in 1X PBS/0.2% Triton X-100 for 5 
minutes at RT. Cells were washed as before, pre-incubated with 100111 equilibration 
buffer (TUNEL kit), and then incubated with 50!11 of the rTdT nick-end labeling reaction 
solution (45!11 Equilibration buffer, 5!11 Fluorescein-tagged dUTP nucleotide mix, and 
1111 rTdT enzyme) for 1 hour in a 37°C humidified chamber. Cells were then incubated 
with 2rnl 2X SSC buffer for 15 minutes at RT, and washed 3x in 1XPBS. Vectashield 
mounting medium containing DAPI was applied to all TUNEL-stained coverslips, and 
mounted on clean slides. Slides were imaged using the Olympus DSU Spinning Disk 
Confocal microscope. Apoptotic index was quantified by counting the number of 
TUNEL-positive nuclei relative to all nuclei. DNasel-treated cells served as a positive 
control. 
2.10.2 Tibialis Anterior Muscle 
2.10.2.1 Hematoxylin and Eosin Staining 
Slides containing frozen TA muscle sections (lO!lm thickness) were thawed and 
fixed in ice-cold acetone for 5 minutes. Slides were then subjected to a series of 
solutions for hematoxylin and eosin staining: 100% ethanol for 2 minutes, 95% ethanol 
for 2 minutes, 70% ethanol for 2 minutes, distilled water for 2 minutes, hematoxylin for 3 
minutes (freshly filtered, Surgipath), 3 rinses in dH20, 3 rinses in distilled water, eosin 
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(freshly filtered, Surgipath) for I minute, 2 rinses in distilled water, 95% ethanol for 5 
minutes, 100% ethanol for 5 minutes, and xylenes (HistoClear II, National Diagnostics) 
for 5 minutes. Cover slips were mounted using 2: I Permount (Fisher): xylenes. 
2.10.2.2 Immunofluorescence 
Transverse TA muscle cryosections (101-!m) were immunostained as described in 
Kanisicak et al. (2009). Briefly, frozen slides were thawed and rinsed 2x in IX PBS. For 
pre-fixed sections (tissue fixed prior to OCT embedding), antigen retrieval was required 
using the following procedure: Slide were incubated in methanol at -20°C for 6 minutes 
and boiled in 95-99°C 10 mM sodium citrate buffer (pH6.0) for I5 minutes. For slides 
not fixed prior to embedding in OCT, tissue was fixed in 4% paraformaldehyde for I5 
minutes at 4°C. All slides, regardless of fixation, were then washed in IX PBS and 
blocked for I hour at RT using M.O.M. blocking solution (Vector Labs) according to the 
manufacturer's instructions. Slides were then incubated with the primary antibody diluted 
in M.O.M. blocking solution for I hpur at room temperature or overnight at 4°C. Primary 
antibodies and dilutions used were as follows: rabbit anti-laminin (1:200; Sigma), mouse 
anti-~-catenin (1:200, BD Transduction Labs), mouse anti-Pax?, rabbit anti-MEF2. Slides 
were then washed in lXPBS and incubated with secondary antibody diluted in M.O.M. 
for 1 hour at room temperature. Secondary antibodies included: anti-mouse Alexa-Fluor 
488 IgG (H+L), anti-mouse Alexa-Fluor 568 IgG1, and Fluorescein anti-rabbit IgG (H+L) 
(1:500; Vector Labs). Vectashield mounting medium with DAPI (Vector Labs) was 
applied to stained tissue sections prior to imaging. All images were taken using an 
Olympus DSU Spinning Disk Confocal microscope or FVlOi confocal imaging system. 
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2.10.2.3 Metamorph Analysis of Cross-Sectional Area 
Dystrophin and laminin co-stained images (1 Ox magnification) for control and 
cardiotoxin-treated T A muscles were used to quantify cross-sectional area of myofibers. 
To ensure accurate quantification, multiple non-overlapping images were taken for each 
section and > 1000 ·myofibers were measured per animal using Metamorph software 
(Molecular Devices). The data was represented as the injured fiber size relative to the 
control uninjured fiber size, normalized to one. Regeneration day 7 studies used anN of 5 
mice for each genotype, Regeneration day 14 studies used anN of 2 for each genotype. 
Statistically significant differences in average CSA was determined using a Students T-
test. A P-value of :S0.05 was considered statistically significant. 
2.11 Statistical Analysis 
All numerical quantification is representative of the mean ± S.E.M. of at least 
three independently performed experiments. Statistically significant differences between 
two populations of data were determined using the student' s T-test. P-values of :S0.05 
were considered to be statistically significant. 
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RT-PCR 
Oligo I Direction I Sequence 5' to 3' 
18SrRNA Forward CATTCGAACGTCTGCCCTAT 
Reverse CCTCCAATGGATCCTCGTTA 
Mef2A Forward ACACGCATAATGGATGAGAGGAACCGAC 
Reverse CAACGATATCCGAGTTCGTCCTGCTTTC 
Mef2B Forward GAAAGAAAGCCGCTCTGCACAG 
Reverse ACCTCTGGCCCCTCCTCCATA 
Mef2C Forward CAGGGACGAGAGAGAGAAGAAAC 
Reverse CAATCTTTGCCTGCTGA TCA TTAG 
Mef2D Forward CTTTCCTCTCTGGCACTAAGGAC 
Reverse CCAGTCTATAACTCTGCATCATC 
MyoD Forward TCGAAGGTCTGCAGGCTCTGC 
Reverse TGCAGTCGATCTCTCAAAGCACC 
Myogenin Forward TGGAGCTGTATGAGACATCCC 
Reverse GAGTTGCA TTCACTGGGCAC 
MCK Forward CTGACCCCTGACCTCTACAAT 
Reverse CATGGCGGTCCTGGATGAT 
qRT-PCR 
Oligo !Direction !Sequence 5' to 3' 
GAPDH Forward TGGCAAAGTGGAGATTGTTGCC 
Reverse AAGATGGTGATGGGCTTCCCG 
Mef2A Forward CAGGTGGTGGCAGTCTTGG 
Reverse TGCTTA TCCTTTGGGCA TTCAA 
Mef2C Forward AGGGAATGGATACGGCAACC 
Reverse CAATGACTGAGCCGACTGGGAG 
Mef2D Forward CGAGATCGCGCTCATCATCTT 
Reverse AGCCGTTGAAACCCTTCTTCC 
p19 Forward CTGAACCGCTTTGGCAAGAC 
Reverse GCCCTCTCTTA TCGCCAGA T 
Cyclin D Forward TGCCATCCATGCGGAAA 
Reverse AGCGGGAAGACCTCCTCTTC 
Cyclin E Forward GTGGCTCCGACCTTTCAGTC 
Reverse CACAGTCTTGTCAATCTTGGCA 
Hgf Forward CTGCTTCATGTCGCCATCC 
Reverse TGGGTCTTCCTTGGTAAGAGTAG 
Fgfbp1 Forward CTAAATCTCTGACGCA TGGCA 
Reverse GAAAACTCCTGATCGGCTTGT 
Myf5 Forward CCTGTCTGGTCCCGAAAGAAC 
Reverse GACGTGATCCGATCCACAATG 
MyoD Forward CCACTCCGGGACA TAGACTTG 
Reverse AAAAGCGCAGGTCTGGTGAG 
Myogenin Forward GAGACA TCCCCCTA TTTCTACC 
Reverse GCTCAGTCCGCTCATAGCC 
MCK Forward CTGACCCCTGACCTCTACAAT 
Reverse CATGGCGGTCCTGGATGAT 
ld3 Forward GCACTCAGCTTAGCCAGGTGG 
Reverse TCCGGAGTGAGCTCAGCTGT 
Ppapdc3 Forward TGTCCAAGCGACTGGGGG T 
Reverse GTCATGATGTCCAAGAGCAGGGC 
sFRP1 Forward CAACGTGGGCTACAAGAAGAT 
Reverse GGCCAGTAGAAGCCGAAGAAC 
sFRP2 Forward CCCCTGTCTGTCTCGACGA 
Reverse CTTCACACACCTTGGGAGCTT 
sFRP4 Forward AGAAGGTCCATACAGTGGGAAG 
Reverse GTTACTGCGACTGGTGCGA 
Axin2 
Ctnna3 
Follistatin 
Dysferlin 
Neogenin 
coo 
Tspan8 
Tspan9 
Tspan32 
Dlk1 
Gt12 
pre-miR-127 
5S rRNA stem loop 
miR540-3p stem loop 
miR433 stem loop 
miR 495 stern loop 
miR 381 stem loop 
miR410s temloop 
5SrRNA 
miR 540-3p 
miR433 
miR 495 
miR 381 
miR410 
ChiP -39 M ef2 
Pax? 
EMSA 
Oligo 
-39 Mef2 
-39 MUT 
Cloning 
Oligo 
-39 Mef2 
-39 MUT 
sFRP2 3'UTR 
sFRP2 3'UTR miR410 MUT 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Forward 
Forward 
Forward 
Forward 
Forward 
Forward 
Forward 
Forward 
Forward 
Forward 
Forward 
Forward 
Reverse 
Forward 
Reverse 
!Direction 
Sense 
Antisense 
Sense 
Antisense 
I Direction 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
Forward 
Reverse 
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TGACTCTCCTTCCAGATCCCA 
TGCCCACACTAGGCTGACA 
ACGCCAATAACCCTGAATATGG 
TTGGAAGGA TTCTGCGGACAA 
TGCTGCTACTCTGCCAGTTC 
GTGGTGCAACACTCTTCCTG 
CAGCCTGATnnTCGAGGGGT 
ACCACCACGAGAAGTTCTGAG 
CTAGCATTGTAGTGAGCTGGAC 
GCACTGGAGTGTATGGAGCATT 
CGAAGAGAGCGGCCTAACTT 
CCCAGGATCACAGTTCCACC 
TCTGGGTA TGTGGTACACTGA T 
AGGGGTTCGTGCTAGAGTCTC 
TGGGCATCTGGCTCTCTGT 
ACCTTGTCCATGTAGACGAAGAA 
TGCGCTA TTGGGCCTTCTA TG 
CACCAGGATGCAGAATGACAG 
AGTGCGAAACCTGGGTGTC 
GCCTCCTTGTTGAAAGTGGTCA 
TGGAATAGGCCAACATCGTCA 
AGGCTCTGTGTCCATGTGTCC 
TTT GAT CAC TGT CTC CAG CCT GCT G 
GAT GAT GAG ACT TCC GAC CAG CCA 
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACAAAGCC 
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACACAGAG 
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACACACCG 
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACAAGAAG 
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACACAGAG 
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGCCAACACAGGC 
GAA TAC CGG GTG CTG TAG GC 
CAAGGGTCACCCTCTGACTCT 
ATCA TGATGGGCTCCTCGGT 
GCCAAACAAACATGGTGCACTT 
GCCTATACAAGGGCAAGCTCTC 
CCGCCAATATAACACAGATGGCC 
TCTGGGGGGCTCA TnnTCCG 
GAGCCGAGGCGAGCTCTA TTC 
Lepper et al. 2009 
Lepper et al. 2009 
!Sequence 5' to 3' 
AAGGCTGCGCCTTTATA TAAACCCCA 
AAGGTGGGGTTTA TATAAAGGCGCAG 
AAGGCTGCGCGGGTATATAAACCCCA 
AAGGTGGGGTTTATATACCCGCGCAG 
!Sequence 5' to 3' 
AA TIACGCGTCTCCTTTCCTAAGCCG 
AATIGCTAGCGATICTICTGTGGGCG 
CTGCGCGGGTATATAAACCC 
GGGTTTATATACCCGCGCAG 
AATTACTAGTTTTCCCAGTGGGGTGG 
AATTACGCGTTAGGTACAACAAGATGTAAAG 
CAGATAAACAGGGGGGTCTTTGTATA 
TATACAAAGACCCCCCTGTTTATCTG 
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Table 2.1 Oligonucleotides Oligonucleotide primer sequences used in all PCRs are 
shown. Underlined sequences refer to mutations incorporated into the primers. 
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CHAPTER3 
:MEF2A Regulates Differentiaton of Skeletal Muscle In Culture 
3.1 Introduction 
During skeletal muscle differentiation MEF2 transcription factors , among other 
proteins, tightly regulate the progression of muscle differentiation from myoblasts to 
myofibers. In particular, MEF2A is known to play an important role during 
cardiomyogenesis in mice (Naya et al. 2002). Approximately 80% of MEF2A knockout 
mice (Mef2a-/- ) exhibit perinatal lethality characterized by right ventricular dilation, 
myofibrillar fragmentation, and mitochondrial disorganization. While 20% of Mef2a-/-
mice survive to adulthood, they are also subject to sudden death characterized by 
mitochondrial deficiency and arrhythmia (Naya et al. 2002). The nature of the MEF2A 
knockout phenotype indicates that MEF2A plays a role in proper cardiomyocyte 
differentiation during embryogenesis and in the maintenance and survival of 
differentiated cardiomyocytes in the adult mouse. However, in contrast to these 
observations, the skeletal muscle of MEF2A knockout mice develops normally and 
exhibits no overt myogenic phenotype (Potthoff et al. 2007b ). This finding would seem to 
suggest that MEF2A is dispensible for skeletal muscle differentiation. However, a study 
performed by Blais et al. (2005) determined that MEF2A associated with the upstream 
regulatory regions of a variety of genes expressed during C2C 12 differentiation, 
indicating that MEF2A may play a role in skeletal myogenesis. It is clear from these 
studies that an unequivocal role for MEF2A in skeletal muscle differentiation remains to 
be determined. To uncover cellular events under the control of MEF2A during this 
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process, I used RNA interference (RNAi) to knockdown the expression of MEF2A 
during the differentiation of C2C12 myoblasts in culture. As described in this chapter, 
knockdown of MEF2A in C2Cl2 myoblasts severely impairs the myogenic 
differentiation process. Loss of MEF2A compromises cell viability, and reduces the 
capacity of myoblasts to differentiate. The differences observed during MEF2A-deficient 
C2C12 differentiation in comparison to in vivo skeletal muscle development may be 
explained, in part, by the altered MEF2 temporal expression pattern in C2C12 cells. I 
demonstrate that in C2C12 cells, which were isolated from adult injured skeletal muscle, 
MEF2A is the earliest MEF2 factor expressed during differentiation. I found the same 
MEF2 expression pattern in primary myocytes isolated from adult mouse skeletal muscle, 
three days post-injury. Together, these data demonstrate that MEF2A plays an important 
role in skeletal muscle differentiation, specifically during adult regenerative myogenesis. 
3.2 MEF2A Knockdown: shRNA Design and Specificity 
MEF2A is required for proper cardiac muscle differentiation as described by 
Naya et al. (2002), however our understanding of its role in skeletal muscle remains 
incomplete. RNAi represents a convenient and commonly used tool for knocking down 
the expression of a gene in order to characterize its function during a cellular process. To 
characterize a potential role for MEF2A in muscle differentiation, Liz Ewen generated a 
short hairpin RNA (shRNA) directed against mouse MEF2A (Figure 3.1) using 
Invitrogen's proprietary algorithm for shRNA design. The MEF2A shRNA was designed 
to target the 3' coding region of mouse MEF2A mRNA, 
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specifically the nucleotides encoding amino acids 324-330 in exon 8 (nucleotides 1306-
1326, NM_001033713.1) such that any rnRNA splice variant would be targeted (Figure 
3.1). The targeted region of the MEF2A rnRNA is highly conserved between mouse, rat, 
and human MEF2A sequences, making this shRNA useful for studying the function of 
MEF2A in a variety of organisms. Additionally, this shRNA (26 nucleotides) was 
designed such that it possesses less than 50% identity with other mouse MEF2 mRNA 
sequences (MEF2B, MEF2C, MEF2D) to impart specificity. 
To express shMef2A in mammalian cells, double-stranded oligonucleotides 
encoding the MEF2A shRNA stem-loop sequence were cloned into the pENTR™/U6 
RNAi entry vector using the BLOCK-iT RNAi designer system (Invitrogen), which 
drives shRNA expression from an RNA Pol III promoter. I then used successful clones 
in transient transfection assays in COS1 cells (African Green Monkey kidney fibroblasts) 
to assess mRNA knockdown efficacy and specificity. For these experiments, COS 1 cells 
were co-transfected with MEF2-FLAG expression plasmids and shMef2A or a negative 
control shRNA (LacZ shRNA), and cultured for an additional 36-48 hours prior to 
harvesting. The negative control in these experiments, LacZ shRNA (shLacZ), encodes 
an shRNA designed to target the bacteriallacZ, a gene which is absent from mammalian 
genomes. As shown in Figure 3.2, shMef2A robustly and specifically knocked down 
MEF2A-FLAG expression, but did not affect MEF2B, MEF2C, or MEF2D expression 
levels. To increase the efficiency of delivery of this molecule into mammalian muscle 
cell lines, I subsequently packaged this shRNA into adenovirus using the BLOCK-iT 
Adenoviral RNAi Expression System (Invitrogen). This system employed the use of a 
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human U6 RNA promoter-driven and pol III-terminated pAd/BLOCK-iT-DEST 
replication incompetent expression vector which contained elements to allow packaging 
of shRNAs into virions. shMef2A and shLacZ viruses amplified in HEK 293A cells 
(human embryonic kidney cells transformed with adenovirus 5 DNA) were subsequently 
purified and titered for use in transient transduction assays in C2C12 skeletal myoblasts 
to assess the ability of shMef2A to knockdown endogenous MEF2A. 
C2C12 cells, mouse skeletal myoblasts isolated from injured mouse hindlimb 
muscle, are capable of differentiation and are widely used to study the myogenic process. 
C2C 12 myoblasts are known to express MEF2A and other myogenic markers, making 
this cell line an attractive model for testing the efficacy of shMef2A against endogenous 
MEF2A. As shown in Figure 3.3, transduction of C2C12 myoblasts with shMef2A 
adenovirus effectively knocked down endogenous MEF2A mRNA and protein 
expression, making adenovirus-mediated MEF2A RNAi an effective method for studying 
MEF2A-loss-of-function in the C2C12 mouse skeletal muscle model of differentiation. 
3.3 :MEF2A Knockdown in C2C12 Cells Inhibits Differentiation 
To determine the phenotypic consequences of knocking down MEF2A in C2C12 
differentiation, proliferating myoblasts were transduced with MEF2A shRNA adenovirus 
(shMef2A) one day prior (DIFF -1) to the induction of differentiation. Transduced cells 
were then induced to differentiate and analyzed three days later (DIFF 3) when multi-
nucleated myotubes are clearly evident. MEF2A knockdown resulted in severely 
compromised myotube formation compared to C2C12 myoblasts transduced with control 
LacZ shRNA adenovirus (shLacZ) (Figure 3.4). MEF2A shRNA transduced cells 
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resulted in noticeably fewer elongated, fused myotubes and an increase in rounded, light 
refractive cells. To better understand the temporal requirement of MEF2A during C2Cl2 
differentiation, cells were also transduced with shMef2A at later time points. For these 
experiments, C2Cl2 cells were differentiated for a period of three or seven days, at which 
point they were transduced with adenovirus as before, and allowed to differentiate in 
culture for an additional four days. As shown in Figure 3.4, transduction of C2Cl2 cells 
with shMef2A on day three (DIFF 3) compromised myotube terminal differentiation 
which occurs between days three and seven of differentiation. Additionally, transduction 
with shMef2A on day seven (DIFF 7) of differentiation, when multi-nucleated myotubes 
have already formed, also resulted in a loss of myotubes suggesting that MEF2A is 
required for the maintenance and survival of differentiated myotubes (Figure 3.4). 
To quantify the differentiation defect in greater detail, shMef2A knockdown 
C2Cl2 cells were immunostained with the terminal differentiation marker a-actinin 
(Figure 3.5). Nuclei present in a-actinin-positive cells were quantified to measure the 
relative differentiation and fusion of myotubes. Immunofluorescence analysis revealed a 
46% reduction in the differentiation index, as determined by the percentage of nuclei 
present in a-actinin positive cells compared to control shLacZ (Figure 3.5, left bar 
graph). Additionally, the presence of a-actinin-positive myotubes, myocytes containing 
three or more nuclei which reflect the fusion of at least three mono-nuclear myoblasts, 
was also measured. This analysis revealed a 49% decrease in myotube formation in 
shMef2A cultures compared with shLacZ, reflecting impairment of myoblast fusion 
(Figure 3.5, right bar graph). 
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3.4 Loss of MEF2A Reduces Cell Viability 
As mentioned previously, transduction of C2C12 myocytes with shMef2A results 
in an increased presence of light-refractive, rounded cells at all time points tested (Figure 
3.4). This cellular appearance is characteristic of the induction of cell death and loss of 
surface adhesion with the extra-cellular matrix. In order to investigate whether loss of 
MEF2A expression results in reduced cell viability, I performed TUNEL staining and 
Western blotting for markers of apoptosis. As shown in Figure 3.6, MEF2A knock down 
resulted in a 1.5-fold increase in TUNEL positive nuclei in shMef2A cultures (45.7% in 
shMef2A cultures relative to 30% in shLacZ cultures). These data were supported by 
increased expression of cleaved-caspase-3, a protease activated in apoptotic pathways, by 
immunoblot (Figure 3.6). Together, these data suggest that the loss of MEF2A during 
C2C12 differentiation reduces cell viability, which may contribute to the overall decrease 
in differentiation observed among this cell population. 
3.5 Loss of MEF2A Dysregulates Myoblast Differentiation on a Molecular Level 
To determine how myoblast differentiation in C2C12 cells was being affected by 
the loss of MEF2A on a molecular level, I performed gene profiling analysis by 
rnicroarray on MEF2A knockdown C2C12 differentiation day three samples. For this 
analysis, RNA from untransduced (UT), shLacZ-transduced (negative control shRNA), 
and shMef2A-transduced samples were pooled from six biological replicate experiments. 
C2C12 myoblasts were transduced at MOl 25 prior to the onset of differentiation and 
then allowed to differentiate in culture for three days. At differentiation day 3 (DIFF3), 
RNA was harvested, assessed for MEF2A knockdown by western blotting (data not 
92 
shown), and pooled with biological replicates for microarray analysis. A single 
Affymetrix Mouse Gene 1.0 ST array was performed for each pooled sample (UT, 
shLacZ, shMef2A) and log2 scale changes in gene expression were generated by 
comparison of UT, shLacZ, and shMef2A profiles by the Boston University Microarray 
Facility. I untransformed the log2 scale data to determine fold changes in gene expression 
among samples. For this analysis, shLacZ vs. UT comparisons were made to rule out 
false positive changes in gene expression due to shRNA expression or viral transduction 
alone. Comparisons were then made between shMef2A and shLacZ gene profiles, 
excluding false positives, to identify genes up or downregulated by the loss of MEF2A 
during C2C12 differentiation. A 1.5 fold cut-off in gene expression change was then used 
to determine the groups of genes most highly dysregulated in MEF2A knockdown 
samples versus negative controls. These genes were then further grouped into functional 
categories on the basis of gene ontology (Figure 3.7). This analysis revealed a wide 
variety of functional categories which were dysregulated by the loss of MEF2A during 
C2C 12 differentiation. 
To validate microarray results and obtain a better understanding as to which genes 
regulating muscle differentiation were perturbed by the absence of MEF2A, I performed 
quantitative PCR analysis on 26 genes selected from the array. With the exception of the 
tetraspanin (Tspan) family of transmembrane proteins, all genes analyzed are known to 
participate in myoblast proliferation or differentiation. As expected, MEF2A transcripts 
were more than 3-fold downregulated in shMef2A samples compared with shLacZ (0.28 
expression relative to 1, Figure 3.8). The expression of other MEF2 factors (MEF2C and 
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MEF2D) was moderately downregulated. However, given the specificity of the MEF2A 
shRNA (Figure 3.2), it is likely that their slight downregulation is a secondary effect of 
the loss of MEF2A in C2Cl2 differentiation. Genes involved in cell proliferation (p19, 
Cyclin E) and myoblast activation (Hgf, Myf5, MyoD) were aberrantly upregulated at 
differentiation day 3, a time at which most of these markers are normally downregulated 
to promote differentiation. MCK, a marker of terminal differentiation, and myoblast 
fusion proteins follistatin and dysferlin were all downregulated in MEF2A-deficient cells 
while inhibitor of differentiation-3 (ld3) was 6-fold upregulated. Furthermore, activation 
of the Wnt signaling pathway in C2C12 cells is necessary for differentiation (Descamps 
et al. 2008). However, upregulation of Wnt inhibitors (sFRPs) and downregulation of a 
component of the active Wnt pathway (Axin2) indicate inhibition of Wnt signals in 
MEF2A-deficient cells (Figure 3.8). Together, these results demonstrate inhibition of 
myoblast differentiation on a molecular level in MEF2A-deficient C2C12 cells. 
3.6 MEF2 Temporal Expression is Reprogrammed in Adult Myoblast 
Differentiation 
Collectively, the results of the C2C12 knockdown experiments revealed for the 
first time that MEF2A is essential for the initiation and maintenance of the myogenic 
differentiation program. This differentiation defect is in stark contrast to MEF2A-
deficient mice which do not display skeletal muscle abnormalities (Potthoff et al. 2007b, 
C. Snyder and F. Naya unpublished data). The phenotypic differences may be explained, 
in part, by the radically different MEF2 temporal expression in C2C12 cells compared to 
muscle development (Edmondson et al. 1994). As shown in Figure 3.9 (left panel), unlike 
94 
embryonic myogenesis, MEF2A is expressed early in proliferating C2C12 myoblasts 
(Mb ). Expression of MEF2A is subsequently upregulated upon induction of myogenic 
differentiation (DIFF 1) and this higher expression is maintained throughout myotube 
differentiation and maturation. Mej2d is expressed in proliferating myoblasts but its 
levels remain constant throughout differentiation. Mej2d expression is activated at the 
onset of differentiation (DIFF 1) while Mej2d is not expressed until differentiation day 
two and its expression is also maintained throughout differentiation. Since C2C 12 
myoblasts were originally isolated from injured muscle (Yaffe and Saxel1977, Blau et al. 
1983), these results suggest that C2C12 differentiation reflects adult regenerative 
myogenesis. To test this hypothesis, I isolated primary myoblasts from injured muscle, 
three days post-injury, and analyzed Mej2 temporal expression. Indeed, the pattern of 
Mej2 expression in proliferating and differentiated primary myoblasts was similar to 
C2C12 cells (Figure 3.9, right panel). Moreover, expression profiles for well-
characterized differentiation markers (MyoD, myogenin, MCK), were highly similar in 
both primary myocytes and differentiating C2C12 cells (Figure 3.9, lower panels) 
Therefore, I postulated that Mej2 expression is reprogrammed in regeneration and that 
the pronounced defect in C2C12 differentiation reflects a specialized function for 
MEF2A in skeletal muscle regeneration. 
3. 7 Discussion 
Previous studies on MEF2A knockout mice concluded that MEF2A is largely 
dispensible for skeletal muscle differentiation as skeletal muscle in these mice develops 
normally and displays no overt phenotype (Naya et al. 2002, Potthoff et al. 2007b). 
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During striated muscle development in mice, MEF2 transcription factors are expressed in 
a specific pattern with MEF2C and MEF2B expressed first, followed approximately one 
day later by the onset of MEF2A and MEF2D (Edmondson et al. 1994, Molkentin et al. 
1996b ). Conditional MEF2C knockout mice display severely attenuated skeletal muscle 
development, myofiber disorganization and perinatal lethality (Potthoff et al. 2007a), 
while other analyses have indicated that MEF2A and MEF2D are dispensible during this 
process (Potthoff et al. 2007b ). These results suggest that the expression timing pattern of 
MEF2 factors during development reflects their relative importance to the skeletal muscle 
differentiation process; and as MEF2A and MEF2D are expressed later in development, 
the loss of expression of these two factors does not appreciably impact developmental 
differentiation. However, in contrast to these skeletal muscle studies in MEF2 knockout 
mice, there remains evidence in the literature that suggest a role for MEF2A in striated 
muscle differentiation. Specifically, MEF2A knockout mice exhibit severe cardiac 
muscle defects, demonstrating that MEF2A is critical to proper striated muscle 
differentiation and the survival and maintenance of terminally differentiated myocytes 
(Naya et al. 2002). Furthermore, ChiP-chip analysis performed by Blais et al. (2005) in 
C2C12 cells concluded that MEF2A binds the upstream regulatory regions of several 
genes upregulated during myogenesis. Considering the discrepant roles for MEF2A 
reported in the literature, it is clear that our current understanding of MEF2A function in 
skeletal muscle differentiation is incomplete. 
To more fully characterize the role of MEF2A in skeletal muscle differentiation, I 
generated MEF2A-specific short-hairpin RNAs (shRNAs) to knock down expression of 
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this factor during myogenesis in C2C12 cells, a mouse myoblast cell line capable of 
differentiation (Blau et al. 1983). Adenovirus expressing MEF2A shRNA specifically and 
effectively knocked down MEF2A expression in myoblasts, significantly impairing 
myogenesis by differentiation day three. C2C12 cells lacking MEF2A expression 
displayed reduced differentiation and fusion, and reduced cell viability. This phenotype 
was persistent over the course of myogenesis, indicating an important role for MEF2A 
during initiation of differentiation, terminal differentiation, and the survival and 
maintenance of terminally differentiated myotubes. 
The differences between the MEF2A knockout skeletal muscle phenotype and 
MEF2A knockdown in C2C12 cells was surprising, considering that C2C12 
differentiation is generally regarded to recapitulate developmental myogenesis. These 
differences, I have found, are likely attributable to a novel MEF2 program expressed by 
C2C12 cells, and the origin of these myoblasts from adult injured muscle. During C2C12 
differentiation, I show that MEF2A is expressed first in myoblasts , followed by MEF2D 
and MEF2C on differentiation days one and two, respectively. Furthermore, C2C12 
myoblasts were isolated from adult injured muscle (Blau et al. 1983), suggesting that 
their differentiation may most accurately reflect regeneration. These results demonstrate 
that MEF2-directed differentiation undergoes transcriptional reprogramming between 
development and adult regeneration, and that impairment of C2C12 differentiation upon 
MEF2A knockdown indicates an important role for MEF2A during adult skeletal muscle 
regeneration. 
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Mef2A shRNA: GGA CTA GTG TAC TCA GCA ATG 
-------G L V Y S A M 
-~ 
Mef2A Exons4-6 Exons 8-10 
Figure 3.1 MeflA shRNA design 
Schematic representation of MEF2A shRNA design against mouse MEF2A mRNA. The 
shRNA is designed to be complimentary to nucleotides 1306-1326 (NM_001033713.1), 
encoding amino acids 324-330 (shown). The complete mouse MEF2A mRNA is depicted 
with untranslated regions (UTR), alternate exons, and functional domains indicated 
(Adapted from Ewen et al. 2011). 
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Mef2A-FLAG Mef2B-FLAG Mef2C-FLAG Mef2D-FLAG 
Figure 3.2 shMef2A specificity and efficacy 
Western blot demonstrating specificity and efficacy of MEF2A knockdown by shMef2A. 
COS 1 cells were transiently co-transfected with MEF2-FLAG expression plasrnids and 
either empty vector, shLacZ, or shMef2A. Protein was harvested from COS 1 cells 36-48 
hours post-transfection and subjected to anti-FLAG immunoblot. MEF2A-FLAG is 
effectively knocked down by shMef2A, while the expression of other MEF2 factors is 
unaffected. GAPDH is shown as a loading control. 
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Figure 3.3 shMef2A knocks down endogenous MEF2A 
Semi-quantitative RT-PCR and Western blot demonstrating knockdown of MEF2A 
rnRNA (left) and protein (right) by shMef2A. C2C12 cells were transduced with shLacZ 
and shMef2A adenoviruses at MOl 25, and then differentiated in culture for three days 
prior to harvesting. These data demonstrate that the MEF2A shRNA effectively knocks 
down endogenous MEF2A expression in muscle at both the rnRNA and protein levels. 
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Figure 3.4 MEF2A knockdown impairs C2C12 myogenesis 
DIFF 7 
DIFF 11 
Bright field imaging analysis of shLacZ and shMef2A transduced C2C12 cells during 
differentiation. Time points at which C2C12 myocytes were transduced with virus and 
subsequently imaged are indicated. These results indicate that MEF2A is necessary for 
proper myogenesis throughout the time course of differentiation, regardless of the onset 
of MEF2A knockdown. White bars, 1 00!-lm. 
101 
shlacZ shMef2A 
•Myotubes 
(3+nuclei) 
Figure 3.5 Differentiation impairment by loss of MEF2A 
Immunofluorescent analysis of a-actinin staining of shLacZ and shMef2A transduced 
C2C12 cultures at differentiation day 3. Differentiation index (lower left graph) reflects 
the average number of nuclei present in a-actinin-positive cells, a marker of the 
commitment to differentiation, relative to all nuclei. Fusion index (lower right graph) 
reflects the average number of nuclei present in a-actinin-positive myotubes, which have 
three or more nuclei. Results shown indicate that differentiation and fusion indices are 
46% and 49% reduced, respectively, following MEF2A knockdown. Error bars represent 
SEM; N=3. **p:SO.Ol. White bars, 100!lm. 
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Figure 3.6 MEF2A knockdown reduces cell viability 
TUNEL and Western blot analysis of the induction of apoptosis m C2Cl2 cells 
transduced with shMef2A as compared to shLacZ. Apoptotic index was quantified as the 
percent of TUNEL-positive nuclei relative to all nuclei present (bar graph, lower left). 
Immunoblot analysis for cleaved-caspase-3 (lower right), revealed increased activated 
caspase-3, a marker of apoptosis, in shMef2A transduced C2C12 cells at differentiation 
day 3. N=3. White bars, lOOj...tm. 
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Figure 3.7 MEF2A knockdown during C2C12 differentiation dysregulates a wide 
variety of genes Pie chart of dysregulated gene categories from rnicroarray data 
comparing shMef2A versus shLacZ transduced C2C12 differentiation day 3 cells. 
Transcripts whose expression was dysregulated 1.5 fold or greater in shMef2A samples 
compared with shLacZ negative control samples on Affymetrix Mouse Gene 1.0 ST 
arrays were grouped into categories on the basis of gene ontology (GO) functions. Genes 
known to regulate myoblast differentiation were included in some of the largest 
dysregulated categories: Cell Membrane, Sarcomeric/Cytoskeletal, and Myoblast Fusion. 
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Category Gene Fold Change SEM P value 
Mef2A 0.2778 0.0156 6E-25 *** 
~ Mef2C 0.8172 0.0410 0.0043 
:E ** 
Mef2D 0.8162 0.0344 0.0018 ** 
Cl) p19 1.3554 0.0894 0.0165 u * 
>-0 CyclinD 0.9157 0.0893 0.3988 
-~ CyclinE 1.3564 0.0791 0.0108 * 
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* 
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0 *** 
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Figure 3.8 Quantitative PCR analysis of dysregulated genes during MEF2A-
deficient C2C12 differentiation Validation of micro array data for 26 genes dysregulated 
in shMef2A transduced C2C12 cells at DIFF3. *ps0.05, **psO.Ol , ***psO.OOl. N::::3. 
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Figure 3.9 MEF2 temporal reprogramming in adult myoblast differentiation 
RT-PCR analysis of Mef2 and myogenic marker gene expression over the time course of 
differentiation in C2C12 cells (left) and primary myocytes isolated from regenerating 
mouse hindlimb muscle (right). All gene expression patterns are shown relative to 
MEF2A. These results demonstrate that C2C12 myoblast differentiation is highly similar 
to differentiation of adult primary myoblasts isolated from regenerating muscle. N=3. 
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Chapter4 
In Vivo Muscle Regeneration is Modulated by MEF2A 
4.1 Introduction 
While MEF2A is thought to be dispensible for skeletal muscle differentiation 
(Potthoff et al. 2007b ), the data discussed in chapter three suggest otherwise. This 
difference, however, is likely context dependent. The results in chapter three suggest that 
in C2C12 cells, a common in vitro model for skeletal muscle differentiation, MEF2A is 
required for proper myogenesis . In the absence of MEF2A, myoblasts fail to differentiate 
normally and exhibit increased cell death. By contrast, in vivo investigations by Potthoff 
et al. (2007b) and F. Naya (unpublished data) indicated that skeletal muscle of MEF2A 
knockout mice differentiates properly during development. However, because C2C12 
myoblasts were originally isolated from adult injured muscle (Yaffe and Saxel 1977, 
Blau et al. 1983), it is likely that differentiation of C2C12 cells more accurately 
recapitulates muscle differentiation during regeneration rather than development. 
Therefore, this key difference may reflect a context-specific function for MEF2A in 
muscle regeneration rather than developmental myogenesis. 
Regeneration occurs in adult skeletal muscle when the resident population of 
tissue-specific stem cells, called satellite cells, is activated to proliferate upon injury or 
exercise. Satellite cell proliferation replenishes the stem cell population in addition to 
producing transit-amplifying progenitors called myoblasts. These myoblasts eventually 
exit the cell cycle and fuse to reform myofibers and repair damaged muscle. While many 
cellular pathways participating in muscle regeneration are thought to recapitulate 
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developmental myogenesis, evidence from the literature suggests that several pathways 
undergo transcriptional reprogramming. Likewise, data from chapter three indicate that 
MEF2 transcription undergoes a reprogramming event between developmental and adult 
myogenesis. In both C2C12 and primary myoblasts, progenitor cells isolated from injured 
muscle, MEF2A is expressed early during the differentiation process. However, during 
embryonic skeletal muscle differentiation, MEF2A is expressed late, following the onset 
of MEF2C and MEF2B (Edmondson et al. 1994, Molkentin et al. 1996b ). This temporal 
shift in MEF2A expression during muscle differentiation therefore likely represents a 
novel function for MEF2A during the process of muscle regeneration. 
In chapter four, this hypothesis was investigated in vivo by performing 
regeneration experiments using cardiotoxin-injured tibialis anterior muscle as a model 
system in mice. Imrnunostaining analyses in wildtype regenerating muscle confirmed 
previously published data demonstrating a dramatic increase in nuclear MEF2A 
following myotoxic injury. Comparison of regeneration in MEF2A knockout (KO) and 
WT skeletal muscle at seven and fourteen days post-injury revealed widespread necrosis 
in MEF2A KO injured muscle accompanied by a delay in recovery of myofiber cross-
sectional area. Furthermore, immunostaining analysis of Pax7, a well-characterized 
marker of satellite cells, revealed for the first time that MEF2A is co-expressed with Pax7 
in a subset of muscle progenitor cells, and that MEF2A knockout muscle exhibits a 
significant decrease in Pax7-positive progenitor cells. Together these data indicate that 
MEF2A is critical for proper muscle regeneration in vivo. 
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4.2 Loss of MEF2A Dramatically Impairs Muscle Recovery After Injury 
To determine whether MEF2A plays a role in skeletal muscle regeneration in 
vzvo, I analyzed the regenerative capacity of MEF2A knockout skeletal muscle. 
Immunoblot analysis confirmed that adult MEF2A knockout mice, derived from a mixed 
genetic background (C57Bl6/129Sv), do not express MEF2A protein in their hindlimb 
muscle (Figure 4.1 ). In order to determine the regenerative capacity of this tissue, muscle 
injury was induced in adult wild type and MEF2A knockout mice by injecting the tibialis 
anterior (TA) muscle with cardiotoxin. TA muscle from MEF2A knockout mice, but not 
wild type, displayed widespread necrosis at various time points after injury (Figure 4.2, 
arrows). Hematoxylin and eosin (H&E) staining of transverse muscle sections revealed a 
similar exent of damage in both WT and KO tissue at day 3 (Figure 4.3). However, by 
day 7, unlike WT muscle, MEF2A KO muscle displayed an intense basophilic 
appearance, consistent with the presence of necrotic tissue (Figure 4.3, middle panels). 
By day 14, necrosis was diminished in MEF2A KO muscle and these areas were largely 
replaced by regenerating myofibers (Figure 4.3, lower panels) suggesting a delay, but not 
a block, in regeneration. 
To characterize this impaired regenerative response in greater detail, cross-
sectional area (CSA) of non-necrotic myofibers possessing centrally located nuclei, a 
hallmark of regenerating myofibers, was measured in TA muscle. Quantitative analysis 
of TA muscle sections at day 7 immunostained with anti-laminin, an antibody that marks 
the myofiber periphery, revealed significantly reduced CSA of regenerating MEF2A KO 
tissue (Figure 4.4). MEF2A KO muscle fibers displayed a slight increase in CSA between 
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day 7 (0.28) and day 14 (0.32), but not to the extent observed in WT muscle between day 
7 (0.46) and day 14 (0.65) compared with uninured controls (normalized to 1) (Figure 
4.4). These data support the notion that muscle regeneration is delayed but not blocked in 
MEF2A KO mice. 
4.3 Primary myoblasts from MEF2A knockout mice are differentiation defective 
Since global MEF2A KO mice were used for this study I next wanted to 
determine whether impaired muscle regeneration could be attributable to a specific defect 
in myoblasts. For this characterization I isolated primary myoblasts from injured WT and 
KO muscle and induced them to differentiate in culture. As shown in Figure 4.5, MEF2A 
KO myoblasts were unable to differentiate effectively, as demonstrated by a 78% 
reduction in a-actinin staining. These results prompted me to analyze the expression of 
Pax?, a muscle-specific marker of muscle progenitors, in uninjured and injured MEF2A 
KO muscle. In uninjured MEF2A KO muscle, I found no significant difference in Pax? 
immunoreactivity (data not shown). By contrast, in regenerating MEF2A KO muscle 
there was an approximately 50% reduction in Pax7+ nuclei compared to WT regenerating 
muscle (Figure 4.6). Consistent with these results, Pax? transcripts were significantly 
downregulated in both regenerating MEF2A KO muscle and in primary myoblasts 
isolated from these mice (Figure 4.7). 
4.4 MEF2A is Co-expressed with Pax7 in Muscle Progenitor Cells 
Because MEF2 has long been considered to be expressed in committed myoblasts 
after Pax? is downregulated (Parker et al. 2003), I wanted to examine muscle progenitors 
in regeneration in greater detail by performing co-localization experiments with MEF2A 
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and Pax7-specific antibodies. Prior to this analysis, characterization of MEF2A 
antibodies (C-21, Santa Cruz Biotechnology) revealed higher reactivity with MEF2A 
compared to other MEF2 proteins (Figure 4.8). In uninjured WT muscle MEF2A and 
Pax7 are not co-expressed (Figure 4.9). In striking contrast, I discovered MEF2A/Pax7+ 
nuclei in regenerating muscle (Figure 4.10). Given this unexpected finding, I isolated 
primary myoblasts from uninjured and injured WT muscle, and single myofibers from 
injured muscle to examine MEF2A and Pax7 co-expression in greater detail. I found that 
MEF2A is co-expressed with Pax7 in activated myoblasts (MyoD+) isolated from 
uninjured muscle (Figure 4.11), indicating that MEF2A is expressed early in satellite 
cells activated from quiescence by physical isolation. In addition, I document the 
existence of MEF2NPax7 + expressing myoblasts in both single myofibers and primary 
myoblasts from injured muscle (Figure 4.12). The above results demonstrate that MEF2A 
is expressed in a subset of activated, but not quiescent, Pax7+ muscle progenitors in adult 
mice suggesting that these previously unrecognized myoblasts participate in regeneration. 
4.5 Discussion 
A common model for studying muscle regeneration in vivo is to induce muscle 
injury by cardiotoxin injection to the tibialis anterior (T A) muscle of the mouse hindlimb. 
Upon cardiotoxin administration, myofibers undergo necrosis and degenerate completely 
between days one and three post-injury. At the same time, resident Pax7-expressing 
quiescent satellite stem cells are activated to divide and produce a proliferating myoblast 
population (Yan et al. 2003). By regeneration day three, degeneration completes with the 
clearance of cell debris by infiltrating inflammatory cells, MEF2A expression peaks, and 
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myoblasts exit the cell cycle and begin fusing with the onset of differentiation (Y an et al. 
2003, Zhao and Hoffman 2004). Seven days post-injury, a mid-point in regeneration, 
newly formed myofibers have recovered approximately 50% of the cross-sectional area 
of uninjured fibers; and by day fourteen, the muscle is nearly completely regenerated 
(Yan et al. 2003). 
Using a cardiotoxin-induced model of muscle injury I have found that muscle 
repair is severely impaired in mice lacking MEF2A. The persistence of necrosis at stages 
of regeneration after cell debris is normally cleared, coupled with dramatically delayed 
myofiber cross-sectional area recovery, indicates that loss of MEF2A debilitates the 
progression of regeneration. It is possible that this phenotype may be due, in part, to the 
effects of MEF2A deletion in inflammatory cells. However, experiments which 
demonstrated differentiation defects in primary myocytes clearly show that the process of 
muscle differentiation is impaired by loss of MEF2A expression. Myoblast isolation 
experiments allowed the separation of a progenitor phenotype from complications 
resulting from prolonged necrosis in vivo. As such, the profound defects I noted in 
primary MEF2A KO myoblast differentiation along with reduced Pax7 expression 
suggests that defective muscle repair in MEF2A KO muscle is likely due to a problem in 
activated progenitors. This hypothesis was corroborated in vivo, through reduced Pax] 
mRNA levels and a significant reduction of Pax7-expressing nuclei. 
Furthermore, I have identified progenitor cells in regenerating muscle that co-
express MEF2A and Pax7, a previously unrecognized population of myoblasts. Muscle 
injury in adult mice triggers the activation of quiescent satellite cells which then 
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transition through incompletely characterized intermediate, myoblast phases. These 
activated satellite cells initially express Pax7 followed by expression of the myogenic 
bHLH factors Myf5 and MyoD (Zammit et al. 2004, Olguin and Olwin 2004, Charge and 
Rudnicki 2004, Zammit 2008). Committed myoblasts subsequently downregulate Pax7 
and induce myogenin prior to the formation of multi-nucleated myotubes. Although 
poorly characterized in skeletal muscle regeneration, MEF2 expression in this pathway 
has long been considered to occur after the downregulation of Pax7. Identification of 
MEF2A/Pax7 + myoblasts in regenerating muscle challenges this paradigm. I have found 
that Pax7+ satellite cells in uninjured muscle in vivo do not express MEF2A, but upon 
activation in culture nearly all Pax7+ cells from uninjured muscle co-express MEF2A and 
MyoD. In the absence of MEF2A, Pax7 expression is significantly reduced in activated 
myoblasts whereas MyoD levels are unaffected. These results suggest that, like MyoD 
(Zammit et al. 2004), MEF2A acts as an important regulatory switch between the 
decision to return to quiescence (MEF2A downregulation) or further commitment to 
myogenesis (MEF2A upregulation). While this hypothesis requires further investigation, 
it may explain why Pax7 expression is decreased in injured but not in uninjured MEF2A 
KO muscle in vivo. Taken together, the presence of MEF2A/Pax7+ myoblasts suggests 
that activated progenitors in regeneration express MEF2A earlier than previously 
appreciated and that these cells provide significant contribution to the regenerative 
process. 
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Figure 4.1 Full-length MEF2A is not expressed in MEF2A knockout skeletal muscle 
Irnmunoblot analysis of tibialis anterior skeletal muscle protein extracts from 2-4 month 
old wild type and MEF2A knockout mice. Uninjured, control (ctl) TA muscle and 
cardiotoxin-injured (ctox) TA muscle samples, seven days post-injury, are shown. 
GAPDH is shown as a loading control. 
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Figure 4.2 Cardiotoxin injury to MEF2A knockout skeletal muscle inhibits repair 
Tibialis anterior skeletal muscle whole mount images from 2-4 month old wild type and 
MEF2A knockout mice. TA muscles were injured with lO[!M cardiotoxin and harvested 
on regeneration day 3, 7 or 14. The white appearance of MEF2A knockout muscle is 
consistent with persistent, widespread necrosis (arrows) after injury. Sample sizes: Day 0, 
N=20 each genotype; Day 3, N=4 each genotype; Day 7, N=12 each genotype; Day 14, 
N=4 each genotype. 
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Figure 4.3 :MEF2A knockout muscle exhibits persistent necrosis after injury 
Hematoxylin and eosin staining of transverse tibialis anterior muscle sections from wild 
type and MEF2A knockout mice. Day 0 panels show control, uninjured TA muscle cross-
sections. Lower panels show TA muscle at three, seven, and fourteen days post-injury 
from the contralateral limbs of wildtype and MEF2A knockout mice. Intense basophilic 
staining (dark purple) in MEF2A knockout tissue post-injury is characteristic of 
widespread necrosis. Day 3, N=2 each genotype; Day 7, N=5 each genotype; Day 14, 
N=2 each genotype. Black bars, 50!-lm. 
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Figure 4.4 Myofiber cross sectional area is reduced in MEF2A knockout 
regeneration 
Immunofluorescence (upper panels) and quantitative (graphs) analysis of regenerating 
myofiber cross sectional area. Cryosections from control (not shown) and cardiotoxin-
injured TA muscle at regeneration days seven and fourteen (Day 7, N=5; Day 14, N=2) 
were immunostained with dystrophin (not shown) and larninin (green) antibodies to mark 
the myofiber periphery. Nuclei were stained with DAPI (blue). Myofiber cross-sectional 
area (CSA) was then assessed for all nascent myofibers with centrally located nuclei 
(arrows) using Metamorph software. Undamaged myofibers (arrow heads) and necrotic 
areas (asterisks) were not included in the analysis. Recovery of myofiber CSA was 
calculated such that the average size of nascent myofibers in regenerating tissue is 
displayed relative to the average CSA of uninjured myofibers from mice of the same 
genotype, normalized to one. CSA increases 4% in KO muscle (0.28 to 0.32) from day 7 
to day 14, while WT muscle increases 19% (0.46 to 0.65). White bars, lOOIJ.m. The CSA 
of~1000 myofibers was measured for the control and cardiotoxin-injured TA muscles of 
each mouse for this study. Error bars represent SEM. Day 7, N=5 each genotype; Day 14, 
N=2 each genotype. *p:::; 0.05, **p :::; 0.01. 
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Figure 4.5 Primary myoblasts from injured MEF2A KO muscle are differentiation 
defective Immunofluorescence of a-actinin (green) and MyoD (red) in primary wild type 
and MEF2A knockout myocytes at differentiation day 3 (DIFF3, upper panels). 
Myogenic lineage commitment and differentiation indices were calculated as the percent 
of nuclei expressing MyoD (left graph) or the percent of nuclei present in a-actinin-
positive cells (right graph), respectively. Sample size was 2:1000 nuclei for each mouse, 
N=2 each genotype. White bars, 20f,lm. Error bars represent SEM. *p ~ 0.05. 
119 
8 
1- 7 3= 
]! 6 
g 5 
z 
+4 j:::' 
~ 3 
Q. 
0 <f. 2 
~ 1 
0 
WT KO 
Figure 4.6 Pax7-positive cells are reduced in MEF2A knockout regeneration 
Immunofluorescence analysis of Pax7 (red) expression in transverse cross sections of 
wild type and MEF2A knockout TA muscle, seven days post-injury. Arrows indicate area 
shown in inset. DAPI is shown as a general nuclear marker (blue). Quantification of the 
average number of Pax7-positive nuclei in each tissue type is displayed relative to the 
total number of nuclei sampled. The percent of nuclei expressing Pax7 is 50% reduced in 
MEF2A KO muscle as compared to wild type. Sample size was 2:1000 nuclei for each 
mouse, N=3 each genotype. Error bars represent SEM, **p::SO.Ol. White bars , 20j..tm. 
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Figure 4. 7 Pax7 expression is reduced in MEF2A knockout regeneration 
Quantitative RT-PCR analysis of Pax7 expression in vivo (left, N=3 each genotype) and 
in primary myocytes (right, N=4 each genotype) isolated from injured wild type and 
MEF2A knockout muscle. Pax7 expression is significantly reduced in MEF2A KO 
samples compared to WT at day three post-injury in vivo, and at differentiation days one 
and three (Dl-D3) in culture. Error bars represent SEM. *p :S 0.05 (A. Rice and C. 
Snyder, unpublished data). 
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Figure 4.8 Mef2 antibody specificity for MEF2A detection 
Western blot analysis of MEF2 (C-21, Santa Cruz Biotechnology) antibody for MEF2A 
versus other MEF2 family transcription factors. COS 1 cells were transfected with MEF2-
FLAG expression plasmids, or empty vector pcDNA3-FLAG, and protein was harvested 
36 hours later and subjected to Western blot. The MEF2 antibody immunoblot 
demonstrates specific detection of MEF2A. A FLAG immunoblot demonstrates the 
expression level of each plasmid, and GAPDH is shown as a loading control. UT, 
untransfected. 
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Figure 4.9 Quiescent Pax7-positive satellite cells do not express MEF2A 
Immunofluorescence analysis of Pax7 (red) and MEF2A (green) expression in transverse 
cross sections of uninjured, control TA muscle from wild type mice. DAPI (blue) is 
shown as a general, nuclear stain. The top left image is shown as a merge of all channels. 
Pax7-positive (arrows) and MEF2A-positive (arrow heads) nuclei are indicated. Co-
expression of Pax7 and MEF2A was not observed in uninjured muscle. Sample size was 
2:100 nuclei for each mouse; N=6. White bars, 20).lm. 
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Figure 4.10 Regenerating muscle progenitors co-express MEF2A and Pax7 
Immunofluorescence analysis and quantification of Pax7 (red) and MEF2A (green) 
expression in transverse cross sections of regenerating (ctox, Day 7) TA muscle from 
wild type mice. Examples from two mice are shown. DAPI (blue) is shown as a general, 
nuclear stain. Seven days post-injury, nuclei co-expressing Pax7 and MEF2A are evident. 
Arrows indicate cells shown in inset. Quantification of the average percent of MEF2A-
positive (16%), Pax7-positive (7%), and MEF2A/Pax7 double-positive (1 %) nuclei 
relative to all nuclei sampled is shown. Sample size was ~1000 nuclei for each mouse; 
N=6. Error bars represent SEM, **p:'SO.Ol. White bars, 20~-tm. 
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Figure 4.11 Primary myoblasts co-express MEF2A and Pax7 
Immunofluorescence analysis of Pax7 (green), MEF2A (red), and MyoD (blue) 
expression in primary myoblasts, 48 hours post-isolation from uninjured wild type 
muscle. DAPI (cyan) is shown as a nuclear stain. Cells co-expressing Pax7, MEF2A, and 
MyoD are evident in satellite cells activated from quiescence (myoblasts) by physical 
isolation. Arrows indicate cells shown in inset. White bars, 20!!m. 
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Figure 4.12 Co-localization of MEF2A and Pax7 in regenerating muscle progenitors 
Immunofluorescence analysis of Pax7 (green) and MEF2A (red) expression in isolated 
WT EDL myofibers post-injury (Myofiber ctox, upper panels), and in primary WT 
myoblasts post-injury (Mb ctox, lower panels). DAPI (blue) is shown as a nuclear stain. 
Seven days post-injury with cardiotoxin, nuclei co-expressing Pax7 and MEF2A are 
evident. MEF2A/Pax7+ nuclei (arrows) and MEF2A single-positive nuclei (arrow heads) 
are indicated. White bars, 20f.tm. 
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Chapter 5 
MEF2A Directs Transcription of a MicroRNA Mega-Cluster to Regulate Wnt 
Signaling in Muscle Regeneration 
5.1 Introduction 
To investigate the mechanism by which MEF2A regulates proper muscle 
regeneration, microarray data comparing MEF2A knockout and wildtype T A muscle 
seven days post-injury were analyzed for dysregulated target genes which may play a role 
in myogenesis. Interestingly, 43 miRNAs present within a one mega-base cluster on 
mouse chromosome 12 were shown to be downregulated in MEF2A knockout 
cardiotoxin-injured muscle. These non-coding RNAs are present in several sub-clusters 
positioned between Gtl2 and Dio3 genes, and are hypothesized to be transcribed as one 
mega-transcript. Data presented in chapter five demonstrate that MEF2A binds a 
consensus MEF2 site within the Gtl2 promoter to regulate the transcription of rniRNAs 
downstream of Gtl2. A subset of the Gtl2-Dio3 rniRNAs represses secreted Frizzled-
related proteins (sFRPs), inhibitors of Wnt signaling. Consistent with these data, Wnt 
signaling is inhibited in regenerating MEF2A knockout muscle. Furthermore, 
overexpression of miR-410 and miR-433, two miRNAs in the mega-cluster that repress 
sFRP2, rescues myotube formation in MEF2A-deficient myoblasts. Thus, rniRNA-
mediated modulation of Wnt signaling by MEF2A is a requisite step for proper muscle 
regeneration. 
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5.2 Gene Expression Profiling of MEF2A-Deficient Regenerating Muscle 
To dissect the molecular mechanisms of defective muscle regeneration in MEF2A 
knockout mice, I subjected RNA from WT and MEF2A knockout injured TA muscle to 
microarray analysis. The most striking result of this gene expression profiling analysis 
was the large number of downregulated genes encoding miRNAs (>40 miRNAs; Figure 
5.1). Further characterization of these miRNAs revealed that they all localize to a single 
locus on mouse chromosome 12 (Figure 5.2) which may explain their coordinate 
downregulation. This locus is known as the Gtl2-Dio3 domain and has been studied 
extensively as one of the few known imprinted regions in the mammalian genome in 
which non-coding RNAs are transcribed from the maternal but not paternal allele. This 
locus is the largest known miRNA cluster in the mammalian genome (Seitz et al. 2004; 
Kircher et al. 2008). 
5.3 Quantitative RT-PCR Validation of Gtl2-Dio3 MicroRNA Cluster 
Dysregulation 
To confirm the microarray data we examined the expression of coding and non-
coding transcripts in the Gtl2-Dio3 locus. Expression of the upstream Dlkl gene, which 
has been shown to play a role in skeletal muscle development and regeneration (Waddell 
et al. 2010), was largely unaffected in regenerating MEF2A KO muscle (Figure 5.3, left 
graph). By contrast, analysis of several precursor miRNA transcripts (Gtl2 and pre-miR-
127/anti-Rtll) and selected, mature miRNA transcripts downstream of Dlkl displayed 
significant downregulation in this tissue (Figure 5.3), in primary KO myoblasts (Figure 
5.4), and in MEF2A-deficient C2C12 cells (Figure 5.5). We also determined that these 
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miRNAs are upregulated in WT primary myoblast and C2C12 differentiation (Figures 5.4 
and 5.6), paralleling the expression profile of MEF2A (Figure 5.7). Furthermore, our 
tissue expression profiling revealed that, in addition to the brain (Seitz et al. 2004, Schratt 
et al. 2006), Gtl2-Dio3 miRNAs are enriched in skeletal muscle and the heart (Figure 
5.8), a pattern which mimics the tissue distribution of MEF2A activity (Naya et al. 1999). 
These data strongly suggest that MEF2A regulates the expression of Gtl2-Dio3 miRNAs. 
5.4 MEF2A Directly Regulates Transcription of the Gtl2-Dio3 MicroRNA Locus 
Previous studies have shown that the non-coding RNAs in the Gtl2-Dio3 cluster 
are coordinately misregulated in mouse models harboring mutations affecting the 
expression of this locus (Lin et al. 2003, Zhou et al. 2010). Along these lines, a mouse 
knockout of the Gt/2 proximal promoter, which exhibits perinatal lethality and delayed 
skeletal muscle development resulted in the coordinated downregulation of miRNAs 
dispersed throughout the Gtl2-Dio3 locus (Zhou et al. 2010). While some reports have 
suggested that transcription of miRNAs within the cluster is regulated by independent 
promoters (Fiore et al. 2009, Song and Wang 2008), the coordinated downregulation of 
all miRs in this cluster in MEF2A-deficient regenerating muscle suggested that these 
miRNAs are coordinately regulated by MEF2A through an upstream cis-acting sequence. 
Upon searching the Gt/2 promoter using the Transcriptional Regulatory Element 
Database (http://rulai.cshl.edu/TRED), I identified a conserved MEF2 site located at 
position -39 (base pairs) upstream of the transcription start site which overlaps the only 
defined TATA box in the entire Gtl2-Dio3 locus (Zhou et al. 2010). In vitro gel shift 
assays showed that MEF2A binds to this MEF2 site but not to a mutant -39 MEF2 (-39 
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MUT) site harboring a mutation that disrupts the MEF2 sequence but not the TATA 
element (Figure 5.9). Nuclear extracts from C2C12 myotubes incubated with the -39 
MEF2 site showed robust DNA binding, and when incubated in the presence of MEF2A 
antibodies this complex was supershifted (Figure 5.9). To demonstrate that MEF2A 
associates with the Gtl2 promoter region harboring the MEF2 site in vivo I subjected 
chromatin from C2C12 myotubes, transfected with MEF2A-FLAG, to chromatin 
imrnunoprecipitation assays (ChiP). These assays revealed enrichment of chromatin 
harboring the -39 MEF2 site in anti-FLAG imrnunoprecipitates, indicating that mouse 
MEF2A indeed associates with the -39 MEF2 site region of the Gtl2 promoter during 
muscle differentiation (Figure 5.10). 
To determine whether MEF2A could activate the Gtl2 proximal promoter 
harboring the MEF2 site I cloned this region into pGL3Basic and used this construct in 
transient transfection assays. COS 1 cells co-transfected with MEF2A and the Gtl2 
promoter reporter resulted in a 3.0-fold activation compared to reporter alone (Figure 
5.11). Mutation of the MEF2 site, without affecting the TATA element, resulted in a 
significant decrease in MEF2A-dependent transcriptional activation (Figure 5.11). Taken 
together, these results suggest that MEF2A directly regulates transcription of the Gtl2-
Dio3 cluster from a conserved MEF2 site in the Gtl2 proximal promoter. 
5.5 Gtl2-Dio3 miRNAs target Wnt signaling inhibitors 
To understand the mechanism by which MEF2A regulates skeletal muscle 
regeneration through this miRNA mega-cluster I subjected all miRNA sequences within 
the cluster to messenger RNA (mRNA) target prediction algorithms (Target Scan and 
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MirANDA). The results of these analyses revealed that nearly half of the miRNAs in the 
Gtl2-Dio3 mega-cluster are predicted to target secreted Frizzled-related proteins (sFRPs) 
1, 2, and 4 (Figure 5.12). sFRPs constitute a well known family of inhibitors in the Wnt 
signaling pathway (Kawano and Kypta 2003, MacDonald et al. 2009), and inhibition of 
Wnt signaling through upregulation of sFRPs has been previously shown to abrogate 
myogenic differentiation (Descamps et al. 2008) 
Given the above results, I examined the expression levels of sFRP 1, -2, and -4 in 
regenerating muscle from wild type and MEF2A knockout mice. I found that expression 
of sFRPl , -2, and -4 was significantly upregulated (Figure 5.13), and that sFRP2 protein 
is upregulated in MEF2A KO muscle (Figure 5.14). I extended these results by 
examining the temporal expression of five selected Gtl2-Dio3 miRNAs and sFRP2 (miR-
540-3p, miR-433, miR-495, miR-381, miR-410) during muscle regeneration. As shown 
in Figure 5.15, between days one and three post-injury when muscle is degenerating, the 
Gtl2-Dio3 miRs are downregulated whereas sFRP2 is upregulated (Figure 5.15, solid red 
and black lines). At these early time points I did not find any significant difference in 
expression of either the miRs or sFRP2 in MEF2A knockout muscle compared to wild 
type. Between days three and seven post-injury, when myoblasts begin forming nascent 
myofibers, rniR expression increased in wild type muscle to near pre-injury levels (Figure 
5.15, solid red line). By contrast, these miRNAs failed to be upregulated by day seven in 
injured MEF2A knockout muscle (Figure 5.15, dashed red line). In a reciprocal fashion, 
the expression of sFRP2 decreased to near pre-injury levels in wildtype muscle between 
days three and seven post-injury, while its expression in MEF2A knockout muscle 
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remained 8-fold upregulated (Figure 5.15, solid and dashed black lines, respectively). 
These results reveal an inverse correlation between Gtl2-Dio3 miRNA levels and sFRP2 
expression in wild type regenerating muscle, which is coordinately dysregulated in 
MEF2A knockout mice. 
5.6 Mega-cluster miRs directly regulate the 3'UTR of sFRP2 
Because most of the miRNAs from the Gtl2-Dio3 mega-cluster are predicted to 
target sFRP2 I focused on this gene to determine whether these miRNAs could directly 
repress its expression. The 3' UTR of murine sFRP2 was cloned into the pMIR-REPORT 
vector (Ambion) and used in transient transfection assays to examine the ability of 
selected miRNAs to repress this reporter. MiRNA mimics (Ambion) were generated for 
miR-410 (located within Mirg) and miR-433 (located within anti-Rtll) because the seed 
sequences of these miRNAs and their target sequences in sFRP2 are absolutely conserved 
between mouse and human (Figure 5.16). Co-transfection of the sFRP2 3'UTR with 
either miR-410 or miR-433 mimics resulted in a significant inhibition of the reporter; 
however, these miRNAs in combination did not further inhibit the reporter (Figure 5.17). 
Mutation of the miR-410 binding site reduced the ability of the miR-410 mimic to repress 
the reporter (Figure 5.17). These results demonstrate that two miRNAs within the Gtl2-
Dio3 mega-cluster are capable of directly inhibiting sFRP2. 
5.7 Inhibition of Wnt activity in MEF2A-deficient C2C12 cells and regenerating 
muscle 
Based on the knowledge that sFRPs are inhibitors in the Wnt signaling pathway, I 
anticipated that upregulation of sFRP2 in regenerating MEF2A KO muscle would inhibit 
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Wnt activity. Initially, I examined sFRP expression and Wnt activity in C2C12 cells 
transduced with shMef2A. At differentiation day three, I observed a significant 
upregulation of sFRP-1, -2, and -4, consistent with my observations in regenerating 
MEF2A KO muscle (Figure 5.18). To determine whether Wnt signaling is inhibited in 
shMef2A cultures where sFRPs are upregulated, I assessed the expression of the 
TOPFLASH (Addgene) Wnt-sensitive luciferase reporter. The TOPFLASH plasmid, 
which harbors eight TCF/Lef binding sites, is activated when TCF and Lef transcription 
factors associate with beta-catenin in the nucleus and bind cis-regulatory elements to 
activate gene transcription (Clevers 2006). Assessment of TOPFLASH luciferase activity 
in MEF2A knockdown at C2C12 differentiation day three revealed a 5-fold decrease in 
TCF/Lef-dependent transcription (Figure 5.19). Supporting these observations, qRT-PCR 
analysis of endogenous Axin2, a Wnt-responsive gene (Clevers 2006), showed a 
significant 2-fold downregulation (Figure 5.20). 
Provided evidence of Wnt inhibition due to MEF2A knockdown in muscle cells in 
vitro, I sought to determine whether Wnt signaling was inhibited during MEF2A KO 
muscle regeneration. Translocation of ~-catenin from the cytoplasm to the nucleus is one 
of the major indicators that the Wnt signaling pathway has been activated (Clevers 2006, 
MacDonald et al. 2009). Therefore, I performed immunostaining analysis using a pan ~­
catenin antibody and found a 4-fold reduction in ~-catenin positive nuclei in MEF2A KO 
regenerating muscle (Figure 5.21, graph). I also noted an apparent increase in 
cytoplasmic ~-catenin immunoreactivity within MEF2A-deficient regenerating myofibers 
(Figure 5.21), suggesting inhibited Wnt signaling and the targeting of this protein for 
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proteasomal degradation. Supporting these observations, western blot analysis revealed a 
reduction in total ~-catenin levels in regenerating MEF2A KO muscle (Figure 5.22). 
Moreover, A.xin2 expression in primary MEF2A KO myocytes was reduced at DIFF 3 
(Figure 5.23) but not earlier time points, whereas sFRP2 was upregulated in proliferating 
myoblasts (Figure 5.24). Taken together, these results indicate that Wnt signaling is 
inhibited in MEF2A-deficient muscle cells in vitro and in vivo resulting in impaired 
skeletal muscle differentiation and regeneration, respectively. Furthermore, these data 
suggest that the onset of Wnt pathway dysregulation occurs in myoblasts (sFRP2 
upregulation) but downstream inhibition (Axin2 downregulation) is not evident until 
nascent myotube formation, when Wnt activity is required for differentiation. 
5.8 miR-410 and miR-433 rescue impaired C2C12 myogenic differentiation 
To demonstrate that miRNAs within this mega-cluster are relevant downstream 
targets of MEF2A in myogenic differentiation I transfected miRNA mimics into 
shMef2A-transduced C2C12 myoblasts. As shown in Figure 5.25, transfection of either 
miR-410 or miR-433 was sufficient to rescue the myogenic differentiation defect, but the 
two miRNAs in combination did not enhance this effect. I then assessed Wnt activity by 
way of Axin2 expression. Axin2 was restored to equal or greater than control levels in the 
presence of the miRNA mimics individually or in combination (Figure 5.26). The above 
results suggest that either miRNA mimic alone is sufficient to rescue Wnt-dependent 
gene expression in MEF2A-deficient myoblasts. These data demonstrate that the Gtl2-
Dio3 miRNAs function downstream of MEF2A to modulate Wnt signaling in myogenic 
differentiation (Figure 5.27). 
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5.9 Discussion 
MEF2A functions in regeneration by controlling transcription of the Gtl2-Dio3 
rniRNA locus. The Gtl2-Dio3 domain is the largest known non-coding RNA cluster in 
mammals and contains more than 40 rniRNAs (Seitz et al. 2004, Kircher et al. 2008). 
Previous studies have suggested that transcription of miRNA sub-clusters within the 
Gtl2-Dio3 locus is regulated by different promoters (Song and Wang 2008, Fiore et al. 
2009). While the aforementioned studies suggest the presence of independent cis-acting 
sequences within the Gtl2-Dio3 locus, our data support the hypothesis that the Gtl2-Dio3 
mega-cluster is coordinately regulated by an upstream MEF2A-dependent promoter. This 
model is based on two observations. First, a mouse knockout of the Gtl2 proximal 
promoter, which harbors the MEF2 binding site, results in the downregulation of 
rniRNAs in the Gtl2-Dio3 cluster (Zhou et al. 2010). Second, we show that the tissue 
expression pattern of multiple rniRNAs distributed throughout the cluster is similar, and 
that they are all downregulated in regenerating MEF2A knockout muscle. Although it is 
formally possible that sub-clusters of rniRNAs within the Gtl2-Dio3 domain are 
differentially regulated by independent cis-acting sequences, the most logical explanation 
for the widespread, coordinate downregulation of this cluster in our and other models is 
through a single upstream control element. It remains to be determined whether the Gtl2-
Dio3 mega-cluster is transcribed as a single, large polycistronic primary RNA transcript. 
Our studies reveal that the Wnt signaling pathway is modulated by MEF2A in 
skeletal muscle regeneration. Although Wnt has been established as an important signal 
in adult regenerative myogenesis, the mechanisms by which this pathway is regulated are 
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incompletely understood (Bracket al. 2008, Otto et al. 2008, Polesskaya et al. 2003). We 
have shown that Wnt activity is inhibited in regenerating muscle lacking MEF2A and in 
Me2A-deficient C2C12 cells. This activity is modulated by controlling the expression of 
Wnt inhibitors through the miRNA pathway. To our knowledge, this is the first evidence 
that MEF2A participates in the regulation of Wnt signaling. Furthermore, we have 
demonstrated that at least two miRNAs in this cluster directly target sFRP2, and that 
overexpression of either one these rescues the myotube differentiation defect in MEF2A-
deficient C2C12 cells. While downregulation of sFRP2 expression by these rniRNAs in 
reporter assays appears moderate, their ability to rescue myotube formation in MEF2A-
deficient cells is robust (Figure 5.27). 
Given the connection of the MEF2A!Gtl2-Dio3 miRNA pathway to regeneration, 
it is tempting to speculate that this genetic pathway also plays an important role in 
muscular dystrophies. It is known that many muscular dystrophies are characterized by 
continuous cycles of degeneration and regeneration, ultimately resulting in the failure to 
form new myofibers because muscle progenitors have been exhausted in this process 
(Wallace and McNally 2009). Recently, it was reported that expression and splicing of 
MEF2A is dysregulated in various muscular dystrophies (Bachinski et al. 2010). Perhaps 
these and other muscle dystrophies are associated with perturbed Gtl2-Dio3 miRNA 
expression resulting from altered MEF2A regulation. Indeed, numerous miRNAs are 
dysregulated in several muscular dystrophies (Eisenberg et al. 2007) and we have found 
that some of these map to the Gtl2-Dio3 locus. Our findings point to the significance of 
further interrogating MEF2A function in muscle diseases involving impaired muscle 
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regeneration, and represent an attractive area of investigation for degenerative muscle 
disorders. 
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# Gene Symbol Fold Change # Gene Symbol 
Fold 
Change 
1 Dlk1 -1.21 25 miR666 -1.36 
2 Gt12/Meg3 -1.91 26 miR543 -1.66 
3 miR770 N/A 27 miR495 -2.26 
4 miR337 -1.73 28 miR667 -1.36 
5 miR540 -1.55 29 miR376c -1.17 
6 miR665 -1.30 30 miR654 N/A 
7 Rtl1 -1.61 31 miR376b -1.25 
8 miR431 -1.23 32 miR376a -1.06 
9 miR433 N/A 33 miR300 -1.44 
10 miR 127 -2.17 34 miR381 -1.48 
11 miR434 -2.47 35 miR487b -1.97 
12 miR 136 -2.58 36 miR539 -2.24 
13 miR 341 -1.43 37 miR382 -1.42 
14 miR370 -1.32 38 miR 134 -1.76 
15 Rian/1 rm/Meg8 -2.06 /MBII-343/miR 882 
39 miR668 -1.25 
40 miR485 -1.84 
16 miR379 -1.68 41 miR 154 -1.62 
17 miR411 -1.43 42 miR496 -1.36 
18 miR299 -1.55 43 miR377 -1 .52 
19 miR380 -1.44 44 miR541 1.05 
20 miR323 -1.90 45 miR409 -2.14 
21 miR758 N/A 46 miR412 -1.70 
22 miR329 -1.60 47 miR369 -1.49 
23 miR494 -1.26 48 miR410 -3.14 
24 miR679 -1.61 49 Dio3 -1.10 
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Figure 5.1 Gene expression profile of Gtl2-Dio3 locus transcripts in MEF2A 
knockout mice 
Gene expression profiling by rnicroarray analysis compared regenerating MEF2A 
knockout TA muscle to wild type TA muscle at regeneration day 7. RNA samples from 
five adult, age (2-4 months old) and sex-matched, MEF2A knockout and wild type mice 
were pooled, reverse transcribed, and subjected to rnicroarray profiling. The Affymetrix 
1.0 ST Gene Array was used to profile expression of genes in the mouse genome. 
MicroRNA transcripts in the Gtl2-Dio3 locus on chromosome 12 are indicated in bold. 
Protein coding and other non-coding transcripts from this locus are shown in regular 
script. Transcripts are listed in numerical order according to their position within the 
locus, and their expression levels are displayed as fold change in MEF2A knockout 
muscle relative to wild type muscle. N=l. Fold change is listed as not available (N/A) for 
those transcripts which were not present on the rnicroarray. 
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Figure 5.2 Diagram depicting the relative positions of microRNAs and other 
transcripts in the Gtl2-Dio3 locus 
Relative positions of transcripts within the Gtl2-Dio3 genomic locus on mouse 
chromosome 12 are displayed. The top ten most downregulated rnicroRNAs, according to 
rnicroarray data, in MEF2A knockout TA muscle compared to wild type are shown. The 
relative positions of downregulated microRNAs demonstrate that MEF2A-loss-of-
function affects the expression of rnicroRNAs throughout the Gtl2-Dio3 mega-cluster. 
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Figure 5.3 RT-PCR analysis of transcripts from the Gtl2-Dio3 microRNA cluster 
locus 
Quantitative RT-PCR (left bar graph) and stem-loop quantitative RT-PCR (right bar 
graph) was performed on transcripts selected throughout the Gtl2-Dio3 locus. Results 
shown here demonstrate the expression of transcripts in MEF2A knockout TA muscle 
samples relative to wild type at regeneration day 7. Wild type expression values were 
normalized to one. These results demonstrate that Dlkl expression is unaffected in 
MEF2A knockout muscle, but Gtl2 and all downstream microRNA transcripts tested 
were significantly downregulated in MEF2A knockout samples. RT-PCR was performed 
on RNA pooled from five mice of each genotype, seven days post-injury, (N2:3, technical 
replicates). Error bars represent SEM. *p:S0.05, **p:SO.Ol, ***p:SO.OOl. 
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Figure 5.4 miRNA expression is decreased during differentiation in MEF2A KO 
myoblasts in culture Stem-loop quantitative RT-PCR analysis of five selected miRNAs 
distributed throughout the Gtl2-Dio3locus during the differentiation of primary wild type 
(WT) and MEF2A knockout (KO) myoblasts. MiRNA expression values in myoblasts 
for each primary cell line was normalized to one. Relative expression of miRNAs 
represents the fold change in expression at differentiation day 1 through day 5 (D1-D5) 
relative to myoblasts. RT-PCR was performed on primary myocytes from two mice of 
each genotype, post-injury. N=2 biological replicates, N~3 technical replicates. Error bars 
represent SEM. (A. Rice, unpublished data). 
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Figure 5.5 miRNA expression is decreased in MEF2A knockdown C2C12 cells 
Stem-loop quantitative RT-PCR analysis of five selected miRNAs distributed throughout 
the Gtl2-Dio3 locus at differentiation day 3 in C2C12 cells transduced with shLacZ or 
shMef2A. MiRNA expression values in shLacZ transduced samples were normalized to 
one. Relative expression of miRNAs represents the fold change in expression in MEF2A 
knockdown at differentiation day 3 relative to the shLacZ negative control. N=4 
biological replicates, N2:3 technical replicates. Error bars represent SEM. * *p~O .Ol , 
***p~O.OOl. (A. Rice and C. Snyder, unpublished data). 
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Figure 5.6 miRNA expression increases during differentiation in C2C12 myoblasts 
Stem-loop quantitative RT-PCR analysis of five selected miRNAs distributed throughout 
the Gtl2-Dio3 locus during the differentiation of C2C12 myoblasts in vitro. miRNA 
expression values in myoblasts for each miRNA was normalized to one. Relative 
expression of miRNAs represents the fold change in expression at differentiation day 1 
through day 5 (Dl-D5) relative to myoblasts, normalized to one. N=4 biological 
replicates, N2:3 technical replicates. Error bars represent SEM. (A. Rice and C. Snyder, 
unpublished data). 
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Figure 5.7 MEF2A expression increases during regeneration in vivo and 
differentiation in vitro 
Western blot (upper panel) and quantitative RT-PCR (graph) analysis of MEF2A 
expression during wild type regeneration in vivo and differentiation of myoblasts in 
culture, respectively. The immunoblot displays MEF2A protein expression as detected 
by the MEF2 antibody in uninjured (ctl) TA protein extracts and at various regeneration 
time points (days 3-14) post-injury. The graph plots MEF2A mRNA expression in 
primary WT myocytes and C2C12 cells over a course of differentiation from myoblasts 
(Mb) through differentiation day 5 (D5), as detected by qRT-PCR. MEF2A expression in 
myoblasts is normalized to one. Relative expression of rniRNAs represents the fold 
change in expression at differentiation day 1 through day 5 (D1-D5) compared to 
myoblasts. N2:3 biological replicates, N2:3 technical replicates. Error bars represent SEM 
(N. Estrella and A. Rice, unpublished data). 
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Figure 5.8 Tissue distribution pattern of Gtl2-Dio3 cluster microRNAs 
Stem-loop quantitative RT-PCR analysis of Gtl2-Dio3 cluster microRNAs in wild type 
tissues. MicroRNA expression levels in the brain are normalized to 100 percent. The 
expression levels of select microRNAs in other tissues are shown relative to the brain. 
These data demonstrate that microRNAs from throughout the cluster are enriched in the 
brain, skeletal muscle, and heart (N=3). Error bars represent SEM. 
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Figure 5.9 MEF2A binds the -39 bp Mef2 site in the Gtl2 proximal promoter 
Electromobility shift assay (EMSA) analysis of MEF2A binding to the -39 MEF2 site 
upstream of Gtl2. The schematic above shows that the MEF2 site is located -39 base pairs 
upstream of the Gtl2 transcription start site and overlaps the only known TA TA box 
(gray) in the 1 megabase miRNA locus on chromosome 12. EMSA analysis showed 
binding of the -39 MEF2 site probe by in vitro translated mouse MEF2A was abolished 
by mutation of the -39 MEF2 site. Incubation of C2C12 myotube nuclear extracts (NE) 
with MEF2A antibodies shifted the MEF2 complex bound to the -39 MEF2 probe (N=4). 
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Figure 5.10 MEF2A associates with the endogenous -39 Mef2 site during myocyte 
differentiation 
Chromatin immunoprecipitation (ChiP) analysis showed 6.5 fold enrichment of the Gtl2 
promoter fragment containing the -39 MEF2 site in MEF2A-FLAG immunoprecipitates. 
For this analysis C2C12 differentiation day three myotubes, transfected with mouse 
MEF2A-FLAG, were subjected to ChiP analysis. Quantitative RT-PCR was used to 
determine fold enrichment of the chromatin region harboring the -39 MEF2 site in anti-
FLAG immunoprecipitates versus anti-HA immunoprecipitates (negative control), 
normalized to one (N=5). Error bars represent SEM. *p:S0.05. 
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Figure 5.11 :MEF2A activates transcription through the -39 Mef2 site 
Luciferase assay analysis of pGL3basic-39 MEF2 site activation by mouse MEF2A was 
performed by transient transfection in COS 1 cells. pGL3basic-39 MEF2 site activation in 
the presence of MEF2A (pcDNA3-MEF2A) versus empty vector (pcDNA3) showed 
three-fold greater luciferase activity. Mutation of the MEF2 site (as shown in Figure 5.9) 
significantly decreased luciferase activity in the presence of MEF2A relative to the wild 
type site. Error bars represent SEM, N2:3. *p:S0.05, **p:SO.Ol. (A. Held, unpublished 
data). 
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Figure 5.12 A majority of mega-cluster miRNAs are predicted to target sFRPs 
Schematic representation of miRs positioned throughout the cluster (colored diamonds) 
which are predicted to target the 3'UTRs of sFRPs -1, -2, and -4 as indicated (TargetScan 
and MirANDA). 
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Figure 5.13 sFRP expression is upregulated in MEF2A KO muscle post-injury 
Quantitative RT-PCR of sFRP expression in TA muscle, seven days post-injury revealed 
significant upregulation in MEF2A KO tissue (N=3 biological replicates; N~3 technical 
replicates). Error bars represent SEM. **p:SO.Ol , ***p:SO.OOl. 
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Figure 5.14 sFRP2 protein is upregulated in MEF2A KO muscle post-injury 
Western blot analysis of sFRP2 protein expression in wild type and MEF2A knockout 
TA muscle, seven days post-injury (N=2, each genotype). Space indicates non-adjacent 
lanes from a single blot. GAPDH is shown as a protein loading control (N. Estrella, 
unpublished data). 
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Figure 5.15 miRNA and sFRP2 changes in gene expression during regeneration 
Representation of cluster miRNA and sFRP2 changes in gene expression (qRT-PCR) 
over a time course in regeneration. MiR expression values represent the average change 
in gene expression of five miRNAs (miR-540-3p, miR-433, miR-495, miR-381, miR-
410) predicted to target the 3'UTR of sFRP2. This data showed no significant difference 
in miRNA and sFRP2 expression at regeneration day 3 between WT and MEF2A KO 
samples. However, at regeneration day seven, sFRP2 showed 8-fold upregulation and 
miRs were 3.7-fold downregulated in MEF2A KO samples compared to WT (N=3, each 
genotype). Error bars represent SEM. ***p<O.OOl. 
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miR-41 0 alignment: 
3' UGUCCGGUAGACACAAUAUA A 5' mmu-miR-410 
I I I I I I 
5' AUUUCAGAUAAACAUUAUAU U 3' mousesFRP2 
3' UGUCCGGUAGACACAAUAUA A 5' hsa-miR-410 
I I I I I I 
5' AUUUCAGAUAAACAUUAUAU u 3' humansFRP2 
miR-433 alignment: 
3' UGUGGCUCCUCGGG UAGUACU A 5' mmu-miR-433 
I I I I I I I 
5' UUCAAACUAAUAAAAUCAUGAc 3' mousesFRP2 
3' UGUGGCUCCUCGGG UAGUACU A 5' hsa-miR-433 
I I I I I I I 
5' UUCAAACUAAUAAAAUCAUGAc 3' humansFRP2 
Figure 5.16 miR-410 and -433 target sequences are evolutionarily conserved 
Sequence alignments of miR-433 and miR-410 seed sequences and predicted 3'UTR 
sFRP2 target sites (red) showed 100% conservation between mouse and human 
sequences (MirANDA). mmu, mus musculus; hsa, homo sapiens. 
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Figure 5.17 miR-410 and -433 inhibit expression of the sFRP2 3'UTR 
Luciferase assay analysis of miR-410 and miR-433 effect on pMIR-REPORT-3 'UTR-
sFRP2 expression. Luciferase activity of the wild type sFRP2 3 'UTR reporter was 
significantly reduced when co-transfected with miR-410 and miR-433 precursor miRNA 
mimics (150nM, Ambion) in COS 1 cells, compared with a non-specific control (NSC) 
miR mimic normalized to one (right graph, N=6). Mutation (MUT) of the miR-410 target 
sequence in the 3'UTR of sFRP2 from TTATAT to GGGGGG reduced luciferase 
inhibition by miR-410 (left graph), compared to miR-NSC (normalized to one). For miR 
cocktail experiments, 75nM miR-410 and 75nM miR-433 was used (150nM total). Error 
bars represent SEM. *p::S0.05, ***p::S0.001 (A. Held and C. Snyder, unpublished data). 
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Figure 5.18 sFRPs are upregulated in MEF2A-deficient C2C12 differentiation 
Quantitative RT-PCR analysis demonstrated upregulation of sFRPl, -2, and -4 in C2C12 
myocytes at differentiation day three (DIFF 3), post-transduction with shMef2A (DIFF -
1, MOl 25). Relative expression is shown as fold change relative to shLacZ (negative 
control) transduced samples, normalized to one. Error bars represent SEM, N=3. 
*p<0.05, **p<0.01, ***p<O.OOl. 
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Figure 5.19 Wnt reporter activity is reduced in MEF2A-deficient C2C12 myocytes 
Luciferase analysis of the TOPFLASH reporter in C2C12 cells at differentiation day 3 
(DIFF 3), post-transduction with shMef2A (DIFF -1, MOl 25), showed a 5.6-fold 
decrease in luciferase activity. Relative luciferase activity is shown as fold change 
relative to shLacZ (negative control) transduced cells. Error bars represent SEM, N=3. 
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Figure 5.20 Axin2 expression is downregulated in MEF2A-deficient C2C12 cells 
Quantitative RT-PCR analysis of Axin2 expression in C2C12 myocytes at differentiation 
day 3 (DIFF3), post-transduction with shMef2A (DIFF -1, MOl 25) demonstrated a 2-
fold downregulation of Axin2 expression. Relative expression is shown as fold change 
relative to shLacZ (negative control) transduced samples, normalized to one. Error bars 
represent SEM, N=3. ***p<O.OOl. 
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Figure 5.21 Nuclear localization of ~-catenin is reduced in MEF2A KO muscle 
Immunostaining and quantification of ~-catenin expression in MEF2A KO and WT T A 
muscle, seven days post-injury. MEF2A KO muscle demonstrated an 80% reduction in 
nuclear ~-catenin staining (arrow heads) compared with WT (arrows), accompanied by an 
increase in cytoplasmic ~-catenin staining (N=3). Quantification of the percent [3-catenin-
positive nuclei reflects the total number of [3-catenin-positive nuclei relative to the total 
number of nuclei. Sample size was 2:1000 nuclei for each mouse; N=3 . Error bars 
represent SEM, ***p:SO.OOl. White bars, 20j.lm. 
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Figure 5.22 ~-catenin protein expression is reduced in MEF2A KO muscle, post-
injury 
Western blot analysis of TA muscle extracts seven days post-injury demonstrated a 
reduction in total ~-catenin expression in MEF2A-deficient muscle (N=3). 
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Figure 5.23 Axin2 expression is downregulated in primary :MEF2A KO myocytes 
Quantitative RT-PCR analysis of Axin2 expression in primary MEF2A KO myocytes at 
differentiation day 3 (DIFF3) demonstrated a 2-fold downregulation of Axin2 expression. 
Relative expression is shown as fold change relative to Axin2 expression in primary WT 
myocyte samples (DIFF3), normalized to one. Error bars represent SEM, N=3 each 
genotype. *p:S0.05. 
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Figure 5.24 sFRP2 expression during primary myocyte differentiation. 
Expression of sFRP2 in WT and MEF2A KO primary myocytes during a differentiation 
timecourse. Myoblast (Mb) and differentiation day 1-5 (DIFF1-5) time points are 
indicated. Relative expression is displayed as fold change relative to WT Mb expression 
levels, normalized to one. Error bars represent SEM. N=2 biological replicates, N2:3 
technical replicates. *p~0.05 (A. Rice, unpublished data). 
162 
miR-NSC miR-410 miR-433 miR-410 + 433 
Figure 5.25 miRNAs 410 and 433 rescue myotube differentiation in MEF2A-
deficient C2C12 cells 
Phase contrast images of C2C12 differentiation rescue experiments at differentiation day 
three (DIFF3). C2C12 cells were transduced with shRNA-adenovirus (shLacZ or 
shMef2A, MOl 25) at DIFF -1 , transfected with miR mimics (40nM miR-410 or miR-
433, Ambion) at DIFF 0, and induced to differentiate in culture for three days (DIFF3). 
For miR cocktail experiments, 20nM miR-410 and 20nM miR-433 was used (40nM 
total). C2C12 myoblasts transfected with either miR-410 or miR-433 exhibited rescued 
mytoube formation in MEF2A-deficient cultures by DIFF3. Combination of miR-410 and 
miR-433 did not further enhance this effect. NSC, non-specific control. Black bars , 
20f!m. N=4. 
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Figure 5.26 miRs 410 and 433 rescue Axin2 expression in MEF2A-deficient C2C12 
myocytes 
Quantitative RT-PCR analysis of Axin2 expression in C2C12 rniRNA rescue 
experiments. Axin2 expression in shMef2A-transduced rniR-NSC samples is significantly 
reduced compared with shLacZ-transduced rniR-NSC samples at differentiation day 
three. However, Axin2 expression is not significantly (n.s.) different from the shLacZ 
miR-NSC negative control in shMef2A-transduced cells transfected with rniR-410, miR-
433, or rniR-410+433. This result demonstrates restoration of Axin2 expression, by miRs 
410 and 433, to levels found in negative control samples. Relative expression is displayed 
as fold change relative to shLacZ rniR-NSC samples, normalized to one. NSC, non-
specific control. Error bars represent SEM, N=4. *p:S0.05 (A. Rice, unpublished data). 
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Figure 5.27 Model of the MEF2A/miR/Wnt pathway in muscle regeneration 
Model of the MEF2A-dependent miRNA pathway controlling Wnt signaling during 
skeletal muscle regeneration. Briefly, after muscle injury MEF2A activates the Gtl2-Dio3 
cluster of miRNAs to inhibit sFRP2 expression. Downregulation of sFRP2 in 
regeneration allows active Wnt signaling to promote the differentiation of regenerating 
myoblasts into mature myotubes. 
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Chapter 6 
Discussion 
6.1 Discussion 
The results of this study reveal an essential role for MEF2A in skeletal muscle 
regeneration. My data demonstrate that regenerating myoblasts initiate a gene program, 
distinct from development, which is characterized by the early expression of MEF2A. 
Accordingly, skeletal muscle lacking MEF2A is unable to regenerate properly in 
response to injury. I show that MEF2A functions in regenerative myogenesis by 
regulating transcription of the Gtl2-Dio3 miRNA mega-cluster and that several of these 
miRNAs target sFRP2, an inhibitor of Wnt signaling. Consistent with these observations, 
injured MEF2A KO muscle exhibits increased sFRP expression and attenuated Wnt 
activity. Furthermore, we have discovered a previously uncharacterized muscle 
progenitor population in regeneration which co-expresses MEF2A and Pax7. These 
results firmly establish a molecular link between two important developmental regulators, 
MEF2 and Wnt, in the process of adult regenerative myogenesis. 
Previous studies on MEF2A KO mice concluded that this factor is largely 
dispensable for the development of skeletal muscle (Potthoff et al. 2007b). By contrast, 
the present study shows that MEF2A is essential for skeletal muscle regeneration. These 
data suggest that the differentiation function of MEF2A in mammalian skeletal muscle is 
context dependent. In mice, MEF2A is expressed after Mef2d, one of the earliest Mef2 
transcripts expressed in developing muscle (Edmondson et al. 1994). But in primary 
myoblasts and C2C12 cells MEF2A is expressed before Mef2d. Moreover, upon injury, 
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expression of MEF2A is upregulated whereas MEF2C is downregulated in regenerating 
muscle (Zhao and Hoffman 2004). Although it remains to be determined whether other 
MEF2 family members function in skeletal muscle regeneration, our data suggest that the 
regulation and/or activity of MEF2A has been reprogrammed such that it plays a more 
prominent role in adult myogenesis. 
Using a cardiotoxin-induced model of muscle injury I have found that muscle 
repair is severely impaired in mice lacking MEF2A. This defect results from impaired 
myogenic differentiation and a significant reduction of Pax7-expressing myoblasts. 
Furthermore, I have identified progenitor cells in regenerating muscle that co-express 
MEF2A and Pax7, a previously unrecognized population of myoblasts. Muscle injury in 
adult mice triggers the activation of quiescent satellite cells which then transition through 
incompletely characterized intermediate, myoblast phases. These activated satellite cells 
initially express Pax7 followed by expression of the myogenic bHLH factors Myf5 and 
MyoD (Zammit et al. 2004, Olguin and Olwin 2004, Charge and Rudnicki 2004, Zammit 
2008). Committed myoblasts subsequently downregulate Pax7 and induce myogenin 
prior to the formation of multi-nucleated myotubes. Although poorly characterized in 
skeletal muscle regeneration, MEF2 expression in this pathway has long been considered 
to occur after the downregulation of Pax7. Identification of MEF2A/Pax7 + myoblasts in 
regenerating muscle challenges this paradigm. I have found that Pax7+ satellite cells in 
uninjured muscle in vivo do not express MEF2A, but upon activation in culture nearly all 
Pax7+ cells from uninjured muscle co-express MEF2A and MyoD. In the absence of 
MEF2A, Pax7 expression is significantly reduced in activated myoblasts whereas MyoD 
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levels are unaffected. These results suggest that, like MyoD (Zammit et al. 2004), 
MEF2A acts as an important regulatory switch between the decision to return to 
quiescence (MEF2A downregulation) or further commitment to myogenesis (MEF2A 
upregulation). While this hypothesis requires further investigation, it may explain why 
Pax7 expression is decreased in injured but not in uninjured MEF2A KO muscle in vivo. 
Taken together, the presence of MEF2A/Pax7+ myoblasts suggests that activated 
progenitors in regeneration express MEF2A earlier than previously appreciated and that 
these cells provide significant contribution to the regenerative process. 
MEF2A functions in regeneration by controlling transcription of the Gtl2-Dio3 
miRNA locus. The Gtl2-Dio3 domain is the largest known non-coding RNA cluster in 
mammals and contains more than 40 miRNAs (Seitz et al. 2004, Kircher et al. 2008). 
According to microarray data presented in chapter 4, Gtl2 and all Gtl2-Dio3 miR 
transcripts included in the mouse Affymetrix 1.0ST array were downregulated in MEF2A 
knockout muscle compared with wildtype muscle seven days post-injury. These results 
indicate that MEF2A coordinately regulates the transcription of the entire Gtl2-Dio3 
locus during muscle regeneration. 
Previous studies have suggested that transcription of miRNA sub-clusters within 
the Gtl2-Dio3 locus is regulated by different promoters (Song and Wang 2008, Fiore et 
al. 2009). For example, Song and Wang (2008) showed that mini-promoters proximal to 
each miR-433 and miR-127 are activated by ERRy, but that miR-433 and 127 can also be 
transcribed together as a single pri-miR. These findings indicate that pri-miR-433-127 
can be transcribed from an upstream region, and that the ERRy-activated sites proximal 
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to miR-433 and 127 may function as alternative downstream promoters. Additionally, 
Fiore et al. (2009) identified a cis-element 20kb upstream of the miR-379-410 cluster 
able to be activated downstream of a viral minimal promoter (in pGL3p) two-fold by the 
constitutively active MEF2-VP16 construct. The distance of this cis-element from the 
rniR-379-410 cluster and its weak activation indicate that this MEF2-bound region may 
act as a long-range enhancer rather than a promoter. Despite the identification of 
independent cis-acting sequences within the Gtl2-Dio3 locus by the aforementioned 
studies, my data support a model wherein the Gtl2-Dio3 mega-cluster is coordinately 
regulated by an upstream MEF2A-dependent promoter. This model is based on two 
observations. First, a mouse knockout of the Gtl2 proximal promoter, which harbors the 
MEF2 binding site, results in the downregulation of miRNAs in the Gtl2-Dio3 cluster 
(Zhou et al. 2010). Second, I show that the tissue expression pattern of multiple miRNAs 
distributed throughout the cluster is similar, and that they are all downregulated in 
regenerating MEF2A knockout muscle. Although it is formally possible that sub-clusters 
of miRNAs within the Gtl2-Dio3 domain are differentially regulated by independent cis-
acting sequences, the most logical explanation for the widespread, coordinate 
downregulation of this cluster in our and other models is through a single upstream 
control element. It remains to be determined whether the Gtl2-Dio3 mega-cluster is 
transcribed as a single, large polycistronic primary RNA transcript. 
My studies reveal that the Wnt signaling pathway is modulated by MEF2A in 
skeletal muscle regeneration. Although Wnt has been established as an important signal 
in adult regeneration, the mechanisms by which this pathway is regulated are 
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incompletely understood (Polesskaya et al. 2003, Brack et al. 2008, Otto et al. 2008). 
Target prediction analyses (MirANDA, Microcosm, TargetScan) performed for all Gtl2-
Dio3 cluster miRs indicated that more than half of these miRs are predicted to target 
secreted Frizzled-related protein family members (sFRPl , 2 and 4), known for their role 
in inhbiting canonical Wnt signaling. Furthermore, I found that the expression of several 
of these miRs (miR-540-3p, miR-433, miR-495, miR-381, miR-410) were coordinately 
regulated with sFRP2 during muscle regeneration, and that miR-433 and miR-410 were 
able to directly regulate the expression of sFRP2. It has previously been reported that 
Wnt signaling promotes the ability of skeletal muscle cells to differentiate during 
regeneration (Polesskaya et al. 2003), and inhibition of Wnt signaling by sFRP 
overexpression prevents myoblast differentiation (Descamps et al. 2008, Levin et al. 
2001). 
The studies described in chapter 5 also demonstrate that sFRP2 regulation of Wnt 
signaling in muscle regeneration occurs downstream of MEF2A. MEF2A-loss-of-
function in vitro and in vivo led to downregulation of Gtl2-Dio3 miRs and the 
upregulation of sFRPs 1, 2 and 4. Furthermore, the upregulation of sFRPs in the absence 
of MEF2A was accompanied by decreased TCF/Lef transcriptional activity and 
decreased Axin2 expression. In vivo, these events coincided with decreased beta-catenin 
protein expression and nuclear localization. Together, these results demonstrate that loss 
of MEF2A induces sFRP upregulation and inhibition of Wnt signaling in muscle 
regeneration. 
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Descamps et al. (2008) demonstrated that while overexpression of sFRPs 1 and 2 
inhibit myoblast differentiation, removal of sFRPs 1 and 2 from myoblast culture 
medium could also restore normal myotube formation via rescue of Wnt signaling. On 
the basis of Descamps' findings, I found that expression of miR-433 and 410 mimics in 
MEF2A knockdown cultures restored myotube formation in C2C12 cells and rescues 
Axin2 expression. 
Collectively, these data couple the function of Gtl2-Dio3 miRs downstream of 
MEF2A to the regulation of sFRP2 and Wnt signaling during muscle differentiation. My 
study is the first demonstration that MEF2A participates in the regulation of Wnt 
signaling to control a biological process, and that MEF2A plays a critical role in the 
differentiation of adult skeletal muscle in mammals. Together these data indicate that 
MEF2A is a key regulator of muscle regeneration, and that further insights into the role 
of MEF2A in this process will contribute to a greater understanding of how 
transcriptional pathways can be manipulated for the promotion of regeneration and the 
treatment of disease. 
6.2 Future Perspectives 
6.2.1 Examination of the Role of MEF2A in Muscular Dystrophy 
Given the connection of the MEF2A!Gtl2-Dio3 miRNA pathway to regeneration 
it is tempting to speculate that this genetic pathway also plays an important role in 
muscular dystrophies . It is known that many muscular dystrophies are characterized by 
continuous cycles of degeneration and regeneration, ultimately resulting in the failure to 
form new myofibers because muscle progenitors have been exhausted in this process as 
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patients age (Wallace and McNally 2009). Recently, it was reported that expression and 
splicing of MEF2A is dysregulated in various muscular dystrophies (Bachinski et al. 
2010), and that MEF2A is upregulated in rnyocytes of the mouse model of Duchenne 
muscular dystrophy, mdx (Yablonka-Reuveni and Anderson 2006). Perhaps these and 
other muscle dystrophies are associated with perturbed Gtl2-Dio3 miRNA expression 
resulting from altered MEF2A regulation. Indeed, numerous miRNAs are dysregulated in 
several muscular dystrophies (Eisenberg et al. 2007) and we have found that some of 
these map to the Gtl2-Dio3locus, notably miR-410. 
Future directions for this area of investigation will include analysis of MEF2A 
loss-of-function in mdx mice. As MEF2A is upregulated in skeletal muscle of mdx mice 
(Yablonka-Reuveni and Anderson 2006), generating a MEF2A knockout mouse line in 
the pure mdx background may provide proof-of-principle amelioration or rescue of 
muscular dystrophy symptoms. It will be interesting to determine whether global MEF2A 
knockout or inducible loss of MEF2A expression influences the process of regeneration 
in mdx muscle, and whether augmentation of MEF2A expression in Pax7+ progenitors 
can preserve the stern cell population later in life in dystrophy-affected muscle. 
Furthermore, it needs to be determined through use of techniques similar to those used in 
this dissertation whether MEF2A misexpression in mdx muscle alters Gtl2-Dio3 cluster 
expression to control sFRP2 and Wnt signaling in dystrophic regeneration. 
The findings described in this dissertation point to the significance of further 
interrogating MEF2A function in muscle diseases involving impaired muscle 
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regeneration, and represent an attractive area of investigation for degenerative muscle 
disorders. 
6.2.2 Characterization of the Pax7/MEF2A Progenitor Population in Adult 
Skeletal Muscle 
Findings detailed in chapter 4 describe the identification of MEF2A co-expression 
with Pax7 in muscle progenitors in vivo during regeneration and in vitro during the 
differentiation of myoblasts isolated post-injury. While MEF2A/Pax7 double positive 
cells were not detected in resting, uninjured TA muscle, MEF2A expression was 
observed in Pax7+ nuclei positioned at the periphery of freshly isolated myofibers from 
injured muscle. These findings indicate that MEF2A is not expressed by quiescent 
satellite cells, but that it is quickly upregulated post-injury in muscle progenitors 
positioned in the satellite cell niche. This upregulation occurs at approximately the same 
time as the onset of MyoD expression, but the order in which MEF2A and MyoD are 
expressed remain unknown. Future studies investigating the role of MEF2A/Pax7 + 
progenitors in regeneration will need to assess the expression timing of MEF2A, MyoD, 
and Myf5 in relation to one another after injury is induced. Further analyses will also 
need to determine whether MEF2A/Pax7+ cells represent a progenitor sub-population 
that contributes to regeneration, or whether the early expression of MEF2A with Pax7 is 
a common feature of all satellite cells and early myoblasts. Additionally, it will be 
interesting to determine whether myogenic progenitor side populations or interstitial 
cells, which are known to contribute to regeneration, express MEF2A at the time Pax7 is 
upregulated. Obtaining a more detailed understanding of where and when MEF2A is 
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expressed during muscle regeneration will provide greater insight into the number of 
progenitor stages which exist between myo-initiation in satellite cells and commitment of 
myoblasts to differentiation. 
6.2.3 Investigation of the Roles of Individual Gtl2-Dio3 Cluster MicroRNAs in 
Muscle Regeneration 
The study described herein details a MEF2A-dependent pathway in skeletal 
muscle regeneration which utilizes the Gtl2-Dio3 cluster of rniRNAs to control Wnt 
singaling via sFRP2. While I have demonstrated that two miRs from this cluster ( 410 and 
433) can directly regulate sFRP2 expression, a cohort of miRNAs within this cluster have 
been shown to be downregulated in MEF2A and Gtl2 mutant mice, both of which display 
aberrant skeletal muscle phenotypes (Zhou et al. 2010, C. Snyder and F. Naya 
unpublished data). Furthermore, dysregulation of the Gtl2-Dio3 miRs have been 
associated with impaired skeletal muscle function in a variety of muscular dystrophies 
(Eisenberg et al. 2007). Together, these studies indicate a role for Gtl2-Dio3 miRNAs in 
skeletal muscle homeostasis, and offer considerable contribution to the repertoire of miRs 
known to be involved in muscle regeneration as only three well-characterized miRNAs 
(miR-1 , 133 and 206) were previously known to modulate this process (Chen et al. 2010, 
Nakasa et al. 2010). 
Future studies regarding the characterization of roles for individual Gtl2-Dio3 
miRNAs in skeletal muscle will involve both loss- and gain-of-function studies. A 
complicating factor in this analysis is that miRs of the Gtl2-Dio3 locus are located in 
such close proximity to one another that generation of knockout mouse models for 
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individual miRs is not possible. Instead, loss-of-function analysis will need to involve the 
generation of transgenic mice overexpressing an anti-miR to an individual Gtl2-Dio3 
miR, or local injection of adenovirus expressing anti-miRs into regenerating muscle. 
Gain-of-function analyses may use similar technical approaches to overexpress individual 
miRNAs in an inducibily conditional manner in mouse skeletal muscle. Furthermore, 
analysis of synthesized miR mimics and anti-miRs to individual Gtl2-Dio3 miRs in a 
primary human skeletal myoblasts will provide a greater understanding of the function of 
these conserved miRs in controlling skeletal muscle differentiation and regeneration in a 
human health-relevant context. 
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APPENDIX 
Supplemental Data 
The purpose of the included appendix is to provide the reader with supplemental 
data beyond the scope of the dissertation. This appendix includes additional microarray 
data from the shMef2A vs. shLacZ C2C12 microarray described in chapter 3 (section 
3.5). Included in the appendix are the top upregulated (Table A.l) and downregulated 
(Table A.2) genes comparing shMef2A and shLacZ arrays at differentiation day 3. The 
appendix also includes additional microarray data from the MEF2A KO vs. WT 
regeneration day 7 microarray described in chapter 5 (section 5.2). Included in the 
appendix are the top upregulated (Table A.3) and downregulated (Table A.4) genes 
comparing MEF2A KO and WT TA arrays. Also included is a table comparing miR gene 
expression values for 5 miRs from the Gtl2-Dio3 cluster predicted to target sFRP2. This 
table compares gene expression values from MEF2A KO vs. WT microarray and qPCR 
analysis at regeneration day 7, as well as qPCR analysis of miR expression in shMef2A 
vs. shLacZ RNA samples in C2C12 cells at differentiation day 3 (Table A.5). 
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# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mANA Accession 
1 1.152424311 21 .01579314 18.23615915 Cck NM 031161 
2 1. 146444885 6.559414299 5.721526069 Cpa1 NM 025350 
3 1.164171819 4.654863943 3. 998433794 Pvalb NM 013645 
4 1.037713365 4.066486995 3.918699646 Car2 NM 009801 
5 0.960371836 3.181978307 3.313277408 Npy1r NM 010934 
6 0.98047381 3.197567911 3.261247651 Pi15 NM 053191 
7 0.882368382 2.859640917 3.24086966 ld3 NM 008321 
8 0.973491306 2.896321993 2.975190404 ldo1 NM 008324 
9 0.918586827 2.677677105 2.914996194 --- ENSMUST00000101859 
10 0.946585022 2.692717722 2.844665464 Snord116 AF241256 
11 0.946585022 2.692717722 2.844665464 Snord116 AF241256 
12 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
13 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
14 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
15 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
16 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
17 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
18 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
19 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
20 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
21 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
22 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
23 0. 946585022 2.692717722 2.844665464 Snord116 NR 002895 
24 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
25 0.946585022 2.692717722 2.844665494 Snord116 NR 002895 
26 0. 946585022 2.692717722 2.844665464 Snord116 NR 002895 
27 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
28 0.946585022 2.692717722 2.844665464 Snord116 NR 002895 
29 0.896144323 2.408974296 2.688154391 -- ENSMUST00000101962 
30 1. 031960679 2.661932521 2.579490262 Ptgfr NM 008966 
31 1.03116843 2.644929008 2.56498253 Dpyd NM 170778 
32 1. 178626003 3.021209022 2.563331383 Lpl NM 008509 
33 1.016646412 2.588429456 2.546046909 Hgf NM_010427 
34 0.824646089 2.081401087 2.523993159 Hist1h2ac NM 178189 
35 1. 086920182 2.595686232 2.388111174 Rgs2 NM 009061 
36 0.898714635 2.133314991 2.373740127 --- ENSMUST00000102025 
37 2.299877468 5.29112683 2.30061249 --- ENSM UST00000099042 
38 0. 942732258 2.157004221 2.288034808 Cxcl5 NM 009141 
39 1. 049761796 2.276538724 2.168624094 lgfbp4 NM 010517 
40 0.454190363 0.957873469 2.108969162 --- ENSMUST00000122361 
41 0.972926011 2.029693661 2.086174734 Snord116 AF241256 
42 1.937108818 4.026454414 2.078589689 -- ENS M UST00000099042 
43 0.814940141 1.670204781 2.049481546 Dnajc12 NM 013888 
44 0.97289499 1.985262804 2.040572543 C1qtnf6 NM 028331 
45 1.141346623 2.273496842 1.991942496 Ramp3 NM 019511 
46 0.994758344 1.980558068 1. 990994175 Osmr NM 011019 
47 1.2840016 2.553859221 1. 988984454 ltm2a NM 008409 
48 1.09547913 2.163787766 1.975197616 Myf5 NM 008656 
49 0.887736856 1.735695654 1.955191611 lslr NM 012043 
50 1.037909749 2.028593782 1. 954499208 Vcam1 NM_011693 
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# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mRNA Accession 
51 1 1 . 933886332 1 . 933886332 -- E NSM UST00000097241 
52 0.923792027 1.784914539 1.93216058 Lphn2 NM 001081298 
53 0.917925517 1. 762737927 1.92034963 Sfrp2 NM 009144 
54 1.072854923 2.050824446 1.911558033 -- NC 005089 
55 0.972638093 1.855605465 1. 907806695 Lphn2 NM 001081298 
56 0.986751013 1.870148717 1.895258979 Nsg1 NM 010942 
57 1.086758214 2.059842578 1.895216941 Acadsb NM 025826 
58 1 1.873109188 1.873109188 Hmcn1 NM 001024720 
59 0.970687622 1.811683576 1.866391963 Fgf7 NM 008008 
60 0.804623623 1 .488462629 1. 849886812 Zfp759 NM 172392 
61 1. 188005899 2.17 4976782 1.830779446 Rps6ka1 NM 009097 
62 1.151463755 2.106473841 1.829387882 Car6 NM 009802 
63 0.994938323 1 . 818529085 1.82778072 Svep1 NM 022814 
64 1.03619103 1.893105746 1.826985267 -- ENSMUST00000095762 
65 1.025306325 1.871432483 1.825242308 Casp4 NM 007609 
66 0. 709679235 1.2855449 1.811444997 ENSMUSG00000073635 ENSMUST00000097674 
67 0.958769553 1 . 727779366 1.802079927 Slc39a10 NM_172653 
68 1.177305716 2.118276621 1. 799257909 Kng2 NM 201375 
69 0. 936775987 1.68534389 1. 799089552 Hist1 h4i NM 175656 
70 0.788544457 1.417402992 1.79749281 Marcksl1 NM 010807 
71 0.992457343 1. 782334351 1. 795880059 F3 NM 010171 
72 0.854365917 1.532139862 1. 793306394 Gja1 NM 010288 
73 1 1.791517331 1.791517331 Sfrp4 NM 016687 
74 0. 983334387 1. 7597 49407 1.78957375 Gulp1 NM 028450 
75 1.070600328 1.905118847 1. 779486515 Sulf2 NM 028072 
76 1.692701989 3.006260442 1. 776012825 --- ENSM UST00000099035 
77 1. 326892046 2.347924471 1. 769491707 - NC 005089 
78 0.98807537 1.738104712 1.759081103 Sh2d4a NM_028182 
79 1.001167247 1.759883586 1. 757831762 Slc1a3 NM 148938 
80 0.94906184 1.66202836 1.751232944 Col12a1 NM 007730 
81 1.037979535 1.815833597 1.749392483 Lphn2 NM 001081298 
82 0.958290519 1.673131687 1. 7 45954545 --- NC_005089 
83 0.822219219 1.434430431 1. 7 44583923 Pcdhb16 NM 053141 
84 1 1.743537024 1. 7 43537024 EG435337 NM 001013824 
85 0.968492204 1.684121238 1.74250887 Arsj NM 173451 
86 0.962647822 1. 66084 7949 1.725291338 Lphn2 NM 001081298 
87 0.981299207 1.68846819 1. 720645627 Map2k6 NM 011943 
88 0.87998022 1.503347992 1. 708388391 Galm NM 176963 
89 0. 97 4576946 1.658912738 1. 702187545 Sparcl1 NM 010097 
90 1 1.701654329 1 . 701654329 Atoh8 NM 153778 
91 1 1.699981445 1.699981445 Sohlh2 NM 028937 
92 1.298485436 2.197449483 1. 694928012 -- NC_005089 
93 0.928973276 1.572088025 1.692285522 Sft2d3 AK011898 
94 1. 784819276 3.018230526 1.691056661 -- NC 005089 
95 1. 020771532 1.721483079 1. 686452869 --- NC 005089 
96 0.909372953 1.533478564 1.686303249 Cfh NM_009888 
97 1 1.684768071 1.684768071 Pcdhb12 NM 053137 
98 1 1.684299851 1.684299851 LOC629446 II LOC629446 BC057932 
99 1.019823155 1.715061131 1.681724054 Lphn2 NM_001081298 
100 0.969211212 1.6284879 1.680219831 Unc5c NM 009472 
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# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mRNA Accession 
101 1.239301318 2.077768613 1.676564515 Fzd4 NM 008055 
102 1.001356021 1.678642485 1.676369293 Cdkn1c NM 009876 
103 1.027055397 1.7180333 1.672775689 Pdgfra NM 011058 
104 0.856029844 1.430315091 1.67087059 Man2b1 NM 010764 
105 0.919516903 1.534082425 1.668356961 Caprin2 NM 181541 
106 0.940837846 1. 568350485 1.666972148 Plxdc2 NM 026162 
107 0.852541519 1.416376684 1.661358014 Aaas NM 153416 
108 1.056178735 1. 752337907 1.659130078 667277 NM 001113356 
109 0.83724746 1.388019658 1.657836808 Ranbp31 NM 198024 
110 0.92438772 1.531741664 1.657033765 Ass1 NM 007494 
111 0.92099613 1.52287022 1. 653503386 Ass1 NM 007494 
112 1 1.653361273 1.653361273 2810021 G02Rik BC096373 
113 0.916456303 1.511666614 1.649469384 4632434111 Rik NM 001080995 
114 1.101140072 1.81618605 1.649368774 Ppm1k NM 175523 
115 1 1.645328893 1.645328893 Pcdh18 NM 130448 
116 1.029288919 1.691876193 1.64373303 Snai2 NM 011415 
117 0.631599091 1.037675243 1.642933402 -- ENSMUST00000101817 
118 0.861367622 1.412118344 1.639391019 Arsa NM 009713 
119 1.119262166 1.832904984 1.637601127 Hist2h3c2 NM_054045 
120 0.834957112 1.366785644 1.636953114 Fam13a NM 153574 
121 0.865477369 1.414812627 1.63471938 Htr2b NM 008311 
122 0.883529371 1.437491076 1.626987312 C1s NM 144938 
123 1.099423331 1. 787543066 1.625891516 -- NC 005089 
124 0.967893354 1.572828098 1.625001444 --- NC 005089 
125 0.803887766 1.302623356 1 . 620404504 2900062L 11 Rik NR 003642 
126 0.955917488 1.54465859 1.61589113 Tex24 NM 001013609 
127 0.91008235 1.46429984 1.608975101 Egfr NM_207655 
128 0.968087932 1.55604092 1.60733428 Col3a1 NM 009930 
129 0.84758796 1.361071635 1.605817566 261 0039C1 ORik NM 025642 
130 1 1. 602216383 1.602216383 Cxcl12 NM 001012477 
131 1.240568158 1. 987194382 1.601842164 -- NC_005089 
132 1.022811297 1 . 633878835 1. 597 439176 Socs3 NM 007707 
133 1.632021428 2.603603935 1.595324602 -- ENSMUST00000099683 
134 1.222879287 1.950570307 1.595063656 Serpinb9e NM 011456 
135 0.968511443 1.543972439 1.59417057 -- NM_001 025575. 1 
136 0.744639989 1.18382514 1.58979528 Ube2v1 NM 023230 
137 0.995483287 1.581877629 1.589054934 Gas1 NM 008086 
138 1.00555361 1.596242675 1.587426726 -- NC 005089 
139 0.960789307 1.52431176 1. 586520321 Letmd1 NM_134093 
140 1.236367812 1.953714962 1.580205294 Gsta4 NM 010357 
141 1 1.580145053 1.580145053 - ENSMUST00000101873 
142 0.926370361 1.463680836 1.580016911 Cmtm3 NM 024217 
143 1 1.57969496 1.57969496 - ENSMUST00000101969 
144 1.024661933 1.61865217 1.579693865 ld2 NM 010496 
145 0.874702911 1.380735522 1.578519409 Thbd NM_009378 
146 1.007514778 1.589828339 1.577970243 Calcr1 NM_018782 
147 1 . 178255977 1.858276266 1.577141387 -- NC 005089 
148 1 . 050015045 1.654110942 1.575321182 Car3 NM 007606 
149 0.932261763 1.467403875 1. 57 4025594 Fahd1 NM_023480 
150 1. 113873964 1. 753004865 1.57379104 --- NC 005089 
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# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mRNA Accession 
151 1.022296014 1.608681815 1.573596878 BC057079 NM 001081184 
152 1 1.568571182 1.568571182 261 0524H06Rik NM 181075 
153 0. 996050642 1.559088691 1.565270504 Lphn2 NM 001081298 
154 1 1.564666297 1.564666297 1810041L15Rik BC062953 
155 0.93192128 1.457575889 1.564054733 Fggy NM 001113412 
156 0.84085445 1.315074015 1 . 563973427 D2hgdh NM 178882 
157 1.019729143 1.591114876 1. 560330884 Fam102b ENSM UST00000046924 
158 0.870913294 1.358491934 1.559847511 Naglu NM 013792 
159 1 1.558229789 1 . 558229789 Ptger4 NM 001136079 
160 0.965352001 1.503178149 1.557129573 Grcc10 NM 013535 
161 0.963299953 1 .496983168 1.554015615 Stmn1 NM 019641 
162 1. 126753554 1.747287488 1.550727293 A poe NM 009696 
163 0.932383901 1 .445601592 1. 550436027 Lgals3bp NM 011150 
164 1.003514178 1.554876505 1.549431527 P2rx:4 NM 011026 
165 0.794510946 1.229038407 1.546911863 -- E NSM UST00000082738 
166 1.24892427 1 . 931844538 1.546806787 -- NC 005089 II NC 005089 
167 1 . 195556242 1.843344859 1.541830316 --- ENSM UST00000099046 
168 0.946270136 1.457045571 1.539777613 Suv39h1 NM 011514 
169 0.995465347 1.531897745 1.538876014 Wee1 NM 009516 
170 0.914058876 1.405322261 1. 537 452672 BC026782 NM 001025575 
171 0.924491525 1.420118186 1. 5361 07306 Ptplad1 NM 021345 
172 1 1.535879467 1.535879467 Mnd1 NM 029797 
173 1 1.53443656 1.53443656 Abca8a NM 153145 
174 1 1.527949646 1. 527949646 Polr3g NM 001081176 
175 1 1.525707073 1.525707073 --- ENSMUST000001 02015 
176 0.901426645 1.373448676 1.523638872 Rnf167 NM 027445 
177 0. 956872096 1.452409226 1.51 7871857 Stmn1 NM 019641 
178 0.99337132 1.505567092 1.51561361 Tmem47 NM 175771 
179 0.868616342 1.315050316 1.513959907 Etv1 ' NM 007960 
180 0.993792115 1.504404993 1. 513802506 Cyb5 NM 025797 
181 0.950914148 1.436909301 1.511082051 Arl6ip1 NM 019419 
182 0.847543899 1.279693224 1. 509884297 -- ENSMUST00000083241 
183 1.032276174 1.557304433 1.508612202 Arl15 NM 172595 
184 0.991844596 1 .494288796 1. 506575528 -- NC_005089 
185 1.071462234 1.612442819 1. 504899349 Nt5c NM 015807 
186 1.034916951 1.55710259 1.504567675 Prrx1 NM 175686 
187 0.927894701 1.395595644 1.504045279 Retsat NM 026159 
188 0.936559138 1 .407856217 1.50322191 Cebpa NM 007678 
189 1.081040071 1.624519431 1.50273748 Ptn NM 008973 
190 0.884119324 1.327756875 1.501784701 Tcn2 NM_015749 
Table A.l Top upregulated genes in MEF2A-deficient C2C12 differentiation Fold 
changes in gene expression taken from C2C12 differentiation day 3 microarray data are 
shown. Fold changes in gene expression are shown for each microarray comparison 
made: shLacZ vs. UT, shMef2A vs. UT, and shMef2A vs. shLacZ where the second set 
in each comparison is normalized to 1. Genes which were upregulated 1.5 fold or more, 
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according to shMef2A vs. shLacZ data, are shown in order from most upregulated to least 
upregulated (#1-190). N=l. 
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# shLacZ vs. UT shMef2A vs. UT shMef2A vs. shLacZ Gene Symbol mANA Accession 
1 0.889739557 0.221649959 0.249117798 Casq1 NM 009813 
2 0.966166007 0.246807818 0.255450736 Myh7 NM 080728 
3 0.913222937 0.254829817 0.279044478 Tspan13 NM 025359 
4 1 0.298052628 0.298052628 Myl2 NM 010861 
5 0.88270422 0.269457566 0.305263711 Fgfbp1 NM 008009 
6 0.744154455 0.229290264 0.308121872 1830127L07Rik ENSMUST000001 00541 
7 0.808065979 0.265057451 0.328014615 Padi2 NM 008812 
8 0.814027817 0.267940023 0.329153399 Hephl1 ENSMUST00000034412 
9 0.960268661 0.3194976 0.332716888 Actn2 NM 033268 
10 1 . 067696049 0.358027423 0.335327103 -- ---
11 1 . 004809493 0.339311916 0.337687809 8030451 F13Rik NM 175418 
12 1.017773124 0.347339887 0.341274376 Fabp3 NM 010174 
13 1.018558611 0.362439224 0.355835413 Pdgfb NM 011057 
14 1. 032367765 0.369697194 0.3581061 Fabp3 NM 010174 
15 0. 945719992 0.346129306 0.365995547 Ppapdc3 NM 145521 
16 0.952884989 0.349810379 0.367106611 Slc44a4 NM_023557 
17 1 0.369639029 0.369639029 Hspb7 NM 013868 
18 0.951010385 0.354896438 0.373178299 Atp1a2 NM 178405 
19 0.98714916 0.368906982 0.373709463 Mef2a NM_001033713 
20 1.019421015 0.382619419 0.375330126 Npnt NM 033525 
21 0.96950954 0.365759946 0.377262864 Myl6b NM 172259 
22 1.141345832 0.430611275 0.377283784 8430408G22Rik BC058515 
23 1 . 026430539 0.392709118 0.382596876 Apobec2 NM 009694 
24 0.879532626 0.337339228 0.383543735 Galnt6 NM 172451 
25 0. 728637928 0.279773457 0.383967737 Gja5 NM 008121 
26 0.982868286 0.378029834 0.384619017 Adamtsl2 NM_029981 
27 0.945256651 0.369256699 0.390641736 Ablim3 NM 198649 
28 0.975495417 0.388041807 0.397789472 Tpm3 NM 022314 
29 0.994362641 0.395548361 0.397790851 Art1 NM_009710 
30 1 . 017794288 0.405048901 0.397967356 Sgcd NM 011891 
31 0. 939419861 0.37768961 0.402045587 Myoz2 NM 021503 
32 1.068733391 0.432728786 0.404898724 Zmynd17 BC119816 
33 0.942425186 0.38521212 0.40874557 Fst NM 008046 
34 1. 016490689 0.41822349 0.411438584 Myom1 NM 010867 
35 1 0.412576056 0.412576056 Tcap NM 011540 
36 0.963495611 0.397732401 0.412801466 Myh3 NM_001099635 
37 0.916517924 0.379633181 0.414212501 Fn3k NM 001038699 
38 0. 979203758 0.406143933 0.414769582 Trp63 NM_001127259 
39 0.958818732 0.397996045 0.415089977 Best3 NM_001007583 
40 0.88174048 0.366565776 0.41572978 Csdc2 NM 145473 
41 0. 945368697 0.396308276 0.41921028 Tuft1 NM 011656 
42 0.927366168 0.391322237 0.421971656 Dhrs7c NM 001013013 
43 1. 039806443 0.438946191 0.422142211 Pstpip1 NM_011193 
44 1 0.422571976 0.422571976 Clic5 NM 172621 
45 1 0.4258821 0.4258821 Tspan8 NM 146010 
46 0.884272544 0.379532938 0.429203576 9930013L23Rik NM_030728 
47 0.843373152 0.363577544 0.431099263 Upk1b NM 178924 
48 1.13844532 0.491442319 0.431678456 Popdc2 NM_001081984 
49 0.93902339 0.413303934 0.44014232 Xirp1 NM 001081339 
50 0.952716579 0.419398614 0.44021341 Msln NM 018857 
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# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mRNA Accession 
51 0. 960502983 0.429231839 0.446882359 A bra NM 175456 
52 1.005156401 0.452555301 0.450233715 ltgb1bp2 NM 013712 
53 0.913453377 0.411580347 0.450576195 Tspan32 NM 020286 
54 0.870950722 0.392564331 0.450730818 Hbegf NM 010415 
55 1.171058381 0.529769246 0.452385 Lrrc39 NM 175413 
56 1 0.452444582 0.452444582 Alpk3 NM 054085 
57 1.000936187 0.453030787 0.452607062 Wsb2 NM 021539 
58 0.928865105 0.421062996 0.453309091 Tspan9 NM 17541 4 
59 1 0.460495512 0.460495512 lsx NM 027837 
60 0.967832976 0.445883896 0.460703352 Erbb3 NM_010153 
61 1.021625896 0.470745106 0.460780318 Txlnb NM 138628 
62 1 . 005835934 0.466143159 0.463438562 Myom3 NM 001085509 
63 0.973167469 0.451870412 0.464329549 Pygm NM 011224 
64 0.869049344 0.405123029 0.466168039 Asb2 NM_023049 
65 1.021868816 0.476506566 0.466308942 Ckm NM 007710 
66 0. 938273224 0.437965763 0.466778495 Mb NM 013593 
67 0. 940822195 0.440564453 0.468275999 Ankrd23 NM 153502 
68 0. 985668892 0.46272694 0.469454747 Jam2 NM_023844 
69 1. 047764873 0.497228881 0.47456151 Dusp14 NM 019819 
70 1 . 135683633 0.540016352 0.47549893 Myo18b Xfv1 912851 
71 0.963730721 0.458520455 0.475776526 Cox6a2 NM 009943 
72 1.017148272 0.484868017 0.476693547 Mmp15 NM_008609 
73 0.991812972 0.474359255 0.478274905 Ldb3 NM 001039074 
74 0.94207185 0.450851117 0.478574025 Myo18b Xfv1 912851 
75 1. 290448888 0.623187413 0.482922973 Fsd2 NM 172904 
76 0.910604188 0.441165231 0.484475293 Nptx1 NM_008730 
77 1.076081986 0.521986717 0.485080806 Alpk2 AY044451 
78 0.981033291 0.477637495 0.486871852 Spire2 NM 172287 
79 1.061281224 0.516884555 0.487038255 Mfsd2 NM_029662 
80 0.964551383 0.469996201 0.487269221 Anxa8 NM 013473 
81 0.914318046 0.44553417 4 0.487285771 Efhd1 NM 028889 
82 1.116110602 0.54387801 0.487297592 Wfdc1 NM 023395 
83 1.047547019 0.513359006 0.4900582 Klhl31 NM_172925 
84 1 . 760985463 0.864533037 0.490937066 -- ENS MUST00000083234 
85 1 . 184356986 0.583999889 0.493094477 Nxf7 NM 130888 
86 1.052702661 0.521073937 0.494986814 Hdac9 NM 024124 
87 0.925631586 0.458674307 0.495525773 Fhl1 NM 001077361 
88 0.987876775 0.490575469 0.496595812 Obsl1 NM 178884 
89 1. 071970348 0.532596185 0.496838542 Tmem65 NM 175212 
90 0.926881622 0.462290622 0.498759076 BC025446 BC025446 
91 1.131130199 0.564480246 0.499040912 Afap111 NM 178928 
92 0.814100043 0.406559948 0.499398018 C33001601 ORik NM_145974 
93 0.945977648 0.472461606 0.499442674 Syt12 NM 134164 
94 1. 050345525 0.525125442 0.499954947 Sorbs2 NM 172752 
95 0.929750162 0.466691469 0.50195363 ltga6 NM_008397 
96 0.876093043 0.441131595 0.5035214 Rasl11b NM 026878 
97 1.552059644 0.782780651 0.504349594 EG547347 ENS MUST00000097330 
98 0.949187496 0.479340917 0.505001298 Stmn2 NM_025285 
99 0.9168451 52 0.463508917 0.505547656 Wsb2 NM 021539 
100 0.946066172 0.478976241 0.506281966 Klhl30 NM_027551 
183 
# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mANA Accession 
101 0.965057628 0.489297223 0.507013477 -- GE NSCAN00000033617 
102 1 0.507084471 0.507084471 Tmem37 NM 019432 
103 0.94704245 0.48044527 0.507311229 Jph1 AK081751 
104 0.89567547 0.457242687 0.510500401 Nuak1 NM 001004363 
105 1.110657505 0.567418856 0. 51 0885537 ltgb1bp3 NM 027120 
106 1.103180606 0.564084031 0.511325188 Myo18b XM 912851 
107 1 0.513215981 0.513215981 Pgm5 NM 175013 
108 0. 991756601 0.510931575 0.515178396 Cacna1s NM 001081023 
109 0.946822569 0.489835079 0.517346222 Kbtbd5 NM 028202 
110 1 . 066454193 0.552134632 0.517729346 Calr4 NM 001033226 
111 0.905027164 0.473223951 0.522883699 Gprc5c NM 001110337 
112 0.993533832 0.519719105 0.523101568 Arhgef6 NM_152801 
113 0. 905665998 0.473988184 0.523358705 -- --
114 0.977292957 0.512234738 0.524136324 Pla1a NM 134102 
115 0.963046257 0.505324138 0.524714295 Ldlrad3 NM 178886 
116 0. 958350302 0.503451253 0.525331136 Fam171a2 NM 199200 
117 1.479659274 0. 778030167 0.525817113 Olfr597 NM 001011845 
118 1 . 021555085 0.537950749 0.526599844 Klhl31 NM 172925 
119 1 0.52780576 0.52780576 Capn3 NM 007601 
120 1.088459705 0.57546257 0.528694418 Myh4 NM 010855 
121 0. 953100994 0. 503916639 0.528712742 Neu2 NM 015750 
122 0. 959552734 0.507880504 0.529288789 Lynx1 NM 011838 
123 1 . 887373563 1 0.529836816 Cyp2d11 NM 001104531 
124 1.03330632 0.548070732 0.530404897 Sh3pxd2a NM 008018 
125 1 . 052404265 0.559031313 0.531194458 Myo18b XM 912851 
126 0. 979673553 0.521127755 0.53194021 Serpine1 NM 008871 
127 0.837304335 0.446181932 0.532879043 1600029021 Rik NM_029639 
128 1 . 055664203 0.563352957 0.533647873 Myo18b XM 912851 
129 1 . 00004 7828 0.534813208 0.53478763 Tns1 BC055076 
130 1.017850728 0.544627222 0.535075731 Nrap NM_008733 
131 1.016888148 0.544975017 0.535924249 11-Mar NM 177597 
132 0.918001872 0.493325922 0.537390976 Cav3 NM 007617 
133 1. 168778059 0.629351976 0.538470047 Myo18b XM_912851 
134 1 . 111625627 0.599368845 0.539182284 Cyfip2 NM_133769 
135 1.047137576 0.565373826 0.539923157 Sprr3 NM 011478 
136 0.85899581 0.46408147 0.540260458 Slc4a3 ENSMUST00000097692 
137 1.061890496 0.575174651 0.541651567 Grhl3 NM_001 013756 
138 0.888232337 0.481268198 0. 541826928 Syngap1 XM_915205 
139 1 0.542742579 0.542742579 Lif NM 008501 
140 0.864564797 0.470201485 0.54385916 Apol9b NM 173743 
141 0.991205433 0.540563123 0.545359322 Ablim1 NM_178688 
142 0.988275376 0.541172712 0.547593034 Grtp1 NM 025768 
143 0. 986943909 0.541075567 0.548233351 lnsig1 NM 153526 
144 1. 043832336 0.572879652 0.548823438 2310039E09Rik NM 026509 
145 1.076613932 0.591756683 0.549646132 Mybpc2 NM 178067 
146 0.91271225 0.502744047 0.550824257 Ccdc109a NM_001 033259 
147 1 . 073680688 0.591707054 0.551101516 Smpx NM_025357 
148 1 0.551960909 0.551960909 Pacsin3 NM 028733 
149 0.899365221 0.496653643 0.552226873 1700031 F05Rik ENSMUST00000048061 
150 0.920917612 0.509643738 0.553408612 Atp6v1c2 NM_133699 
184 
# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mANA Accession 
151 0.915587074 0.506727138 0.553445055 Gprc5c NM 001110337 
152 0.851363415 0.471357634 0.553650329 Sult2b1 NM 017465 
153 0.903942556 0.501549153 0.554846267 Dok7 NM 172708 
154 1 . 016055353 0.56376468 0.554856266 Myo18b Xl\11 912851 
155 1 0.555011665 0.555011665 P2ry2 NM 008773 
156 1.01443259 0.563651367 0.555632156 Pmaip1 NM 021451 
157 0. 968432902 0.53879561 0.556358224 Ndrg4 NM 145602 
158 0.887172161 0.494010633 0.556837393 Plcg2 NM 172285 
159 1. 07 4933939 0.599570372 0.557774158 Asb14 NM 080856 
160 0. 936698071 0.523801465 0.559199897 Cd36 NM 007643 
161 0.907933161 0.507888953 0.559390245 Pde2a NM 001008548 
162 0.965501229 0.540187065 0.559488739 Fads3 NM 021890 
163 0.983604336 0.550861293 0.56004358 Emp2 NM 007929 
164 1.014359465 0.5681 72929 0.560129765 Sgcg NM 011892 
165 1.015373139 0.569735023 0.561109016 100039967 XR 031603 
166 0.948228723 0.532287282 0.561349038 Fyn NM 001122893 
167 1.046261877 0.587915614 0.561920134 Ryr1 NM 009109 
168 1.049515156 0.590099851 0.562259485 Rrad NM 019662 
169 1.10902893 0.623616065 0.562308204 Csrp3 NM 013808 
170 0. 969350286 0.54531056 0.562552638 Mustn1 NM 181390 
171 1 . 008506233 0.567406664 0.56262088 Klf10 NM 013692 
172 0.972966474 0.548463303 0.56370216 Musk NM 001037127 
173 0.993801759 0.561158413 0.564658301 Casq2 NM 009814 
174 1. 028898023 0.581132885 0.564810964 Tmod1 NM 021883 
175 0.916973534 0.518295582 0.565224145 Gjd4 NM_153086 
176 0.912231567 0.516038282 0.565687815 Thop1 NM 022653 
177 0.982377893 0.556103761 0.566079271 Tnnc2 NM 009394 
178 1. 020630033 0.577891278 0.56621034 C1qtnf3 NM 030888 
179 0.997740125 0.569809271 0.571099885 Tmem184a NM_144914 
180 0.909447965 0.520356043 0.572166922 Tnc NM_011607 
181 1. 003033645 0.574265183 0.572528335 Tekt5 NM 001099275 
182 0.99657411 0.575230868 0.57720832 Galntl4 NM 173739 
183 0.875974028 0.505703616 0.57730435 Col18a1 NM 009929 
184 0.89892646 0.519577189 0.577997437 Pkp1 NM 019645 
185 1.047049029 0.605302829 0.578103615 -- ENSMUST00000118619 
186 1.114100206 0.644298884 0.578313225 Lrrc2 NM_028838 
187 0.893111374 0.516956216 0.578826148 Sema4d NM 013660 
188 0. 986408406 0.571183813 0.579054081 Tuba4a NM 009447 
189 0.980425559 0.567784354 0.57912031 Dmpk NM 032418 
190 0. 996418698 0.577485249 0.579560831 Plekha7 NM_172743 
191 1.02067814 0.591628723 0.579642788 Tor3a NM 023141 
192 0. 999832965 0.579987214 0. 5800841 08 Fstl3 NM 031380 
193 1.52080481 0.88417019 0.581383084 -- ENSMUST00000082931 
194 0. 994334383 0.578221837 0.581516487 Unc45b NM 178680 
195 0. 941409946 0.547934747 0.582036285 Gys1 NM 030678 
196 1.015359063 0.59108356 0.582142398 Dysf NM 021469 
197 0.966825882 0.56412274 0.583479146 Trim16 NM 053169 
198 1 . 441383265 0.842497903 0.584506511 --- -
199 1.007596489 0.590141983 0.585692774 Ablim2 NM_177678 
200 0. 954254507 0.559968664 0.5868127 Mypn BC052872 
185 
# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mRNA Accession 
201 0.956390696 0.562270788 0.587909094 Erbb2 NM 001003817 
202 0.978788462 0.576089952 0.588574523 Mtss11 BC060632 
203 0.918080777 0.541311146 0.589611676 Jph1 NM 020604 
204 0. 978249925 0.578364938 0.591224106 Osbpl3 NM 027881 
205 0.95043838 0.563341242 0.59271727 Pbx3 NM 016768 
206 0.930303268 0.55146453 0.592779311 Fgfrl1 NM 054071 
207 0. 969007677 0.574560214 0.5929367 Myl4 NM 010858 
208 0. 953003224 0.565350705 0.593230632 Neb NM 010889 
209 1 0.593655961 0.593655961 Gins4 NM 024240 
210 1.005109722 0.596723294 0.593689705 Cdc42se2 NM 178626 
211 1 0.594293703 0.594293703 Kank1 NM 181404 
212 0.962399635 0.573871646 0.59629246 Jup NM 010593 
213 1 0.596411508 0.596411508 Klk1b26 NM 010644 
214 1 0.596540916 0.596540916 Clic3 NM 027085 
215 1 0.596633959 0.596633959 Na\12 NM 175272 
216 0.96778803 0.578554591 0.59781127 Rbm38 NM 019547 
217 0. 9941 06277 0.594621692 0.598147005 Krt19 NM 008471 
218 0.952825547 0.570151806 0.598380058 Nexn NM 199465 
219 0.982363593 0.588634905 0.599202688 Ahr NM 013464 
220 0.918670877 0.550614306 0.599359705 Stom NM 013515 
221 1 0.599533386 0.599533386 Phospho1 NM 153104 
222 1 . 038802218 0.622937358 0.599668876 Trim63 NM 001039048 
223 1.121561709 0.673441718 0.600449991 Atg4a NM 174875 
224 1 . 038534397 0.623588402 0.600450407 Myo18b Xfv1 912851 
225 1 0.602131292 0.602131292 Camk2a NM 177407 
226 0.923900889 0.556776413 0.602636516 Pmepa1 NM 022995 
227 0.968506744 0.585281669 0.604313468 Obscn BC060226 
228 1.042321254 0.630305868 0.604713629 Etl4 NM 001081006 
229 0.991030937 0.599387956 0.604812558 Gadd45b NM 008655 
230 1.006242479 0.608701995 0.604925759 Myo18a NM 011586 
231 0. 993587549 0.602088305 0.605974084 Pdlim4 NM 019417 
232 0.91125896 0.552515943 0.606321548 Gprc5b NM 022420 
233 0. 97 47 47193 0.592566922 0.607918572 Pfkm NM 021514 
234 1 0.607975461 0.607975461 Pde4dip NM 001 039376 
235 1 . 002705541 0.609633463 0.607988525 Tnfrsf22 NM 023680 
236 0.989655284 0.601727001 0.608016761 Prkag3 NM_153744 
237 0.951390154 0.578891148 0.608468718 Fam101b ENSMUST00000021207 
238 0.988994224 0.602359217 0.609062422 Synpo21 NM 175132 
239 1 . 034404173 0.631059525 0.610070552 Tnnt1 NM 011618 
240 1. 029289632 0.628315032 0.610435597 Best1 NM_011913 
241 0. 916093019 0.559292155 0.610518958 Rftn2 NM 028713 
242 0.96037117 0.587301407 0.611535858 Cmah NM 00111111 0 
243 1.027572367 0.628970823 0.612093944 Rassf7 NM 025886 
244 0.948724428 0.581166722 0.612576955 Myo18b Xfv1 912851 
245 0.981957167 0.602297844 0.613364681 Ckb NM 021273 
246 0. 980880983 0.602043652 0.613778493 Myom2 NM 008664 
247 1 . 002063546 0.615316677 0.614049558 Mylk2 NM 001081044 
248 1 0.61466021 0.61466021 Krt80 NM_028770 
249 1 0.614960648 0.614960648 4930523C07Rik ENS MUST00000060298 
250 1.074301546 0.660795607 0.615093229 Sms AF031486 
186 
# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mRNA Accession 
251 0. 925903664 0.570138764 0.61576467 Bhlhe40 NM 011498 
252 0.985650445 0.60703222 0.615869676 Adssl1 NM 007421 
253 0. 978242466 0.602709203 0.616114332 Prune NM 173347 
254 1 . 009458779 0.621957541 0.616129706 Ccdc134 NM 172428 
255 0.932946334 0.575560304 0.616927559 Fgd3 NM 015759 
256 0.88636634 0.546950433 0.617070401 EG433367 XM 994738 
257 1. 007 406539 0.622057997 0.617484574 Srpk3 NM 019684 
258 1.110913125 0.686498751 0.617958988 Sh3bgr NM 015825 
259 1.22795356 0.758957497 0.618066939 Olfr288 NM 001011733 
260 0.964515949 0.597150299 0.619119155 Slco3a1 NM 023908 
261 1.164891027 0.72215929 0.619937208 Diablo NM 023232 
262 1.13112471 0.701358027 0.620053669 84galnt3 NM 198884 
263 1. 138022436 0.7059383 0.620320196 Cd28 NM 007642 
264 0. 953543725 0.591651278 0.620476295 Ubap2 NM 026872 
265 0.941451709 0.584531225 0.620882855 Hspb2 NM 024441 
266 0.9688935 0.601628577 0.62094397 Mospd1 NM 027409 
267 0.899602765 0.559077426 0.621471441 Nes NM 016701 
268 1 0.623034086 0.623034086 Gdf11 NM 010272 
269 0.936941579 0.58405211 0.623360221 Sh3bp4 NM 133816 
270 0.958202844 0.600348031 0.62653543 4631416L12Rik NM 001081295 
271 1.064997468 0.667390474 0.626659212 Cpd NM 007754 
272 0.928906955 0.582136749 0.626690053 Ubash3b NM 176860 
273 1 0.626744789 0.626744789 Dusp27 NM 001033344 
274 0.962962819 0.604071824 0.627305449 Txndc13 NM 029148 
275 0. 945568578 0.593281211 0.627433298 Egln3 NM 028133 
276 0.968690703 0.608713809 0.628388202 Fhl3 NM 010213 
277 1 . 1 09505639 0.697539103 0.628693608 Gpr20 NM_173365 
278 0. 992308076 0.624222385 0.629061075 Kcnq4 NM 001081142 
279 1 . 04997 4289 0.660795607 0.62934456 Sms NM 009214 
280 1.291641768 0.813034231 0.62945799 Ppp1r3g AK079637 
281 1.5880056 1 0.629720701 --- GENSCAN00000040477 
282 1.013268138 0.638102902 0.629747328 Pgam2 NM 018870 
283 0.99167205 0.625243041 0.630493761 1700055N04Rik AK081788 
284 0.949268424 0.59851902 0.630505561 Sox11 NM_009234 
285 0. 987893893 0.623229747 0.630867091 Cacnb1 NM 031173 
286 1.048465943 0.661652675 0.631067399 6430548M08Rik BC027126 
287 1.001422656 0.632268828 0.631370605 Atpgd1 BC023699 
288 0.964517955 0.609022317 0.631426625 Hrc NM_010473 
289 0.918158417 0.580773689 0.632541921 Klf5 NM 009769 
290 0.974289214 0.618635702 0.634961049 Rassf3 NM 138956 
291 0.993460836 0.631119017 0.635273172 Cabc1 NM 023341 
292 0.921468657 0.586973794 0.636998111 Tbx15 NM_009323 
293 1 . 034041437 0.65875367 0.637066994 Tnfrsf23 NM 024290 
294 1. 00057 4091 0.637702305 0.637336416 Sgca NM 009161 
295 0.926715881 0.590699788 0.637411963 Apol9b NM_173743 
296 1 . 088507992 0.693829939 0.63741373 Atg4a NM 174875 
297 0.957647754 0.610471141 0.637469402 Jph2 BC022635 
298 0.99685944 0.635539632 0.637541871 Usp13 NM 001013024 
299 1.02499367 0.653778573 0.637836693 Fam167a NM 177628 
300 1 0.637883117 0.637883117 -- GENSCAN00000017733 
187 
# sh La cZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol m RNA Accession 
301 0.980121155 0.625448066 0.638133421 Shisa4 NM 175259 
302 0.987338713 0.630934436 0.63902532 Heg1 NM 175256 
303 1.081357829 0.691050956 0.639058541 S100a4 NM 011311 
304 1. 701235659 1.087491406 0.639236193 
-- ENSMUST00000083216 
305 1.435596191 0.918198513 0.639593863 Myef2 BC060946 
306 0.95537498 0.61138794 0.639945522 Myo1c NM 008659 
307 1.391603295 0.890999174 0.640268083 Glrx3 NM 023140 
308 0.95098995 0.609032026 0. 640418993 Sorcs2 NM 030889 
309 1.03229764 0.661670103 0.640968339 Dnase111 NM 027109 
310 0.945122344 0.605966104 0.641150966 Cdc42ep2 NM 026772 
311 0.951771394 0.61023211 0.641154077 Pea15a NM 011063 
312 0.968014122 0.62083853 0.641352761 Eno3 NM 007933 
313 0.969430918 0.621803223 0.641410555 Hspb1 NM 013560 
314 0.966295937 0.620192507 0.641824604 Gaml4 NM_001015046 
315 0. 976292938 0.628891482 0. 644162687 Mef2c NM 025282 
316 0.899592164 0.579606227 0.644298884 Mgll NM 011844 
317 0. 957767907 0.617967555 0.645216394 Rhobtb2 NM 153514 
318 1.042400008 0.672881798 0.64551208 Mylk4 ENSMUST00000057428 
319 1.087779393 0.702663566 0.645961461 Enah NM 010135 
320 1.380486711 0.892551302 0.646548275 BC089597 NM 145424 
321 0.991680299 0.641311863 0.646692149 Prkaa2 NM 178143 
322 0. 933295601 0.603623551 0.646765666 Slc4a3 NM 009208 
323 1 0.647893235 0.647893235 Stard10 NM 019990 
324 0. 992727044 0.644289952 0.649010174 Cacnb3 NM 007581 
325 1 . 003849505 0.651924139 0.649424177 Cbr2 NM 007621 
326 0.897037996 0.582909977 0.649816373 Pacsin1 NM 011861 
327 1 . 198539952 0.779493015 0.650368821 Mapre3 NM 133350 
328 0.981152979 0.638696301 0.650965053 Ctrb1 NM 025583 
329 0.928835488 0.605542448 0.651937243 Jph2 NM 021566 
330 1.575618214 1.027380788 0.652049321 --- ENSMUST00000083377 
331 0.96421047 0.628785999 0.652125256 Tgfb3 NM 009368 
332 0.929505947 0.606586796 0.652590549 Obscn AY603754 
333 1 0.653094199 0. 653094199 Mal NM_010762 
334 1. 0404 7 4062 0.679942663 0.653493142 Serpinb9b NM 011452 
335 1 0.653506278 0.653506278 Fras1 NM 175473 
336 0.93945828 0.614482573 0.654081811 Cilp NM_173385 
337 0.977893325 0.640082158 0.654552129 Tspan7 NM_019634 
338 0.973957011 0.638185175 0.655249839 Hspb1 NM 013560 
339 1.007117492 0.660029769 0.655365212 Cpne2 NM 153507 
340 1.101482062 0.722147277 0.655614197 Prkar2a NM 008924 
341 0.939613925 0.616649668 0.65627983 Mid1 NM_010797 
342 0.94049032 0.617650235 0.656732155 Trim47 NM 172570 
343 1.012977409 0.66527236 0.656749454 Myo18b xrv1_912851 
344 1.103124023 0. 726499142 0.658583376 Sirpa NM 007547 
345 0.942238378 0.620641899 0.658688834 Mef2d NM_133665 
346 0. 907019203 0.597628146 0.658892495 Kif1c NM 153103 
347 1 . 083780804 0.714116323 0.658912134 Crabp2 NM 007759 
348 0.972247146 0. 641 033208 0.659331539 Tmem132a NM_133804 
349 0.976655724 0.643948849 0.65934068 Loxl2 NM 033325 
350 1.133375562 0.747598718 0.65962135 Myo18b xrv1 912851 
188 
# shlacZ vs. UT shMef2A vs. UT shMef2A vs. shlacZ Gene Symbol mRNA Accession 
351 1.23430078 0.814232098 0.659670731 Serpinb6c NM 148942 
352 1 0.660335448 0.660335448 Gpr97 NM 173036 
353 1.04742867 0.691867175 0.660538703 Bzw2 NM 025840 
354 1.04303025 0.689242228 0.660807515 Rab40b NM 139147 
355 1.034347532 0.683514098 0.660816676 Dyrk2 NM 001014390 
356 1 0.661199711 0.661199711 lldr2 FJ024494 
357 1 . 082962284 0.716177451 0.661313382 Cmbl NM 181588 
358 0. 960049036 0.635348915 0.661787983 -- ENSMUST00000053322 
359 1.016704198 0.674336222 0.663257045 Cacng1 NM 007582 
360 1.037038173 0.68785005 0.663283251 -- ENSMUST00000117318 
361 0.960598193 0.637240118 0.663378426 Xaf1 NM 001 037713 
362 0.902051058 0.598414484 0.663393141 2310014011 Rik AK009333 
363 1.021841901 0.678296992 0.663798374 Als2cl NM 146228 
364 1. 10567 4705 0.734381693 0.664193265 Rnu7 NR_024201 
365 1 0.664245751 0.664245751 - NM 133183.1 
366 0. 987864449 0.656939765 0.665010028 Trim72 NM 001 079932 
367 0.943091072 0.627228492 0.66507733 Pik3c2b BC132141 
368 0.951950855 0.633496257 0.665471598 Bok NM_016778 
369 0.998828575 0.664861157 0.665640906 Fndc5 NM 027402 
370 0.956287949 0.637459239 0.666597587 Wdr16 NM 027963 
371 1.016204671 0.677469546 0.666666436 Myh8 NM_177369 
372 1 . 008527204 0.672464494 0.666778735 Sr1 NM 175347 
373 0.975169561 0.650300753 0.666859159 Lmod2 NM 053098 
374 0.982229461 0.655178536 0.667032056 Chrd NM_009893 
375 1.633173428 1.089741537 0.667254021 --- ENSMUST00000082652 
376 0. 968315437 0.646538416 0.667694009 Lims2 NM 144862 
377 0.951104654 0.635365209 0.668028704 Ptprf NM 011213 
378 0.948402914 0.633643814 0.668116688 lgfbp6 NM 008344 
379 1. 004468276 0.672166245 0.669176181 Trim54 NM 021447 
380 0.981457703 0.656802717 0.669211434 Sik1 NM 010831 
381 1.017513545 0.681365592 0.669637859 Csrp2 NM 007792 
382 0.954541614 0.639292467 0.66973766 Cryab NM_009964 
Table A.2 Top downregulated genes in :MEF2A-deficient C2C12 differentiation Fold 
changes in gene expression taken from C2C12 differentiation day 3 microarray data are 
shown. Fold changes in gene expression are shown for each microarray comparison 
made: shLacZ vs. UT, shMef2A vs. UT, and shMef2A vs. shLacZ where the second set 
in each comparison is normalized to 1. Genes which were downregulated 1.5 fold (0.67) 
or more, according to shMef2A vs. shLacZ data, are shown in order from most 
downregulated to least downregulated (#1-382). N=l. 
189 
# MEF2A KO vs. WT Gene Symbol mANA Accession 
1 11.96615707 Mmp9 NM 013599 
2 10.56259931 Clec4e NM 019948 
3 9.876227024 Lyz1 NM 013590 
4 7.446265206 Clec4d NM 010819 
5 6.687291472 OTTM USG00000007 428 NM 001134675 
6 6.604768522 Clec4n NM 020001 
7 6. 168817646 Clec5a NM 001038604 
8 5.328069865 Acp5 NM 0011 02404 
9 5.301321368 Spp1 NM_009263 
10 5.105007215 Mup1 NM 031188 
11 4. 982687171 Mup2 NM 008647 
12 4. 924338717 Sfrp2 NM_009144 
13 4.864987169 Tm4sf19 BC147727 
14 4. 706178365 111m NM 031167 
15 4.694218513 Mup2 NM 008647 
16 4.675802521 Pla2g7 NM_013737 
17 4.58332948 Mup2 NM 008647 
18 4.580687043 Saa3 NM 011315 
19 4.474331039 Atp6\0d2 NM_175406 
20 4.458025905 Nhedc2 NM 178877 
21 4.305799077 Msr1 NM 031195 
22 4.277441132 Mup2 NM_001 045550 
23 4. 21 0118965 ltgb2 NM 008404 
24 4.104174294 Mup2 NM 001 045550 
25 4.090734768 Mup2 NM_001 045550 
26 3. 997887845 Ccr1 NM_009912 
27 3. 957060163 Gpr137b-ps NR 003568 
28 3.890506527 Gpnmb NM 053110 
29 3.866716519 Ctsk NM_007802 
30 3.676020979 Slc37a2 NM 020258 
31 3. 619283201 Bst1 NM_009763 
32 3. 607726568 Plek NM 019549 
33 3.605041831 Mup2 NM 001 045550 
34 3.580293849 Gpr137b NM_031999 
35 3.483911557 Cd84 NM_013489 
36 3.47719506 It gam NM_001 082960 
37 3.392486325 Mmp19 NM 021412 
38 3.348077678 Tm7sf4 NM 029422 
39 3.324070545 AdamS NM_007403 
40 3.317848474 Stap1 NM 019992 
41 3.31754492 117r NM 008372 
42 3. 301569464 Anxa8 NM 013473 
43 3.284370768 F10 NM_007972 
44 3. 220420327 Lilrb4 NM_013532 
45 3.156787175 Lcp1 NM 008879 
46 3.138758434 limp1 NM 001044384 
47 3.068632758 Lgals3 NM 010705 
48 3.068154217 Tnn NM_177839 
49 3. 057320927 Rgs1 NM_015811 
50 3.048211484 Cd14 NM_009841 
190 
# MEF2A KO vs. WT Gene Symbol mRNA Accession 
51 3. 036499223 H\Cn1 NM 001042489 
52 3. 029252841 --- ENSM UST00000083236 
53 3. 016544 782 Slc7a11 NM 011990 
54 2.983368112 Emb NM 010330 
55 2.978974966 Fabp5 BC100543 
56 2. 97 4571795 Ltbp2 NM 013589 
57 2. 958083957 Cd53 NM 007651 
58 2. 952508064 Crabp2 NM 007759 
59 2. 890594023 ltgax NM 021334 
60 2. 878725046 Alox5ap NM 009663 
61 2.83187385 Slc20a1 NM 015747 
62 2.824632153 --- NM 009017.1 
63 2.814939665 Fxyd5 NM 008761 
64 2. 788097 4 7 4 Mmp12 NM 008605 
65 2. 777390435 Cd200r1 NM 021325 
66 2.77605086 Capg NM 007599 
67 2. 772520255 Mpv17 // Gtf3c2 ENSMUST000001 01411 
68 2.75246649 Ms4a6d NM 026835 
69 2. 751240007 Lat2 NM 020044 
70 2.742310632 Rnf149 NM 001033135 
71 2. 723919372 Cd68 NM 009853 
72 2.71793697 Anxa1 NM 010730 
73 2.710851341 Pira11 NM 011088 
74 2.708171306 EG622976 NM 001037917 
75 2.699138486 Cd109 NM 153098 
76 2.696974723 Enpp1 NM 008813 
77 2.696524235 Pira11 NM 011088 
78 2. 67 4258636 Slc11a1 NM 013612 
79 2. 669796908 Sfrp1 NM 013834 
80 2.666915288 llr13 NM 205820 
81 2. 655955546 C5ar1 NM 007577 
82 2.646810669 Tnc NM 011607 
83 2.63564671 Ccl3 NM 011337 
84 2.629455352 Cd9 NM 007657 
85 2.626912233 Lipa NM 021460 
86 2.622193226 D230039L06Rik BC120791 
87 2.621791575 Sh3bgrl3 NM 080559 
88 2. 618357336 Fabp5 NM 010634 
89 2. 615368077 Ctsl NM 009984 
90 2.611350298 Dpep2 NM 176913 
91 2. 609209886 Gp49a NM 008147 
92 2.609052546 An pep NM 008486 
93 2. 579159509 lgsf6 NM 030691 
94 2.576756123 --- GENSCAN00000030224 
95 2.572045207 Cfh NM 009888 
96 2.568149164 Ass1 NM 007494 
97 2. 563345598 Cd200r4 NM 207244 
98 2.544871833 Hal NM 010401 
99 2.540655911 Csf1 NM 007778 
100 2.537831 Ptk2b NM 172498 
191 
# MEF2A KO vs. WT Gene Symbol mRNA Accession 
101 2. 530849994 Gusb NM 010368 
102 2.530592132 Tyrobp NM_011662 
103 2.526816678 Clec4a2 NM_011999 
104 2.522450573 Klk1b22 NM 010114 
105 2.510197711 AI cam NM_009655 
106 2.497417464 Myo1f NM_053214 
107 2.49003669 F13a1 NM 028784 
108 2.48730599 Xist NR_001463 
109 2.477685374 My of NM 001099634 
110 2.472106677 Rasgef1b NM 145839 
111 2.4708407 Ass1 NM_007494 
112 2.466142218 Laptm5 NM_010686 
113 2.459385687 Tomm22 NM 172609 
114 2.446563961 Myo1d NM_177390 
115 2.43678151 --- ---
116 2.436464159 112rg NM 013563 
117 2.435940678 5430435G22Rik NM 145509 
118 2.43427642 Slit2 NM_178804 
119 2.427348072 Ha\Cr2 NM 134250 
120 2.418447131 Atp6ap2 NM 027439 
121 2. 405863848 Fblim1 NM_133754 
122 2. 399255832 Fcer1g NM_010185 
123 2.387273733 4732429016Rik NM 145437 
124 2.381827612 Ctss NM_021281 
125 2.381104603 Gla NM 013463 
126 2.362455247 Nfam1 NM 028728 
127 2. 360797012 Glipr1 NM_028608 
128 2.349129098 Fgr NM_010208 
129 2.344727069 Srgn NM 011157 
130 2.344314294 Fam129b BC027843 
131 2.342162218 Aph1c NM_026674 
132 2.341777488 Thbs1 NM 011580 
133 2. 340467935 Sc4mol NM 025436 
134 2. 339871 009 Cstb NM_007793 
135 2.335721072 4930506M07Rik NM_001114312 
136 2.330428096 Cotl1 NM_028071 
137 2.32847598 Soat1 NM 009230 
138 2.327241616 Naps a NM_008437 
139 2.326785147 --- GENSCAN00000031449 
140 2.324816746 Fam105a BC052328 
141 2.322304258 --- NM_001 025575.1 
142 2.314003425 Gm885 BC139224 
143 2.311254294 --- mmu-mir-692-1 II mmu-mir-692-1 
144 2.309259015 Gbgt1 NM_139197 
145 2.303419213 F7 NM 010172 
146 2.29936102 Dennd4a XM_001476259 
147 2.294217229 Dpep2 AK089165 
148 2. 2937 497 49 Gm2a NM 010299 
149 2.292867521 Ccr5 NM 009917 
150 2.292867521 Ccr5 NM 009917 
192 
# MEF2A KO vs. WT Gene Symbol mRNA Accession 
151 2.289300742 Adamts3 NM 001081401 
152 2.287760456 Gnptab NM 001 004164 
153 2.27633833 Tnfrsf26 NM 175649 
154 2.270893424 Lyz2 NM 017372 
155 2.266576728 Dhrs3 NM 011303 
156 2.259077868 --- ---
157 2. 255890435 Galnt6 NM 172451 
158 2.247340925 Abcg3 NM 030239 
159 2.246825373 Ncf2 BC003730 
160 2.244148274 Arpc5 NM 026369 
161 2.242047743 --- ENS M UST00000079568 
162 2.23669106 Lilrb3 NM 011095 
163 2.235372096 Dennd4a xrv1 001476259 
164 2.233807708 Btk NM_013482 
165 2. 226650304 Nfkbie NM 008690 
166 2.220825441 Sema7a NM 011352 
167 2.215448822 C3 NM_009778 
168 2.21505727 Plaur NM_011113 
169 2.214157731 Pira3 NM 011090 
170 2.21246403 Kcnn4 NM 008433 
171 2.210681214 Sod3 NM_011435 
172 2.210592341 Apobec1 NM_031159 
173 2.204137155 --- ENS MUST00000083002 
174 2. 194870772 Csf2rb NM_007780 
175 2. 192855884 --- ---
176 2.192854364 Gja5 NM_008121 
177 2.189365769 ldi1 NM 177960 
178 2. 1877 48655 Fcgr3 NM_010188 
179 2.18704666 ld2 NM_010496 
180 2.18647977 Gpr39 BC085285 
181 2.1863661 06 Loxl3 NM_013586 
182 2.1837 48936 1118 NM_133212 
183 2.181308767 Cd33 NM_001111 058 
184 2.18087 4876 Clec4a1 NM 199311 
185 2.180840108 Atp8b4 NM 001080944 
186 2. 180838596 Olfr1034 NM_001 011872 
187 2.176501478 Sgms2 NM_028943 
188 2. 175041609 Ncf4 NM 008677 
189 2.167322734 OTTMUSG00000016703 NM_177843 
190 2.166134762 2310014H01Rik BC150725 
191 2.164710354 111 r1 NM_008362 
192 2.16424676 Serpinb8 NM_011459 
193 2. 160325946 Gcnt1 NM 173442 
194 2. 158713822 Ar111 NM 177337 
195 2. 155902598 Mpeg1 NM_010821 
196 2.149595193 Stac2 NM_146028 
197 2. 145821395 OTTM USG00000000971 NM 001081957 
198 2.144370213 Sqle NM 009270 
199 2.144309273 Sirpa NM_007547 
200 2.135346214 Vav1 NM_011691 
193 
# MEF2A KO vs. WT Gene Symbol mRNA Accession 
201 2. 133011879 Tnfsf8 NM 009403 
202 2.133011879 Mctp1 NM 030174 
203 2.131027189 Cyba NM 007806 
204 2. 130669757 Cd48 NM 007649 
205 2.118814079 . Gpr183 NM 183031 
206 2.109121198 Ms4a14 ENS M UST00000067600 
207 2. 108782057 Arhgap4 NM 138630 
208 2.107851162 Galnt7 NM 144731 
209 2. 1 03080393 Sfpi1 NM 011355 
210 2.10264603 DockS NM 177780 
211 2.101481855 --- ---
212 2. 1 00970638 Prkcb NM 008855 
213 2.094778932 Clec7a NM 020008 
214 2.094363704 --- ENS M UST00000055026 
215 2.094150314 Myo5a NM 010864 
216 2.09342031 --- AK040583 
217 2.087142349 ltgb3 NM_016780 
218 2. 086394541 Has2 NM 008216 
219 2.086255713 ldi1 NM_145360 
220 2.084951754 Ptprc NM 001111316 
221 2.084242292 Atp6v1a NM 007508 
222 2.081392431 Pdgfc NM_019971 
223 2.080665431 D10Bwg1379e NM 001 033258 
224 2.080131883 Trp\Q NM_011706 
225 2.078425448 Hpse NM_152803 
226 2.074901715 --- mmu-mir-223 II mmu-mir-223 
227 2.074635663 Lrrc25 NM_153074 
228 2.074329386 Slc41a2 NM_177388 
229 2. 071350935 Cd52 NM_013706 
230 2. 070871449 Emp3 NM_010129 
231 2. 069994594 F63011 ON24Rik BC119790 
232 2. 062555585 Dmxl2 NM_172771 
233 2.061912341 Crip1 NM_007763 
234 2. 058870372 AB124611 AB124611 
235 2.05801857 Dab2 NM_023118 
236 2. 05507 4934 Ms4a7 NM_027836 
237 2.053248153 Pqlc3 NM_172574 
238 2.0522109 Msn NM_010833 
239 2. 050862827 Mgat5 NM_145128 
240 2.046463591 Rgs18 NM_022881 
241 2.044426221 Ptafr NM_001 081211 
242 2. 044352534 Dennd4a XI\II_001476259 
243 2. 040893641 Frrs1 NM_001113478 
244 2.037591717 --- ---
245 2. 037 406707 Cd180 NM_008533 
246 2. 035235866 Serpine2 NM_009255 
247 2.032241706 C3ar1 NM_009779 
248 2.032231845 LOC280487 X16670 
249 2.032231845 LOC280487 X16670 
250 2.032231845 --- AK145655 
194 
# MEF2A KO vs. WT Gene Symbol mRNA Accession 
251 2.032231845 --- AK145655 
252 2. 032231845 --- AK145655 
253 2.032231845 LOC280487 X16670 
254 2.032231845 --- AK145655 
255 2.032231845 100043775 XM 001480931 
256 2.032231845 --- AK145655 
257 2.032231845 --- AK145655 
258 2.032231845 --- AK145655 
259 2.032231845 LOC280487 X16670 
260 2.032231845 --- AK145655 
261 2.032231845 --- AK145655 
262 2.032231845 LOC280487 X16670 
263 2. 032231 845 100043775 XM_001 480931 
264 2.032231845 LOC280487 X16670 
265 2.032231845 LOC280487 X16670 
266 2.032231845 100043775 XM_001480931 
267 2.032231845 LOC280487 X16670 
268 2.032231845 --- AK145655 
269 2.032231845 --- AK145655 
270 2. 032231845 --- AK145655 
271 2. 032231 845 --- AK145655 
272 2. 032231845 --- AK145655 
273 2.032231845 100043775 XM_001480931 
274 2. 032231 845 --- AK145655 
275 2.032231845 --- AK145655 
276 2. 032231845 --- AK145655 
277 2. 032231845 --- AK145655 
278 2.032231845 LOC280487 X16670 
279 2. 032231845 LOC280487 X16670 
280 2. 032231845 LOC280487 X16670 
281 2. 032231845 LOC280487 X16670 
282 2. 032231845 LOC280487 X16670 
283 2.032231845 --- AK145655 
284 2.032231845 LOC280487 X16670 
285 2.032231845 --- AK145655 
286 2.032231845 --- AK145655 
287 2.032231845 --- AK145655 
288 2. 032231845 --- AK145655 
289 2.032231845 100043775 XM_001480931 
290 2.032231845 --- AK145655 
291 2. 032231845 --- AK145655 
292 2. 032231 845 LOC280487 X16670 
293 2. 032231845 LOC280487 X16670 
294 2. 032231845 --- AK145655 
295 2. 032231 845 --- AK145655 
296 2.032231845 LOC280487 X16670 
297 2.032231845 LOC280487 X16670 
298 2.024726441 Fnip2 AK122512 
299 2.021593597 Hsd17b11 NM_053262 
300 2.020645165 Ccl7 NM_013654 
195 
# MEF2A KO vs. WT Gene Symbol m RNA Accession 
301 2.014251737 --- ENS M UST00000082713 
302 2. 009050739 Edil3 NM 001037987 
303 2. 007302435 Cpxm2 NM 018867 
304 2.00677518 Slco2a1 NM 033314 
305 2. 006668077 118ra NM 178241 
306 2. 006430244 Myo1d NM 177390 
307 2. 004150708 EG434172 NM 001033782 
308 2.00238446 Sirpb1 NM 001002898 
309 2. 001938979 Scpep1 NM 029023 
310 2. 001633722 AF251705 NM 134158 
311 2. 000708522 Dmxl2 NM 172771 
312 2. 000532408 Arhgap25 NM 001037727 
Table A.3 Top upregulated genes in MEF2A KO muscle at regeneration day 7 Fold 
changes in gene expression are shown from regeneration day 7 microarray data 
comparing MEF2A KO and WT TA muscle samples. WT gene expression values are 
normalized to 1. Genes which were upregulated 2 fold or more are shown in order from 
most upregulated to least upregulated (#1-312). N=l. 
196 
# MEF2A KO vs. WT Gene Symbol mRNA Accession 
1 0.21013509 11 00001 E04Rik AB073967 
2 0.26919397 --- ENS M UST00000082757 
3 0. 313026565 --- NC 005089 II NC 005089 
4 0.318217702 --- mmu-mir-410 II mmu-mir-410 
5 0.347920044 Olfr859 NM 146526 
6 0.352462335 Atp1b4 NM 133690 
7 0.36239275 Aldh1a1 NM 013467 
8 0.379133016 --- ENSMUST00000118495 
9 0.380782214 Rnu3b1 NR 004415 
10 0.380782214 Rnu3b1 NR_004415 
11 0.380782214 Rnu3b1 NR 004415 
12 0.380782214 Rnu3b1 NR 004415 
13 0.383756476 Retnla NM_020509 
14 0.387 418835 --- mmu-mir-136 II mmu-mir-136 
15 0.396918029 Nos1 NM 008712 
16 0.399917134 Kcnc4 NM 145922 
17 0.402775825 E030037K03Rik E NSM UST00000097 462 
18 0.402775825 100042747 XM 001476146 
19 0.405333691 --- mmu-mir-434 II mmu-mir-434 
20 0.415508818 Mettl11b BC157906 
21 0.420127 463 --- ENSMUST00000082521 
22 0.434878714 Frzb NM 011356 
23 0.440515595 Ctnna3 NM_177612 
24 0.4407 46189 --- ENSMUST00000119395 
25 0.442311298 --- mmu-mir-495 II mmu-mir-495 
26 0.445728155 --- mmu-mir-539 II mmu-mir-539 
27 0.44 7796141 Asb11 NM_026853 
28 0.449865301 Mylk4 ENSMUST00000057428 
29 0.450956944 --- ENS M UST00000093725 
30 0.455201432 --- ---
31 0.455953309 Prr19 BC147639 
32 0.456493429 --- NC_005089 
33 0.457356164 Olfr107 NM_146511 
34 0.457703427 --- ENSMUST000001 03551 
35 0.457703427 Trav16dldv11 ENSM UST000001 03606 
36 0.458459755 Slc38a3 NM 023805 
37 0.460115831 --- mmu-mir-127 II mmu-mir-127 
38 0.460576083 EG434275 XR_031249 
39 0.464382657 --- ENSMUST00000089396 
40 0.465890236 TubaS NM_017379 
41 0.465949336 Opn1mw NM_008106 
42 0.467882119 --- mmu-mir-409 II mmu-mir-409 
43 0.4 71336725 --- GENSCAN00000028775 
44 0.472215401 D7Bwg0826e AK141792 
45 0.472331285 Olfr1167 NM_146294 
46 0.47388996 --- GE NSCAN00000035087 
47 0.479608456 Tmem92 NM 001 034896 
48 0.481 097 431 --- NC 005089 
49 0.481264862 Olfr1347 NM_146385 
50 0.483200549 83-12 NM_020568 
197 
# MEF2A KO vs. WT Gene Symbol mANA Accession 
51 0.484033565 3110035E14Rik BC066997 
52 0.484281568 Rhox9 NM 023894 
53 0.484779299 Gpr55 NM 001 033290 
54 0.484779299 231001 OM20Rik BC125555 
55 0.48511712 Rian AF357355 
56 0.485488154 Klk1 b11 NM 010640 
57 0.485488154 Olfr1245 NM 146788 
58 0.48633017 100043404 XM 001478876 
59 0.487291175 Scoc NM 001 039137 
60 0.487802481 --- ---
61 0.488751149 Art3 NM 181728 
62 0.490289578 ENSMUSG00000074855 ENS M UST00000099432 
63 0.490775794 Ostn NM 198112 
64 0.491185201 Neu2 NM 015750 
65 0.492069841 Ela3 NM 026419 
66 0.493624532 Rax NM 013833 
67 0.49640309 BC023105 II BC023105 BC023105 
68 0.497611592 Krtap7-1 ENSMUST00000056118 
69 0.497611592 --- ENSMUST00000101292 
70 0.497611937 --- ---
71 0.497611937 --- ENSMUST00000117058 
72 0.499484218 170004 7G07Ri k ENSM UST00000065508 
73 0.499565586 EG240921 ENSMUST00000037976 
74 0.499763693 Olfr373 II Olfr373 NM 146539 
75 0.501475457 LOC382133 BC089466 
76 0.50339263 --- E NSM UST00000083028 
77 0.50339263 Crhr2 NM 009953 
78 0.504342602 --- GENSCAN00000011253 
79 0.506448684 --- GENSCAN00000015939 
80 0.506668485 --- mmu-mir-487b II mmu-mir-487b 
81 0.506813901 Nudt19 AK045908 
82 0.509185062 Tet1 AK129421 
83 0.510123334 EG329126 XR 001880 
84 0.510543573 --- ---
85 0.512075698 Asb14 NM 080856 
86 0.513707 485 Ptpn3 ENSMUST00000075637 
87 0.514040879 Tdgf1 NM 011562 
88 0.516507427 lfnb1 NM 010510 
89 0.516507427 Asb4 NM 023048 
90 0.516998858 Cabp4 NM 144532 
91 0.51921825 Olfr1506 NM 146265 
92 0.51921825 Olfr1506 NM 146265 
93 0.521242274 --- E NSM UST00000082466 
94 0.521366214 4921504E06Rik BC132142 
95 0.521681074 ltgb1bp3 NM 027120 
96 0.52195524 LOC382133 BC089466 
97 0.522940605 Meg3 NR 003633 
98 0.525980055 --- mmu-mir-323 II mmu-mir-323 
99 0.526446927 --- ENSMUST00000082745 
100 0.527611165 Aldh1a7 NM 011921 
198 
# MEF2A KO vs. WT Gene Symbol mRNA Accession 
101 0.528142081 Asb10 NM 080444 
102 0.528909209 Cyp2d9 NM 010006 
103 0.529392257 Fras1 NM 175473 
104 0.52996831 Phox2a NM 008887 
105 0.531425735 Chodl NM 139134 
106 0.532533061 Mbd311 NM 028557 
107 0.532533061 --- ENSMUST00000122311 
108 0.532533061 Leng1 NM 027203 
109 0.532533061 Hamp NM 032541 
110 0.53253343 Olfr714 II Olfr714 NM 147033 
111 0.532879412 Scn4b NM 001 013390 
112 0.53320529 AI pi NM 001081082 
113 0.534296696 --- G E NSCAN00000027737 
114 0.534706826 --- 00267101 
115 0.535646829 Tmprss9 NM 001081688 
116 0.538107008 --- ENSM UST00000099327 
117 0.538107381 Rpl31 NM 025425 
118 0.538432724 Olfr923 NM 146816 
119 0.538432724 Pld5 NM_176916 
120 0.538766107 Sh3rf2 NM_172966 
121 0.540725013 Car14 NM 011797 
122 0.541042189 Ssty2 L04850 
123 0.54105794 Olfr1358 ENSMUST00000095474 
124 0.54106394 --- ---
125 0.541114573 LOC1 00046618 XM_001476513 
126 0.543082394 1700016H 13Ri k BC049644 
127 0.543428826 EG436003 NM 001127686 
128 0.54361682 Rsad2 NM_021384 
129 0.543787917 --- NC_005089 
130 0.54399338 LOC382133 BC089466 
131 0.544843954 --- mmu-mir-485 II mmu-mir-485 
132 0.54488361 Upk1b NM_178924 
133 0.54524593 --- ENSM UST00000120478 
134 0.54524593 ENSMUSG00000073646 ENSMUST00000097689 
135 0.545510549 Rdh7 NM 017473 
136 0.546284351 Diras1 NM_145217 
137 0.547438954 --- NC 005089 
138 0.548411223 Pfkfb1 NM 008824 
139 0.549184191 Crym NM_016669 
140 0.549618321 Kcng4 NM_025734 
141 0.549695053 --- ENSMUST00000072368 
142 0.550974326 --- ENSM UST00000081336 
143 0.551193966 Lynx1 NM_011838 
144 0.551289107 Tmem45b NM_144936 
145 0.553241774 Nel12 NM_016743 
146 0.553567826 -- ---
147 0.554888958 Fbp2 NM_007994 
148 0.555027823 LOC100040364 II LOC100042481 ENSMUST00000111413 
149 0.555027823 LOC1 00041409 XR_032682 
150 0.555112467 Ssty2 L04850 
199 
# MEF2A KO vs. WT Gene Symbol mRNA Accession 
151 0.555112467 
152 0.555201742 Ssty2 NM 023546 
153 0.555291416 --- G ENSCAN00000027848 
154 0. 555291416 MGC107098 BC089465 
155 0.555291416 --- ---
156 0.555291801 EG328839 ENSMUST00000097307 
157 0.555291801 --- ENS M UST00000083868 
Table A.4 Top downregulated genes in MEF2A KO muscle at regeneration day 7 
Fold changes in gene expression are shown from regeneration day 7 rnicroarray data 
comparing MEF2A KO and WT TA muscle samples. WT gene expression values are 
normalized to 1. Genes which were downregulated 1.8 fold (0.55) or more are shown in 
order from most downregulated to least downregulated (#1-157). N=l. 
200 
MEF2A KO vs. WT shMef2A vs. shlacZ 
Gene Microarray Regeneration Day 7 Symbol C2C12 DIFF3 
miR 540 0.65 0. 44 ± 0. 1 0 ** 0.63 ± 0.03 *** 
miR 433 N/A 0.17 ± 0.02 *** 0.71 ± 0.07 ** 
miR 495 0.44 0.25 ± 0.02 *** 1.47 ± 0.51 
miR 381 0.68 0.52 ± 0.19 * 0.59 ± 0.11 ** 
miR 410 0.32 0.46 ± 0.21 * 0.36 ± 0.02 *** 
Table A.5 Comparison of changes in miR gene expression from microarray and 
qPCR analyses Fold changes in gene expression are displayed for Gtl2-Dio3 miRs 
according to MEF2A KO vs. WT microarray and qPCR data at regeneration day 7, and 
shMef2A vs. shLacZ qPCR data at differentiation day 3. KO and shMef2A gene 
expression values are normalized to WT and shLacZ controls, respectively, normalized to 
1. Microarray N=l, qPCR N~3 . ±reflects SEM. *p ~ 0.05, **p ~ 0.01, ***p ~ 0.001. 
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